Heterocyclic derivatives as MALT1 inhibitors

By providing a compound or pharmaceutical composition thereof for the treatment of MALT1 mediated diseases, the problem of limited effectiveness of existing MALT1 inhibitors is solved, and effective treatment of MALT1 mediated diseases is achieved, especially in the case of drug resistance. .

CN119095837APending Publication Date: 2024-12-06C4X DISCOVERY
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202380032315.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-29
Filing Date
2023-02-03
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Existing MALT1 inhibitors have limited effectiveness in the treatment of MALT1-related diseases, especially in drug resistance, and lack of effective drugs to inhibit MALT1-mediated multiple diseases.

Method used

Provided a novel compound or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of a disease mediated by MALT1 by administering to a subject a therapeutically effective amount of a compound or a pharmaceutically acceptable salt thereof Salt, specifically includes the treatment of lymphoma, leukemia, cancer and inflammatory diseases.

Benefits of technology

This compound or its pharmaceutical composition can effectively inhibit MALT1 and significantly improve the therapeutic effect, especially in the case of drug resistance, providing a multi-pronged treatment regimen for MALT1-mediated diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119095837A_ABST
    Figure CN119095837A_ABST
Patent Text Reader

Abstract

The present invention relates to compounds of formula (I) as MALT1 inhibitors. The compounds have structural formula I as defined herein. The invention also relates to processes for preparing these compounds, pharmaceutical compositions comprising them and their use in the treatment of diseases or conditions associated with MALT1. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to compounds that are MALT1 inhibitors. The present invention also relates to methods for preparing these compounds, pharmaceutical compositions containing them, and their use in treating diseases or disorders associated with MALT1. Background Art

[0002] Mucosa-associated lymphoid tissue lymphoma translocator 1 (MALT1) is an intracellular protein that plays a key role in antigen receptor-induced NF-kB pathway activation in T and B lymphocytes through scaffold and protease functions. Antigen receptor triggering leads to the formation of the CBM complex, which contains the CARMA or CARD proteins, BCL10, and MALT1, which subsequently acts as a scaffold to recruit the ubiquitin ligase TRAF6 and the kinases TAK1 and IKK. This leads to NF-kB activation through IKK-dependent phosphorylation and proteasomal degradation of the NF-kB inhibitor IkB, allowing NF-kB to translate into the nucleus and initiate transcription of target genes (doi.org / 10.1038 / ni1568; doi:10.1007 / s00018-015-2059-z). In addition, MALT1 proteolytically cleaves multiple substrates involved in the regulation of the NF-kB pathway, including RelB, A20, CYLD, regnase-1, HOIL, BCL10, and NIK; as well as autoproteolytic cleavage (doi:10.1016 / j.biochi.2015.09.018). The overall effect of these cleavage events is thought to be an amplification of the magnitude and duration of the NF-kB response (doi:10.1016 / j.biochi.2015.09.018).

[0003] Several genetic evidences suggest that MALT1 plays a key role in immune responses. Mice lacking the MALT1 protein are viable but show impairments in the generation and activation of Treg cells and less activated T cells in the periphery. MALT1 KO mice are protected in inflammatory models of MS (EAE) and rheumatoid arthritis (doi:10.4049 / jimmunol.1201351). Mice expressing proteolytically inactivated MALT1 show defects in multiple immune cell types, including mature T and B cells and Treg cells, and develop progressive multi-organ inflammatory pathology (doi:10.4049 / jimmunol.1402254; doi:10.3389 / fimmu.2020.00745). A small proportion of human patients with defective MALT1 expression and / or function display combined immunodeficiency (doi:10.1007 / s 10875-014-0125-1; doi:10.1016 / j.jaci.2013.04.047).

[0004] The highly aggressive activated B cell (ABC) subtype of diffuse large B cell lymphoma (DLBCL) depends on constitutively activated NF-kB activation through the CARMA1-BCL10-MALT1 pathway for survival and proliferation (doi.org / 10.1038 / nature04687). This constitutive NF-kB activation often occurs due to multiple oncogenic mutations in pathway genes, including CARD11, MYD88, CD79A / B, and A20 (doi:10.1038 / nature 07968; doi:10.1016 / j.ccr.2012.11.003). Preclinical studies suggest that MALT1 protease inhibition may be an effective therapeutic principle for ABC-DLBCL, as treatment with the MALT1 inhibitor z-VRPR-fmk reduced the expression of NF-kB target genes, accompanied by decreased cell growth and survival (doi:10.1073 / pnas.0907511106; doi:10.1084 / jem.20091167), and small molecule MALT1 inhibitors have also been shown to be active in xenograft models of ABC-DLBCL (doi:10.1016 / j.ccr.2012.11.002; doi:10.1016 / j.ccr.2012.11.003). Chronic activation of the BCR-mediated CBM-NF-kB pathway has been identified in a subset of mantle cell lymphoma (MCL) cell lines, suggesting that a subset of MCL may also respond to MALT1 inhibition (doi:10.1038 / nm.3435). In MALT lymphoma, a type of non-Hodgkin lymphoma (NHL), the fusion protein cIAP2-MALT1 leads to constitutive activation of the NF-kB pathway, and these patients may also benefit from treatment with MALT1 inhibitors (doi10.1074 / jbc.M605116200). MALT1 inhibition may have a role in the treatment of several solid tumor types, such as glioblastoma, breast cancer, melanoma, lung cancer, prostate cancer, pancreatic cancer, and osteosarcoma (doi:10.1038 / s41388-019-0958-4; doi:10.15252 / embj.2019102030; doi:10.1111 / jcmm.15383; doi:10.1038 / oncsis.2017.68; doi:10.1038 / onc.2015.146; doi:10.3390 / biomedicines9030250; doi:10.1002 / ijc.32567).

[0005] BTK inhibitors such as ibrutinib are important therapies for the treatment of cancers such as MCL and chronic lymphocytic leukemia (CLL), but their effectiveness is limited due to primary or acquired resistance (doi:10.3390 / cancers12051328). MALT1 is located downstream of BTK in the NF-kB activation pathway and may therefore be an effective target in combination with BTK inhibitors or in BTKi-resistant (BTKi-refractive) tumors. MALT1 has been shown to be constitutively active in CLL cell lines, and treatment with the MALT-1 inhibitor MI-2 is effective in both naive and ibrutinib-resistant cell lines (doi:10.1158 / 0008-5472.CAN-17-2485). MALT1 inhibition also showed synergy with the mTORC1 inhibitor rapamycin in ABC-DLBCL cell lines, PDX, and in vivo models, providing further possibilities for combination therapy and strategies to alleviate MALT1i resistance (doi:10.1182 / blood.2019004713).

[0006] MALT1 inhibitors have also been proposed as effective treatments for a range of cancers as immunomodulatory therapies, independent of dysregulation of the NF-kB pathway (doi:10.1038 / s 41586-019-1215-2; WO2018 / 226150 & WO2018 / 141749). Genetic evidence from MALT1-deficient mice suggests that MALT1 promotes the development of Treg cells in vivo, which in turn inhibit multiple types of immune cells, suppressing anti-tumor immune responses. Further studies targeting the CBM complex (either by MALT1 inhibition or CARMA1 loss in Treg cells) resulted in increased effector activity of Treg cells and enhanced control of tumor growth. In both poorly immunogenic and immunogenic murine melanoma models, MALT1 inhibitors synergized with anti-PD1 therapy (doi:10.1038 / s41586-019-1215-2), suggesting the potential combination of MALT1 inhibitors with immunotherapies including anti-PD1, anti-PD-L1, and anti-CTLA4.

[0007] In addition to its use in oncology indications, small molecule MALT1 inhibitors may also be effective therapies for inflammatory diseases such as multiple sclerosis, psoriasis, ulcerative colitis, and rheumatoid arthritis. MI-2 has been shown to inhibit monocyte differentiation into osteoclasts in the presence or absence of TNFa and to ameliorate pathological bone erosion and synovitis in a mouse collagen-induced arthritis (CIA) model, suggesting a role for MALT1 inhibitors in the treatment of rheumatoid arthritis (doi:10.1038 / s41598-017-12349-9). The scaffold protein CARD14 forms a signaling complex with BCL10 and MALT1 in keratinocytes, and this process is enhanced in the presence of pathogenic CARD14 mutations, which in turn are associated with susceptibility to psoriasis (doi:10.1016 / j.jid.2016.09.031). MALT1 inhibitors have also been successfully tested in mouse models of multiple sclerosis and ulcerative colitis (doi:10.1186 / 1742-2094-11-124). Pharmacological inhibition of MALT1 protease activity has been shown to suppress endothelial activation by increasing MCPIP1 expression, inhibiting TNFa-induced VCAM-1 expression in HUVECs and LPS-induced VCAM-1 expression in mice, suggesting a possible role for MALT1 inhibitors in the treatment of vascular inflammatory diseases such as atherosclerosis (doi:10.1016 / j.cellsig.2018.05.009).

[0008] Homozygous MALT1 W580S mutations have been identified in patients with combined immunodeficiency (CID). This is associated with low MALT1-W580S protein levels, resulting in reduced magnitude but prolonged duration of NF-kB activation due to impaired negative feedback through reduced HOIL1 cleavage, clinically manifested as increased cutaneous and gastrointestinal inflammation and increased susceptibility to infection (doi.org / 10.1016 / j.jaci.2013.10.045). Small molecule ligands known to bind to the allosteric site of wild-type MALT1 have also been shown to bind to the W580S mutant, leading to stabilization of the enzyme and reconstitution of protein levels, even after ligand clearance. Both scaffold and protease functions are restored; thus, in the case of the W80S MALT1 mutation, allosteric MALT1 inhibitors may be able to act as “molecular correctors” (doi.org / 10.1038 / s41589-018-0222-1).

[0009] Clinical and preclinical studies of various MALT1 inhibitors are ongoing. JNJ-67856633 is a small molecule MALT1 inhibitor currently being studied in PhI in patients with NHL and CLL. A review of the patents on MALT1 inhibitors was recently published (doi:10.1080 / 13543776.2021.1951703).

[0010] Therefore, given the role of MALT1 in multiple indications, there is a continuing need for drugs that can inhibit MALT1. Summary of the invention

[0011] In one aspect, the invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof.

[0012] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the invention as defined herein, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

[0013] In another aspect, the invention relates to a compound of the invention as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in therapy.

[0014] In another aspect, the invention relates to a compound of the invention as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or condition mediated by MALT1.

[0015] In another aspect, the present invention relates to a method of treating a disease or condition mediated by MALT1, said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the present invention as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.

[0016] Examples of diseases or conditions mediated by MALT1 include:

[0017] i) Lymphomas, leukemias, carcinomas and sarcomas; e.g. non-Hodgkin lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia, lymphoblastic T-cell leukemia, chronic myeloid leukemia (CML), hairy cell leukemia, acute lymphoblastic T

[0018] leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal cancer / colon cancer, prostate cancer, including non-small cell lung cancer, stomach cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, Ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial carcinoma, vulvar cancer, esophageal cancer, salivary gland cancer, nasopharyngeal cancer, cheek cancer, oral cancer, or GIST (gastrointestinal stromal tumor);

[0019] and

[0020] ii) Immune diseases, including autoimmune diseases and inflammatory diseases; for example, arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatitis, Crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allogeneic transplant rejection, acute or chronic graft-versus-host disease, dermatitis including atopic dermatitis, dermatomyositis, psoriasis, Behcet's diseases, uveitis, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Sjoergen's syndrome, syndrome, vesicular disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic disorders, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, lung disease including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, berylliosis, or polymyositis.

[0021] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition for use in the treatment of non-Hodgkin lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

[0022] In another aspect, the present invention provides a method for treating non-Hodgkin lymphoma (IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0023] The present invention further provides a process for the synthesis of a compound as defined herein or a pharmaceutically acceptable salt thereof.

[0024] In another aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, which can be obtained by a synthetic method defined herein, or obtained by a synthetic method defined herein, or directly obtained by a synthetic method defined herein.

[0025] In another aspect, the present invention provides novel intermediates as defined herein, which are suitable for use in any of the synthetic methods described herein.

[0026] Preferred, suitable and optional features of any particular aspect of the invention are also preferred, suitable and optional features of any other aspect. DETAILED DESCRIPTION

[0027] definition

[0028] Unless otherwise stated, the following terms used in the specification and claims have the following meanings.

[0029] It should be understood that references to "treating" or "treating" include prevention as well as alleviation of established symptoms of a condition. Thus, "treating" or "treating" a state, disorder, or condition includes: (1) preventing or delaying the onset of clinical symptoms of the state, disorder, or condition that develops in a person who may be suffering from or susceptible to the state, disorder, or condition but does not yet experience or show clinical or subclinical symptoms of the state, disorder, or condition, (2) inhibiting the state, disorder, or condition, i.e., arresting, reducing, or delaying the development of the disease or its recurrence (in the case of maintenance treatment) or at least one clinical or subclinical symptom thereof, or (3) relieving or ameliorating the disease, i.e., causing regression of the state, disorder, or condition or at least one clinical or subclinical symptom thereof.

[0030] "Therapeutically effective amount" refers to the amount of a compound that, when administered to a mammal for treating a disease, is sufficient to achieve treatment of the disease. "Therapeutically effective amount" will vary depending on the compound, the disease and its severity, and the age, weight, etc. of the mammal being treated.

[0031] In this specification, the term "alkyl" includes straight and branched chain alkyl groups. When a single alkyl group such as "propyl" is mentioned, only the straight chain form is referred to, and when a single branched alkyl group such as "isopropyl" is mentioned, only the branched form is referred to. For example, "(1-6C)alkyl" includes (1-4C)alkyl, (1-3C)alkyl, propyl, isopropyl and tert-butyl. Similar conventions apply to other groups, for example, "phenyl (1-6C)alkyl" includes phenyl (1-4C)alkyl, benzyl, 1-phenylethyl and 2-phenylethyl.

[0032] In this specification, the term "alkylene" includes straight chain and branched divalent alkyl groups. For example, "C 1-4 "Alkylene" includes methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene and butylene.

[0033] In this specification, the term "alkoxy" includes straight and branched chain alkyl groups bonded to oxygen alone. For example, "C 1-4 "Alkoxy" includes methoxy, ethoxy, isopropoxy and tert-butoxy.

[0034] The term "(m-nC)" or "(m-nC) group" used alone or as a prefix refers to any group having from m to n carbon atoms.

[0035] "Cycloalkyl" refers to a hydrocarbon monocyclic or bicyclic ring containing carbon atoms. Examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl. Bicyclic rings may be fused or spiro-linked; examples of bicyclic cycloalkyls include bicyclo[2.2.2]octane, bicyclo[2.1.1]hexane, bicyclo[1.1.1]pentane, spiro[2.4]heptane, bicyclo[4.1.0]heptane, and bicyclo[2.2.1]heptane.

[0036] The term "halo" refers to fluoro, chloro, bromo and iodo.

[0037] As used herein, the term "haloalkyl" refers to an alkyl group in which one or more hydrogen atoms are replaced by a halogen (eg, fluorine) atom. Examples of haloalkyl groups include fluoroalkyl groups such as -CHF 2 , –CH 2 CF 3 , or perfluoroalkyl / alkoxy groups, such as –CF 3 or –CF 2 CF 3 .

[0038] The term "heterocyclyl", "heterocyclic" or "heterocycle" refers to a non-aromatic saturated or partially saturated monocyclic, fused, bridged or spiro bicyclic heterocyclic ring system. The monocyclic heterocyclic ring contains about 3 to 12 (suitably 3 to 7) ring atoms, with 1 to 5 (suitably 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur in the ring. The bicyclic heterocyclic ring contains 7 to 17 member atoms in the ring, and 7 to 12 member atoms are suitable. The bicyclic heterocyclic ring can be a fused ring, a spiro ring or a bridged ring system. Examples of heterocyclic groups include cyclic ethers, such as oxirane, oxetane, tetrahydrofuran, dioxane and substituted cyclic ethers. Nitrogen-containing heterocyclic rings include, for example, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, tetrahydrotriazinyl, tetrahydropyrazolyl, etc. Typical sulfur-containing heterocycles include tetrahydrothiophene, dihydro-1,3-dithiol, tetrahydro-2H-thiopyran and hexahydrothiophene. Other heterocycles include dihydrooxathiols, dihydroisoxazolyls (such as 4,5-dihydroisoxazolyls), dihydropyridyls (such as 1,2-dihydropyridyls or 1,6-dihydropyridyls), tetrahydrooxazolyls, tetrahydrooxadiazolyls, tetrahydrodioxazolyls, tetrahydrooxathiazolyl, hexahydrotriazinyl, tetrahydrooxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolane, octahydrobenzofuranyl, octahydrobenzimidazolyl and octahydrobenzothiazolyl. For sulfur-containing heterocycles, SO or SO 2 Examples include the sulfoxide and sulfone forms of tetrahydrothiophene and thiomorpholinyl, such as tetrahydrothiophene 1,1-dioxide and thiomorpholinyl 1,1-dioxide. Suitable values ​​for heterocyclic groups with 1 or 2 oxo (=O) or thio (=S) substituents are, for example, 2-oxopyrrolidinyl, 2-thiopyrrolidinyl, 2-oxoimidazolidinyl, 2-thioimidazolidinyl, 2-oxopiperidinyl, 2,5-dioxopyrrolidinyl, 2,5-dioxoimidazolidinyl or 2,6-dioxopiperidinyl. Specific heterocyclic radical is a saturated monocyclic 3-7 membered heterocyclic radical containing 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur, such as azetidinyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, tetrahydrothienyl, tetrahydrothienyl 1,1-dioxide, thiomorpholinyl, thiomorpholinyl 1,1-dioxide, piperidinyl, homopiperidinyl, piperazinyl or homopiperazinyl. As will be appreciated by the skilled artisan, any heterocycle can be connected to another group by any suitable atom, such as by carbon or nitrogen atom. Suitably, the term "heterocyclic radical", "heterocyclic" or "heterocycle" refers to a 4, 5, 6 or 7 membered monocycle as defined above.

[0039] The term "heteroaryl" or "heteroaromatic" refers to an aromatic monocyclic, bicyclic or polycyclic ring containing one or more (e.g., 14, particularly 1, 2 or 3) heteroatoms selected from nitrogen, oxygen or sulfur. Examples of heteroaryl are monocyclic and bicyclic groups containing 5-12 ring members, more typically 5-10 ring members. Heteroaryl can be, for example, a 5- or 6-membered monocyclic or 9- or 10-membered bicyclic ring, such as a bicyclic structure formed by fused 5- and 6-membered rings or two fused 6-membered rings. Each ring can contain up to about 4 heteroatoms typically selected from nitrogen, sulfur and oxygen. Typically, the heteroaryl ring will contain up to 3 heteroatoms, more typically up to 2, such as a single heteroatom. In one embodiment, the heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atom in the heteroaryl ring can be basic, such as in the case of imidazole or pyridine, or substantially non-basic, such as in the case of indole or pyrrole nitrogen. Typically the number of basic nitrogen atoms present in a heteroaryl group, including any amino substituents on the ring, will be less than five. Suitably the term "heteroaryl" or "heteroaromatic" refers to a 5 or 6 membered monocyclic heteroaryl ring as defined above.

[0040] Non-limiting examples of heteroaryl groups include furanyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazolyl, benzofuranyl, indolyl, isoindolyl, benzothiophenyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, purinyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalin ... oxazinyl, pyrid ... Examples of some aromatic heteroaryl groups include, for example, tetrahydroisoquinolyl, tetrahydroquinolyl, 2-oxo-1,2,3,4-tetrahydroquinolyl, dihydrobenzothiophenyl, dihydrobenzofuranyl, 2,3-dihydrobenzo[1,4]dioxy, benzo[1,3]dioxolyl, 2,2-dioxo-1,3-dihydro-2-benzothiophenyl, 4,5,6,7-tetrahydrobenzofuranyl, indolyl, 1,2,3,4-tetrahydro-1,8-naphthyridinyl, 1,2,3,4-tetrahydropyrido[2,3-b]pyrazinyl, 3,4-dihydro2Hpyrido[3,2-b][1,4]oxazinyl, 4,5,6,7-tetrahydrobenzo[d]isoxazolyl, yl, 4,5,6,7-tetrahydro-[1,2,3]triazolo[1,5-a]pyridinyl, 5,6-dihydro-8H-[1,2,4]triazolo[3,4-c][1,4]oxazinyl, 5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazolyl, 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolyl, 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridinyl, 6,7-dihydro-4H-[1,2,3]triazol[5,1-c][1,4]oxazinyl and 1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazol-5-yl.

[0041] Non-limiting examples of five-membered heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl, and tetrazolyl.

[0042] Non-limiting examples of six-membered heteroaryl groups include, but are not limited to, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl, and triazinyl.

[0043] Specific non-limiting examples of bicyclic heteroaryl groups containing a six-membered ring fused to a five-membered ring include, but are not limited to, benzofuranyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzisothiazolyl, isobenzofuranyl, indolyl, isoindolyl, indolizinyl, indolyl, isoindolinyl, purinyl (e.g., adeninyl, guaninyl), indazolyl, benzodioxolyl, pyrrolopyridine, and pyrazolopyridinyl.

[0044] Specific non-limiting examples of bicyclic heteroaryl groups containing two fused six-membered rings include, but are not limited to, quinolinyl, isoquinolinyl, chromanyl, thiochromanyl, chromenyl, isochromenyl, chromanyl, isochromanyl, benzodioxanyl, quinolinyl, benzoxazinyl, benzodiazinyl, pyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl, phthalazinyl, naphthyridinyl, and pteridinyl.

[0045] Specific non-limiting examples of bicyclic heteroaryl groups containing a five-membered ring fused to a five-membered ring include, but are not limited to, 6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazolyl, 5,6-dihydro-4H-pyrrolo[1,2-c][1,2,3]triazolyl, and 1,4,5,6-tetrahydrocyclopenta[d][1,2,3]triazol-5-yl.

[0046] The term "aryl" refers to a cyclic or polycyclic aromatic ring having 5 to 12 carbon atoms. The term aryl includes monovalent and divalent species. Examples of aryl include, but are not limited to, phenyl, biphenyl, naphthyl, etc. In this embodiment, aryl is phenyl or naphthyl, especially phenyl.

[0047] The term "optionally substituted" refers to both substituted and unsubstituted groups, structures or molecules.

[0048] When optional substituents are selected from "one or more" groups, it is understood that this definition includes all substituents selected from one specific group or substituents selected from two or more of the specific groups.

[0049] The phrase "compounds of the present invention" refers to those compounds disclosed herein, including both generic compounds and specific compounds.

[0050] Compounds of the present invention

[0051] In a first aspect, the present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof:

[0052]

[0053] in:

[0054] X 1 is N or CH;

[0055] X 2 Yes O, NR 7 or CR 8 R 9 ;

[0056] X 3 is N or CH;

[0057] X 4 Is N or CR 10 ;

[0058] The condition is X 3 and X 4 It can’t all be N;

[0059] R 1 Selected from hydrogen, C 1-4 Alkyl, hydroxyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, halogen, NR 11 R 12 , C 3-7 Cycloalkyl and OC 3-7 Cycloalkyl;

[0060] R 2 Selected from hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, halogen, cyano, NR 13 R 14 、C(O)OR 15 、C(O)NR 16 R 17 , OR 18 , 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl and phenyl, wherein the 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Substitution of alkyl, halogen and cyano groups;

[0061] R 3 and R 4 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, hydroxyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, cyano, NR 19 R 20, 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl, wherein the C 1-4 Alkyl, 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Alkyl, hydroxyl, C 1-4 Alkoxy, halogen and cyano substituents; or

[0062] R 3 and R 4 Together with the carbon atoms to which they are attached, they form an oxo group, a 4- to 7-membered heterocyclic ring, or a 3- to 6-membered cycloalkyl ring;

[0063] R 5 Selected from hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy and C 1-4 Haloalkyl;

[0064] R 6 Selected from hydrogen, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, cyano and C 1-4 Haloalkyl;

[0065] R 7 It is hydrogen, C 1-4 Alkyl, C 3-7 cycloalkyl, 5- or 6-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein the C 1-4 Alkyl, C 3-7 Cycloalkyl, 5- or 6-membered heteroaryl and 4- to 7-membered heterocyclyl are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-4 Alkoxy, halogen and cyano are substituted; or R 7 and R 3 Together with the atoms to which they are attached, they form a 5- or 6-membered heterocyclic ring, optionally substituted by one or more selected from C 1-4 Alkyl, C 1-4 Substitution of alkoxy, halogen and cyano substituents;

[0066] R 8 and R 9 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, hydroxyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, cyano, NR 21 R 22 , 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl, wherein the C 1-4Alkyl, 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-4 Alkoxy, halogen and cyano substituents; or

[0067] R 8 and R 9 Together with the carbon atoms to which they are attached, they form a 4- to 7-membered heterocyclic ring or a 3- to 6-membered cycloalkyl ring;

[0068] R 10 Selected from C(O)NR 23 R 24 , C 1-4 Haloalkoxy, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-7 Cycloalkyl, 4- to 7-membered heterocyclyl, and 5- or 6-membered heteroaryl, wherein the C 3-7 Cycloalkyl, 4- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-3 Alkylene-R 25 , hydroxyl, NR 26 R 27 and halogen substituted substituents;

[0069] R 11 and R 12 are independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl and C 1-4 haloalkyl; or R 11 and R 12 Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocyclic ring;

[0070] R 13 and R 14 are independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl and C 1-4 haloalkyl; or R 13 and R 14 Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocyclic ring;

[0071] R 15 H or C 1-4 alkyl;

[0072] R 16 and R 17 are independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl and C 1-4 haloalkyl; or R16 and R 17 Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocyclic ring;

[0073] R 18 Selected from hydrogen, C 1-4 Alkyl, C 1-3 Alkylene-R 23 , C 1-4 Haloalkyl, C 3-7 Cycloalkyl, 4- to 7-membered heterocyclyl, and 5- or 6-membered heteroaryl;

[0074] R 19 , R 20 , R 21 and R 22 Each independently selected from H and C 1-4 alkyl;

[0075] R 23 and R 24 are independently selected from hydrogen, C 1-4 Alkyl and C 3-7 Cycloalkyl;

[0076] R 25 Selected from OH, C 1-4 Alkoxy, C 3-7 Cycloalkyl, NR 28 R 29 、C(O)OR 30 and C(O)NR 31 R 32 ;

[0077] R 26 , R 27 , R 28 , R 29 , R 30 , R 31 and R 32 Each independently selected from H and C 1-4 Alkyl; and

[0078] n is 0, 1 or 2.

[0079] Specific compounds of the present invention include, for example, compounds of Formula I or pharmaceutically acceptable salts thereof, wherein, unless otherwise specified, X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 18 , R 23 , R 24 Each of and n has any meaning defined in any of paragraphs (1) to (94) above or below. For the avoidance of doubt, the scope of the present invention includes compounds of Formula I or pharmaceutically acceptable salts thereof, wherein any substituent definition defined herein may be combined with any other substituent definition also defined herein:

[0080] (1)X 1 is N;

[0081] (2)X 1 It is CH;

[0082] (3)X 2 Is O or NR 7 ;

[0083] (4)X 2 It is O;

[0084] (5)X 2 YesNR 7 ;

[0085] (6)X 2 Yes CR 8 R 9 ;

[0086] (7)X 3 is N;

[0087] (8)X 3 It is CH;

[0088] (9)X 4 is N;

[0089] (10)X 4 Yes CR 10 ;

[0090] (11)X 3 and X 4 One of them is N, and the condition is X 3 and X 4 It can’t all be N;

[0091] (12)X 3 is N, and X 4 Yes CR 10 ;

[0092] (13)R1 Selected from hydrogen, C 1-4 Alkyl, hydroxyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, halogen, NR 11 R 12 and C 3-7 Cycloalkyl;

[0093] (14)R 1 Selected from hydrogen, C 1-4 Alkyl, hydroxyl, C 1-4 Alkoxy and NR 11 R 12 ;

[0094] (15)R 1 Selected from H, C 1-4 Alkyl and NR 11 R 12 ;

[0095] (16)R 1 Selected from H, methyl and NH 2 ;

[0096] (17)R 1 is selected from H and methyl;

[0097] (18)R 1 It is hydrogen;

[0098] (19)R 2 Selected from hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, halogen, cyano, OR 18 , 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl and phenyl, wherein the 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Substitution of alkyl, halogen and cyano groups;

[0099] (20)R 2 Selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl, halogen, cyano, OR 18 , 5- or 6-membered heteroaryl and phenyl, wherein the 5- or 6-membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Substitution of alkyl, halogen and cyano groups;

[0100] (21)R 2 Selected from hydrogen, C 3-7 Cycloalkyl, halogen, cyano, OR 18 , 5- or 6-membered heteroaryl and phenyl;

[0101] (22)R 2 is selected from hydrogen, cyclopropyl, halogen, cyano, methoxy, 5-membered heteroaryl and phenyl;

[0102] (23)R 2 is selected from halogen, cyano, methoxy, 5-membered heteroaryl and phenyl;

[0103] (24)R 2 is selected from halogen and cyano;

[0104] (25)R 2 selected from chlorine and bromine;

[0105] (26)R 2 It is bromine;

[0106] (27)R 3 and R 4 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, hydroxyl, C 1-4 Alkoxy, halogen, cyano, 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl, and phenyl;

[0107] (28)R 3 and R 4 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 alkoxy, halogen and cyano;

[0108] (29)R 3 and R 4 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkynyl, C 1-4 Alkyl halides and cyano groups;

[0109] (30)R 3 and R 4 are independently selected from hydrogen, C 1-4 alkyl, ethynyl, trifluoromethyl, and cyano;

[0110] (31)R 3 and R 4 independently selected from hydrogen, methyl, ethyl, propyl, isopropyl, trifluoromethyl and cyano;

[0111] (32)R 3 is hydrogen or methyl, and R 4is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, trifluoromethyl and cyano;

[0112] (33)R 3 is hydrogen, and R 4 is selected from hydrogen, methyl and trifluoromethyl;

[0113] (34)R 3 and R 4 It's all hydrogen;

[0114] (35)R 3 is a methyl group, and R 4 is selected from methyl and cyano;

[0115] (36)R 3 and R 4 All are methyl;

[0116] (37)R 3 and R 4 Together with the carbon atoms to which they are attached, they form a 4- to 7-membered heterocyclic ring or a 3- to 6-membered cycloalkyl ring;

[0117] (38)R 3 and R 4 Together with the carbon atoms to which they are attached, they form a 5- to 6-membered heterocyclic ring or a 3- to 5-membered cycloalkyl ring;

[0118] (39)R 3 and R 4 Together with the carbon atoms to which they are attached, they form a 5-membered heterocyclic ring;

[0119] (40)R 1 and R 2 It can’t all be hydrogen;

[0120] (41)R 2 and R 3 It can’t all be hydrogen;

[0121] (42)R 1 , R 2 and R 3 It can’t all be hydrogen;

[0122] (43)R 1 , R 2 , R 3 and R 4 It can’t all be hydrogen;

[0123] (44)R 5 Selected from H and C 1-4 alkyl;

[0124] (45)R 5 is selected from H and methyl;

[0125] (46)R 5 It is hydrogen;

[0126] (47)R 6 Selected from halogen, C 1-4 Alkyl, C 1-4 Alkoxy, cyano and C 1-4 Haloalkyl;

[0127] (48)R 6 Selected from halogen, cyano and C 1-4 Haloalkyl;

[0128] (49)R 6 Selected from halogen and C 1-4 Haloalkyl;

[0129] (50)R 6 is selected from chloro, bromo and trifluoromethyl;

[0130] (51)R 6 is selected from chloro and trifluoromethyl;

[0131] (52)R 6 It is chlorine;

[0132] (53)R 7 It is hydrogen, C 1-4 alkyl or a 4- to 7-membered heterocyclic group, wherein the C 1-4 The alkyl group and the 4 to 7 membered heterocyclic group are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-4 Substitution of alkoxy, halogen and cyano substituents;

[0133] (54)R 7 It is hydrogen, C 1-4 Alkyl or 4 to 7 membered heterocyclic group;

[0134] (55)R 7 Is H or C 1-4 alkyl;

[0135] (56)R 7 is hydrogen or methyl;

[0136] (57)R 7 It is C 1-4 alkyl;

[0137] (58)R 7 It is methyl;

[0138] (59)R 7 and R 3 together with the atoms to which they are attached form a 5- or 6-membered heterocyclic ring, optionally substituted with one or more substituents selected from methyl, methoxy, fluoro, chloro and cyano;

[0139] (60)R 7 and R 3 Together with the atoms to which they are attached, they form a 5- or 6-membered heterocyclic ring;

[0140] (61)R 7 and R 3 Together with the atoms to which they are attached, they form a 5- or 6-membered heterocyclic ring;

[0141] (62)R 7 and R 3 Together with the atoms to which they are attached, they form a pyrrolidine ring, a piperazine ring, or a piperidine ring;

[0142] (63)R 7 and R 3 Together with the atoms to which they are attached, they form a pyrrolidine or piperidine ring;

[0143] (64)R 8 and R 9 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 Haloalkoxy, halogen, cyano, NR 21 R 22 , 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl, wherein the C 1-4 Alkyl, 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-4 Substitution of alkoxy, halogen and cyano substituents;

[0144] (65)R 8 and R 9 are independently selected from hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, halogen, and cyano;

[0145] (66)R 8 and R 9 are independently selected from hydrogen, C 1-4 Alkyl and C 1-4 Haloalkyl;

[0146] (67)R 8 and R 9 Each independently selected from H and C 1-4 alkyl;

[0147] (68)R 8 and R9 are independently selected from hydrogen and methyl;

[0148] (69)R 8 and R 9 It's all hydrogen;

[0149] (70)R 8 and R 9 Together with the carbon atoms to which they are attached, they form a 4- to 6-membered heterocyclic ring or a 3- to 5-membered cycloalkyl ring;

[0150] (71)R 8 and R 9 Together with the carbon atoms to which they are attached, they form a 3- to 5-membered cycloalkyl ring;

[0151] (72)R 8 and R 9 Together with the carbon atoms to which they are attached they form a cyclopropyl ring;

[0152] (73)R 10 Selected from C(O)NR 23 R 24 , C 1-4 Haloalkoxy, C 3-7 Cycloalkyl and 5- or 6-membered heteroaryl, wherein the C 3-7 Cycloalkyl and 5- or 6-membered heteroaryl are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-3 Alkylene-R 25 , hydroxyl, NR 26 R 27 and halogen substituted substituents;

[0153] (74)R 10 Selected from C(O)NR 23 R 24 , C 1-4 haloalkoxy, 4 to 7 membered heterocyclyl and 5- or 6-membered heteroaryl, wherein the 4 to 7 membered heterocyclyl and 5- or 6-membered heteroaryl are optionally substituted by one or more selected from C 1-2 Alkyl, C 1-2 Alkylene-R 25 and halogen substituted substituents;

[0154] (75)R 10 Selected from C(O)NR 23 R 24 , C 1-2 haloalkoxy and 5- or 6-membered heteroaryl, wherein the 5- or 6-membered heteroaryl is optionally substituted by one or more selected from C 1-2 Alkyl, C 1-2 Alkylene-R 25 and halogen substituted substituents;

[0155] (76)R 10 is a 5- or 6-membered heteroaryl group, optionally substituted by one or more selected from C 1-4 Alkyl, C 1-3 Alkylene-R 25 , hydroxyl, NR 26 R 27 and halogen substituted substituents;

[0156] (77)R 10 is a 5- or 6-membered heteroaryl group, optionally substituted by one or more selected from C 1-2 Alkyl and C 1-2 Alkylene-R 25 Substituents are substituted;

[0157] (78)R 10 is triazolyl, optionally substituted by one or more selected from C 1-2 Alkyl and C 1-2 Alkylene-R 25 Substituents are substituted;

[0158] (79)R 10 is triazolyl, optionally substituted by one or more selected from methyl and CH 2 -R 25 Substituents are substituted;

[0159] (80)R 10 is 2H-1,2,3-triazol-2-yl, optionally substituted with one or more selected from C 1-2 Alkyl and C 1-2 Alkylene-R 25 Substituents are substituted;

[0160] (81)R 10 is 2H-1,2,3-triazol-2-yl, optionally substituted by one or more selected from methyl and CH 2 -R 25 Substituents

[0161] replace;

[0162] (82)R 10 is 2H-1,2,3-triazol-2-yl;

[0163] (83)R 11 and R 12 are independently selected from hydrogen and methyl;

[0164] (84)R 11 and R 12 It's all hydrogen;

[0165] (85)R 13 and R14 are independently selected from hydrogen and methyl;

[0166] (86)R 13 and R 14 It's all hydrogen;

[0167] (87)R 18 Selected from H and C 1-4 alkyl;

[0168] (88)R 18 It is C 1-4 alkyl;

[0169] (89)R 18 It is methyl;

[0170] (90)R 23 and R 24 independently selected from hydrogen, methyl and cyclopropyl; for example selected from hydrogen and methyl; or selected from methyl and cyclopropyl;

[0171] (91)R 23 and R 24 It's all hydrogen;

[0172] (92) n is 0 or 1;

[0173] (93) n is 0;

[0174] (94)n is 1;

[0175] Suitably, X 1 As defined in any of paragraphs (1) to (2) above. Preferably, X 1 As defined in paragraph (1) above.

[0176] Suitably, X 2 As defined in any of paragraphs (3) to (6) above. Preferably, X 2 As defined in paragraph (3) above.

[0177] Suitably, X 3 As defined in any of paragraphs (7) to (8) above. Preferably, X 3 As defined in paragraph (7) above.

[0178] Suitably, X 4 As defined in any of paragraphs (9) to (10) above. Preferably, X 4 As defined in paragraph (10) above.

[0179] Suitably, X 3 and X 4 As defined in any of paragraphs (11) to (12) above. Preferably, X 3 and X4 As defined in paragraph (12) above.

[0180] Suitably, R 1 As defined in any of paragraphs (13) to (18) above. In one embodiment, R 1 As defined in paragraph (18) above.

[0181] Suitably, R 2 As defined in any of paragraphs (198) to (26) above. In one embodiment, R 2 As defined in paragraph (26) above.

[0182] Suitably, R 3 and R 4 As defined in any of paragraphs (27) to (39) above. In one embodiment, R 3 and R 4 As defined in paragraphs (33) to (36) above.

[0183] Suitably, R 1 To R 4 As defined in any of paragraphs (40) to (43) above.

[0184] Suitably, R 5 As defined in any of paragraphs (44) to (46) above. In one embodiment, R 5 As defined in paragraph (46) above.

[0185] Suitably, R 6 As defined in any of paragraphs (47) to (52) above. In one embodiment, R 6 As defined in any of paragraphs (51) to (52) above.

[0186] Suitably, R 7 As defined in any of paragraphs (53) to (58) above. In one embodiment, R 7 As defined in paragraph (58) above.

[0187] Suitably, R 7 and R 3 As defined in any of paragraphs (59) to (63) above. In one embodiment, R 7 and R 3 As defined in paragraph (63) above.

[0188] Suitably, R 8 and R 9 As defined in any of paragraphs (64) to (72) above. In one embodiment, R8 and R 9 As defined in any of paragraphs (67) to (69) above.

[0189] Suitably, R 10 As defined in any of paragraphs (73) to (82) above. In one embodiment, R 10 As defined in paragraph (82) above.

[0190] Suitably, R 11 and R 12 As defined in any of paragraphs (83) to (84) above. In one embodiment, R 11 and R 12 As defined in paragraph (84) above.

[0191] Suitably, R 13 and R 14 As defined in any of paragraphs (85) to (86) above.

[0192] Suitably, R 18 As defined in any of paragraphs (87) to (89) above. In one embodiment, R 18 As defined in paragraph (89) above.

[0193] Suitably, R 23 and R 24 As defined in any of paragraphs (90) to (91) above. In one embodiment, R 23 and R 24 As defined in paragraph (91) above.

[0194] Suitably, n is as defined in any of paragraphs (92) to (94) above. In one embodiment, n is as defined in paragraph (94) above.

[0195] Conveniently, the compound of formula (I) has one of the sub-structural formulae (IA) to (IJ) described below.

[0196] In another group of compounds, the compound has the structural formula IA shown below:

[0197]

[0198] Where X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 and R6 As defined above.

[0199] In another group of compounds, the compounds have the structural formula IA shown above, wherein X 1 As defined in any of paragraphs (1) to (2); 2 As defined in any of paragraphs (3) to (6); 3 As defined in any of paragraphs (7) to (8); 4 As defined in any of paragraphs (9) to (10); R 1 As defined in any of paragraphs (13) to (18) above; 2 As defined in any of paragraphs (19) to (26) above; 3 and R 4 As defined in any of paragraphs (27) to (39) above; R 5 As defined in any of paragraphs (44) to (46) above; and R 6 As defined in any of paragraphs (47) to (52) above.

[0200] In another group of compounds, the compound has the structural formula IB shown below:

[0201]

[0202] Where X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 10 and n are as defined above.

[0203] In another group of compounds, the compounds have the structural formula IB shown above, wherein X 1 As defined in any of paragraphs (1) to (2); 2 As defined in any of paragraphs (3) to (6); 1 As defined in any of paragraphs (13) to (18) above; 2 As defined in any of paragraphs (19) to (26) above; 3 and R 4 As defined in any of paragraphs (27) to (39) above; R 5 As defined in any of paragraphs (44) to (46) above; R 6 As defined in any of paragraphs (47) to (52) above; 10As defined in any of paragraphs (73) to (82) above; and n is as defined in any of paragraphs (92) to (94) above.

[0204] In another group of compounds, the compound has the structural formula IC shown below:

[0205]

[0206] Where X 1 , X 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 10 As defined above.

[0207] In another group of compounds, the compounds have the structural formula IC shown above, wherein X 1 As defined in any of paragraphs (1) to (2); 2 As defined in any of paragraphs (3) to (6); 1 As defined in any of paragraphs (13) to (18) above; 2 As defined in any of paragraphs (19) to (26) above; 3 and R 4 As defined in any of paragraphs (27) to (39) above; R 5 As defined in any of paragraphs (44) to (46) above; R 6 As defined in any of paragraphs (47) to (52) above; and R 10 As defined in any of paragraphs (73) to (82) above.

[0208] In another group of compounds, the compound has the structural formula ID shown below:

[0209]

[0210] Where X 1 , X 2 , R 1 , R 2 , R 3 , R 4 and R 6 As defined above.

[0211] In another group of compounds, the compounds have the structural formula ID shown above, wherein X 1 As defined in any of paragraphs (1) to (2); 2As defined in any of paragraphs (3) to (6); 1 As defined in any of paragraphs (13) to (18) above; 2 As defined in any of paragraphs (19) to (26) above; 3 and R 4 As defined in any of paragraphs (27) to (39) above; and R 6 As defined in any of paragraphs (47) to (52) above.

[0212] In another group of compounds, the compound has the structural formula IE shown below:

[0213]

[0214] Where X 1 , X 2 , R 1 , R 3 , R 4 and R 6 As defined above.

[0215] In another group of compounds, the compounds have the structural formula IE shown above, wherein X 1 As defined in any of paragraphs (1) to (2); 2 As defined in any of paragraphs (3) to (6); 1 As defined in any of paragraphs (13) to (18) above; 3 and R 4 As defined in any of paragraphs (27) to (39) above; and R 6 As defined in any of paragraphs (47) to (52) above.

[0216] In another group of compounds, the compound has the structural formula IF shown below:

[0217]

[0218] Where X 1 , X 2 , R 1 , R 3 and R 4 As defined above.

[0219] In another group of compounds, the compounds have the structural formula IF as shown above, wherein X 1 As defined in any of paragraphs (1) to (2); 2 As defined in any of paragraphs (3) to (6); 1 As defined in any of paragraphs (13) to (18) above; and R3 and R 4 As defined in any of paragraphs (27) to (39) above.

[0220] In another group of compounds, the compound has one of the structural formulas IG, IH or IJ as shown below:

[0221] Where X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 10 As defined above.

[0222] In another group of compounds, the compound has one of the structural formulas IG, IH or IJ as shown above, wherein X 2 As defined in any of paragraphs (3) to (6); 3 As defined in any of paragraphs (7) to (8); 4 As defined in any of paragraphs (9) to (10); R 1 As defined in any of paragraphs (13) to (18) above; 2 As defined in any of paragraphs (19) to (26) above; 3 and R 4 As defined in any of paragraphs (27) to (39) above; R 5 As defined in any of paragraphs (44) to (46) above; R 6 As defined in any of paragraphs (47) to (52) above; and R 10 As defined in any of paragraphs (73) to (82) above.

[0223] In embodiments of the compounds of Formula I or Formulas IA to IJ, when X 2 Is O or NR 7 When R 3 and R 4 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, C 1-4 haloalkoxy, halogen, cyano, 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl, and phenyl; wherein said C 1-4Alkyl, 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Alkyl, hydroxyl, C 1-4 Alkoxy, halogen and cyano are substituted; or R 3 and R 4 Together with the carbon atoms to which they are attached, they form an oxo group, a 4- to 7-membered heterocyclic ring, or a 3- to 6-membered cycloalkyl ring.

[0224] Specific compounds of the present invention include any of the following: 5-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,4-dihydroquinoline-1(2H)-carboxamide;

[0225] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-bromo-3,4-dihydroquinoline-1(2H)-carboxamide;

[0226] N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-methoxy-3,4-dihydroquinoline-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide;

[0227] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2-methyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide;

[0228] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2-cyano-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide;

[0229] N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-cyano-3,4-dihydroquinoline-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(pyridin-3-yl)-3,4-dihydroquinoline-1(2H)-carboxamide;

[0230] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(oxazol-2-yl)-3,4-dihydroquinoline-1(2H)-carboxamide;

[0231] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(thiazol-2-yl)-3,4-dihydroquinoline-1(2H)-carboxamide;

[0232] cis-N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-bromo-3,4-dimethyl-3,4-dihydroquinoline-1(2H)-carboxamide;

[0233] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-phenyl-3,4-dihydroquinoline-1(2H)-carboxamide;

[0234] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide;

[0235] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(1,3,4-thiadiazol-2-yl)-3,4-dihydroquinoline-1(2H)-carboxamide;

[0236] 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,3-dimethyl-3,4-dihydroquinoline-1(2H)-carboxamide;

[0237] 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-4-methyl-3,4-dihydroquinoxaline-1(2H)-carboxamide;

[0238] 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,4-dihydro-1,7-naphthyridine-1(2H)-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-cyano-2-methyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide;

[0239] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0240] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethynyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide;

[0241] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0242] N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-cyclopropyl-3,4-dihydro-1,7-naphthyridine-1(2H)-carboxamide;

[0243] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2,2-dimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide;

[0244] N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyclopropyl-2,2-dimethyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0245] (S)-1-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-6a,7,8,9-tetrahydropyrido[3,4-e]pyrrolo[1,2-a]pyrazine-5(6H)-carboxamide;

[0246] (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1,2-dimethyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide;

[0247] 8'-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-4,5-dihydro-2H-spiro[furan-3,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-carboxamide;

[0248] 1-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-6,6a,7,8,9,10-hexahydro-5H-bipyrido[1,2-a:3',4'-e]pyrazine-5-carboxamide;

[0249] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-methyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide;

[0250] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-methyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0251] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1,2,2-trimethyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide;

[0252] 8-Chloro-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0253] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide;

[0254] (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethyl-1-methyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide;

[0255] (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-isopropyl-1-methyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide;

[0256] 7-amino-8-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0257] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide;

[0258] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0259] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0260] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0261] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0262] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0263] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0264] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-isopropyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0265] 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-cyclopropyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0266] N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyano-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0267] N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyano-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0268] N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-methoxy-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0269] 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-cyano-3,4-dihydro-1,7-naphthyridine-1(2H)-carboxamide;

[0270] N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-cyano-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0271] 8-Cyano-N-(5-cyano-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0272] 8-cyano-N-(6-(cyclopropyl(methyl)carbamoyl)-5-(difluoromethyl)pyridin-3-yl)-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0273] 8-cyano-7-methyl-2-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; and

[0274] N-(5-chloro-6-(difluoromethoxy)pyridin-3-yl)-8-cyano-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0275] or a pharmaceutically acceptable salt thereof.

[0276] The various functional groups and substituents that make up the compounds of the invention are typically selected so that the molecular weight of the compound does not exceed 1000. More typically, the molecular weight of the compound will be less than 750, such as less than 700, or less than 650.

[0277] Suitable or preferred features of any compound of the invention may also be suitable features of any other aspect.

[0278] Suitable pharmaceutically acceptable salts of the compounds of the invention are, for example, acid addition salts of the compounds of the invention with sufficient basicity, for example, with, for example, inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, trifluoroacetic acid, formic acid, citric acid or maleic acid. In addition, suitable pharmaceutically acceptable salts of the compounds of the invention with sufficient acidity are alkali metal salts, such as sodium or potassium salts, alkaline earth metal salts, such as calcium or magnesium salts, ammonium salts or salts formed with organic bases providing physiologically acceptable cations, such as salts formed with methylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

[0279] Compounds that have the same molecular formula but differ in the nature or order of bonding of their atoms or the arrangement of their atoms in space are called "isomers". Isomers that differ in the arrangement of their atoms in space are called "stereoisomers". Compounds that differ in the arrangement of their atoms in space are called "stereoisomers". Stereoisomers that are not mirror images of each other are called "diastereomers" and those that are non-superimposable mirror images of each other are called "enantiomers". When a compound has an asymmetric center, for example it is bonded to four different groups, a pair of enantiomers may exist. Enantiomers can be characterized by the absolute configuration of their asymmetric center and described by the R- and S-sequence rules of Cahn and Prelog, or by the way in which the molecule rotates the plane of polarized light and is designated as right-handed or left-handed (i.e., as (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. Compounds containing equal proportions of enantiomers are called "racemic compounds".

[0280] The compounds of the present invention typically have one or more asymmetric centers; therefore, such compounds can be produced in the form of individual (R) or (S) stereoisomers or mixtures thereof. Unless otherwise indicated, the description or naming of a particular compound in the specification and claims is intended to include its individual enantiomers, diastereomers, and mixtures, racemic or other forms thereof. Methods for determining stereochemistry and separating stereoisomers are well known in the art (see discussion in Chapter 4 of "Advanced Organic Chemistry", 4th edition J. March, John Wiley and Sons, New York, 2001), for example by synthesis from optically active raw materials or by resolution of racemic forms. Some compounds of the present invention may have geometric isomeric centers (E and Z isomers). It should be understood that the present invention includes all optical isomers, diastereomers and geometric isomers and mixtures thereof having MALT1 inhibitory activity.

[0281] The present invention also includes compounds of the present invention as defined herein, which contain one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H. 2 H(D) and 3 H(T); C can be in any isotopic form, including 12 C. 13 C and 14 C; and O can be in any isotopic form, including 16 O and 18 O and so on.

[0282] It will also be appreciated that certain compounds of the invention may exist in solvated as well as unsolvated forms, such as hydrated forms. It will be appreciated that the invention encompasses all such solvated forms which possess MALT1 inhibitory activity.

[0283] It is also to be understood that certain compounds of the invention may exhibit polymorphism and that the invention encompasses all such forms which possess MALT1 inhibitory activity.

[0284] Compound of the present invention can exist with many different tautomeric forms, and all these forms are included when mentioning compound of the present invention.In order to avoid doubt, when a kind of compound can exist with one in several tautomeric forms, and only specifically describe or show one, all other are included in compound of the present invention.The example of tautomeric form comprises keto-, enol-and enolate-form, for example following tautomer pair: keto / enol (as shown below), imines / enamine, amide / imino alcohol, amidine / amidine, nitroso-group / oxime, thioketone / enethiol and nitro / aci-nitro.

[0285]

[0286] The compounds of the present invention containing amine functional groups can also form N-oxides. The compounds of formula I containing amine functional groups mentioned herein also include N-oxides. When the compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form N-oxides. Specific examples of N-oxides are N-oxides of nitrogen atoms of tertiary amines or nitrogen-containing heterocycles. N-oxides can be formed by treating the corresponding amine with an oxidant (e.g., hydrogen peroxide or peracid (e.g., peroxycarboxylic acid)), see, for example, Jerry March's "Advanced Organic Chemistry", 4th edition, Wiley Interscience, pages. More specifically, N-oxides can be prepared by the procedure of LW Deady (Syn. Comm. 1977, 7, 509-514), in which an amine compound is reacted with meta-chloroperbenzoic acid (MCPBA) in, for example, an inert solvent (e.g., dichloromethane).

[0287] The compounds of the present invention can be administered in the form of prodrugs that decompose in the human or animal body to release the compounds of the present invention. Prodrugs can be used to change the physical properties and / or pharmacokinetic properties of the compounds of the present invention. Prodrugs can be formed when the compounds of the present invention contain suitable groups or substituents, and the modifying groups can be attached to the groups or substituents.

[0288] Therefore, the present invention includes those compounds of formula I as defined above, when obtained by organic synthesis, and when obtained in the human or animal body by cleavage of its prodrug. Therefore, the present invention includes those compounds of formula I produced by organic synthesis methods, and such compounds produced in the human or animal body by metabolism of precursor compounds, i.e., compounds of formula I, which can be synthetically produced compounds or metabolically produced compounds.

[0289] Suitable pharmaceutically acceptable prodrugs of the compounds of formula I are drugs that, based on sound medical judgment, are suitable for administration to the human or animal body without undesirable pharmacological activity and undue toxicity.

[0290] Various forms of prodrugs have been described, for example in the following documents:

[0291] a) Methods in Enzymology ,Vol. 42 , p.309-396, edited by K.Widder et al. (Academic Press, 1985);

[0292] b) Design of Pro-drugs, edited by H. Bundgaard, (Elsevier, 1985);

[0293] c) A Textbook of Drug Design and Development, edited by Krogsgaard-Larsen and H.Bundgaard, Chapter 5 "Design and Application of Pro-drugs", by H.Bundgaardp.113-191 (1991);

[0294] d) H.Bundgaard, Advanced Drug Delivery Reviews , 8 ,1-38(1992);

[0295] e) H.Bundgaard et al., Journal of Pharmaceutical Sciences , 77 ,285(1988);

[0296] f) N. Kakeya et al., Chem.Pharm.Bull. ,32 ,692(1984);

[0297] g) T. Higuchi and V. Stella, "Pro-Drugs as Novel Delivery Systems", ACSSymposium Series, Volume 14; and

[0298] h) E. Roche (editor), "Bioreversible Carriers in Drug Design", Pergamon Press, 1987.

[0299] The in vivo effects of the compounds of Formula I may be exerted in part by one or more metabolites formed in the human or animal body following administration of the compounds of Formula I. As described above, the in vivo effects of the compounds of Formula I may also be exerted by the metabolism of precursor compounds (prodrugs).

[0300] It will also be appreciated that the compounds of Formula I may also be covalently linked (at any suitable position) to other groups, for example, solubilizing moieties (e.g., PEG polymers), moieties that enable them to bind to a solid support (e.g., biotin-containing moieties), and targeting ligands (e.g., antibodies or antibody fragments).

[0301] synthesis

[0302] In the descriptions of the following synthetic methods and in any referenced synthetic methods for preparing starting materials, it is understood that all proposed reaction conditions, including the choice of solvents, reaction atmospheres, reaction temperatures, duration of experiments and work-up procedures, can be selected by one skilled in the art.

[0303] Those skilled in the art of organic synthesis will appreciate that the functionality of the various parts of the molecule must be compatible with the reagents and reaction conditions used.

[0304] The necessary starting materials can be obtained by standard methods of organic chemistry. The preparation of such starting materials is described in conjunction with the following representative method variants and in the accompanying examples. Alternatively, the necessary starting materials can be obtained by procedures similar to those described, which procedures are within the ordinary skill of organic chemists.

[0305] It should be understood that during the synthesis of the compounds of the invention in the methods defined below, or during the synthesis of certain starting materials, it may be necessary to protect certain substituents to prevent them from undesirable reactions. A skilled chemist will understand when such protection is required and how to place such protecting groups in appropriate positions and then remove them.

[0306] For examples of protecting groups, see one of the many general texts on the subject, such as "Protecting groups in Organic Synthesis (3rd edition), John Wiley & Sons, NY (1999)", T. Greene & P. ​​Wuts. Protecting groups can be removed by any convenient method described in the literature or known to the skilled chemist to be suitable for removing the protecting group in question, such method being selected so as to achieve removal of the protecting group with minimal interference with other groups in the molecule.

[0307] Thus, if reactants include groups such as amino, carboxyl or hydroxy, it may be necessary to protect this group in some of the reactions mentioned herein.

[0308] For example, suitable protecting groups for amino or alkylamino groups are, for example, acyl groups, for example, alkanoyl groups such as acetyl; alkoxycarbonyl groups, for example, methoxycarbonyl, ethoxycarbonyl or tert-butyloxycarbonyl; arylmethoxycarbonyl groups, for example, benzyloxycarbonyl; or aroyl groups, for example, benzoyl. The deprotection conditions for the above-mentioned protecting groups must vary with the choice of protecting groups. Thus, for example, acyl groups such as alkanoyl or alkoxycarbonyl or aroyl groups can be removed by, for example, hydrolysis with a suitable base such as an alkali metal hydroxide such as lithium hydroxide or sodium hydroxide. Alternatively, acyl groups such as tert-butyloxycarbonyl can be removed, for example, by treatment with a suitable acid such as hydrochloric acid, sulfuric acid or phosphoric acid or trifluoroacetic acid, and arylmethoxycarbonyl groups such as benzyloxycarbonyl can be removed, for example, by hydrogenation over a catalyst such as palladium on carbon, or by reaction with a Lewis acid such as BF 3 .OET 2 A suitable protecting group for an amino or alkylamino group is, for example, a substituted benzyl group, such as 4-methoxybenzyl or 2,4-dimethoxybenzyl. Such a protecting group can be removed, for example, by treatment with a suitable acid, such as hydrochloric acid, sulfuric acid or phosphoric acid or trifluoroacetic acid. A suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group, which can be removed by treatment with an alkylamine, such as dimethylaminopropylamine, or with hydrazine.

[0309] Those skilled in the art will recognize that the compounds of the present invention can be prepared in a known manner in a variety of ways. The compounds of formula I can be prepared by the methods given below, by the methods given in the general procedures or syntheses of the embodiments, or by similar methods. The described routes are merely examples of some methods that can be used to synthesize compounds of formula I, and those skilled in the art will understand that the order of reaction steps is not limited to those described. It should also be understood that the allocation of nucleophiles and electrophiles is not limited to those described herein, and in some cases, it may be appropriate to reverse the allocation. Different methods of synthetic chemistry strategies are described in "Organic Synthesis: The Disconnection Approach", Second Edition, S. Warren and P. Wyatt (2008).

[0310] The compound of formula I, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X 1 , X 2 , X 3 and X 4 As defined above, it can be prepared by condensing compounds of formula II and formula III using a suitable coupling agent in step (A) (Scheme A). Suitable coupling agents include, for example, phosgene, diphosgene, triphosgene, phenyl chloroformate, 4-nitrophenyl chloroformate or 1,1-carbonyldiimidazole.

[0311] Plan A

[0312]

[0313] The compound of formula I, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , X 1 , X 2 , X 3 and X 4 As defined above, it can also be prepared by converting the acid of formula IV into the corresponding isocyanate using, for example, diphenylphosphoryl azide in step (b) and coupling with an amine of formula II, as shown in Scheme B

[0314] Plan B

[0315]

[0316] The general preparation methods of some typical compounds of formula II are described below and are generally prepared from starting materials that are either commercially available or prepared by standard synthetic methods commonly used by those skilled in the art of organic chemistry. Compounds of formula III and IV can be prepared using similar reaction schemes described in WO2015181747, WO2017081641, WO2018020474 and WO202008222.

[0317] The compound of formula II, wherein R 1 , R 2 , R 3 , R 4 and X 1 As defined above, and X 2 =O, can be formed as shown in Scheme C.

[0318] Plan C

[0319]

[0320] Alkylation step (c) of a suitable phenol of formula V with a suitable alkylating agent of formula VI containing a leaving group (LG) provides a compound of formula VII. Suitable bases include, for example, sodium hydride, sodium bis(trimethylsilyl)amide, lithium diisopropylamide or triethylamine, and leaving groups include, for example, chlorine, bromine or iodine. Another route to prepare a compound of formula VII includes step (f) of replacing a suitable aromatic leaving group in a compound of formula IX with a suitable alcohol. Suitable leaving groups include, for example, fluorine or chlorine. Reduction of the nitro group in the compound of formula VII with a suitable reducing agent followed by cyclization to obtain a cyclic amide compound of formula VIII step (d). Suitable reducing agents include, for example, zinc in acetic acid, iron in acetic acid or palladium on carbon in the presence of hydrogen. Reduction of the compound of formula VIII with a suitable reducing group step (e) obtains a compound of formula II. Suitable reducing agents include, for example, BH 3 -Me 2 S, lithium aluminum hydride or BH 3 -THF.

[0321] The compound of formula II, wherein R 1 , R 2 , R 3 , R 4 , R 7 and X 1 As defined above, and X 2 =N 7 , can be formed as shown in Scheme D. Step (g) of displacing a suitable leaving group in a compound of Formula IX with a suitable amino ester of Formula X provides a compound of Formula XI. Suitable leaving groups include, for example, fluorine or chlorine. Steps (d) and (e) are as described in Scheme C.

[0322] Plan D

[0323]

[0324] The compound of formula II, wherein R 1 , R 2 , R 7 and X 1 As defined above, and X 2 =NR 7 , which can be formed as shown in Scheme E. The primary amine of Formula XIII is replaced with a suitable leaving group, and step (h) provides a compound of Formula XIV. Suitable leaving groups include, for example, fluoride or chloride. Step (d) As described in Scheme C, a suitable "ethylene synthon" can be used to achieve ring closure to provide a compound of Formula II. Suitable ethylene synthons include, for example, in the presence of a reducing agent such as NaBH(OAc) 3 The presence of glyoxal or ethylene dibromide in the presence of a base such as triethylamine.

[0325] Plan E

[0326]

[0327] The compound of formula II, wherein R 1 , R 2 , R 3 , R 4 , X 1 and X 2 As defined above, it can be formed as shown in Scheme F.

[0328] Plan F

[0329]

[0330] With a suitably protected diamine of formula XVII (wherein X 2 YesNR 7 ) or ethanolamine (where X 2 is O) selectively displaces the leaving group LG in the compound of formula XVI 1 , to obtain the compound of formula XVIII in step (j). Suitable LG 1 Leaving groups include, for example, fluoride or chloride. Selective removal of the protecting group PG 1 Step (k) yields a compound of formula XIX. 1 This includes, for example, tert-butyloxycarbonyl, which can be removed with acid at room temperature. Transition metal-catalyzed leaving groups LG 2The cyclization step (1) is substituted by a nitrogen atom to give a compound of formula XX. Suitable transition metal catalyzed cyclizations include, for example, the use of Pd in ​​the presence of BINAP and a suitable base such as tert-BuONa. 2 (dba) 3 With a suitable leaving group LG 2 For example, bromine or iodine reaction. Removal of the last protecting group PG step (m) yields a compound of formula II. Suitable PG includes, for example, 2,4-dimethoxybenzyl, which can be removed with acid at elevated temperature.

[0331] The compound of formula II, wherein R 1 , R 2 , R 3 , R 4 , R 8 , R 9 and X 1 As defined above, and X 2 =CR 8 R 9 , which can be formed as shown in Scheme G. The compound of formula XXI is converted into a suitable organometallic reagent and then added to the compound of formula XXII, step (n) to obtain the compound of formula XXIII. For example, it can be converted into a suitable organometallic reagent by reaction with tetrakistriphenylphosphine palladium and a suitable base such as sodium carbonate. Steps (d) and (e) are described for Scheme C. By treating the compound of formula XXIV and R with a suitable base 4 -LG step (o), further substituents can be introduced, such as R 4 Suitable bases include, for example, sodium hydride, sodium bis(trimethylsilyl)amide and lithium diisopropylamide, and suitable LGs include, for example, bromine, iodine or triflate.

[0332] Plan G

[0333]

[0334] The compound of formula II, wherein R 1 , R 2 , R 3 , R 4 , X 1 and X 2 As defined above, it can be formed as shown in Scheme H. Alkylation step (p) of the compound of formula XXVI prepared as described in Schemes C and D, wherein R 3 and R 4 is H, using a suitable base and R 3 LG and R 4 LG, resulting in the formation of a compound of formula XXVII - sequentially (R 3 ≠R 4 ) or possibly in a single step (R3 =R 4 ). Suitable bases include, for example, sodium hydride, sodium bis(trimethylsilyl)amide and lithium diisopropylamide, and suitable LG include, for example, bromine, iodine or triflate. Step (e) is as described in Scheme C.

[0335] Scheme H

[0336]

[0337] The compound of formula II, wherein R 1 , R 2 , R 3 , R 4 , X 1 and X 2 As defined above, the bromo compound of formula XXVIII can be formed as shown in Scheme I. 2 This transformation includes, for example, converting the bromine into the corresponding boronic acid / ester, followed by reaction with a suitable R 2 -Br reaction or with appropriate R 2 -B(OH) 2 Step (e) is as described in Scheme C.

[0338] Scheme I

[0339]

[0340] The compound of formula II, wherein R 1 , R 2 , R 3 , R 4 and X 1 As defined above, and X 2 does not exist, can be formed as shown in Scheme J. By using a suitable base and R 3 LG and R 4 LG, the alkylation step (q) of the compound of formula XXX leads to the formation of the compound of formula XXXI - which can be carried out in sequence (R 3 ≠R 4 ) or possibly in a single step (R 3 =R 4 ). Suitable bases include, for example, sodium hydride, sodium bis(trimethylsilyl)amide and lithium diisopropylamide, and suitable LG include, for example, bromine, iodine or triflate. Step (e) is as described in Scheme C.

[0341] Plan J

[0342]

[0343] The compound of formula II, wherein R 1 , R 2 , R 8 , R 9 , R 3 , R 4 and X 1 As defined above, X 2 Yes CR 8 or CR 9 , which can be formed as shown in Scheme K. Reduction of the pyridyl ring of the compound of formula XXXII in step (r) provides a compound of formula II. Suitable reduction conditions include, for example, hydrogen in the presence of platinum (IV) oxide or in IrCl 2 (COD) in the presence of hydrogen.

[0344] Plan K

[0345]

[0346] The compound of formula II, wherein R 1 , R 2 , R 8 , R 9 , R 3 , R 4 and X 1 As defined above, this may be formed as shown in Scheme L. A ring expansion step of the ketone of formula XXXIII may form a compound of formula XXV. Suitable reducing conditions include, for example, the use of sodium azide in the presence of an acid such as sulfuric acid. Step (e) is as described in Scheme C.

[0347] Plan L

[0348]

[0349] The compound of formula II, wherein R 1 , R 2 , R 8 , R 9 , R 3 , R 4 and X 1 As defined above, and X 2 Yes CR 8 R 9 , which can be formed as shown in Scheme M. A suitable cyclization step (t) of an acrylamide of formula XXXIV can provide an amide of formula XXXV. Suitable cyclization conditions include, for example, the use of aluminum chloride. Step (e) is as described in Scheme C.

[0350] Plan M

[0351]

[0352] Pharmaceutical composition

[0353] The compounds of the present invention are usually, but not necessarily, formulated into pharmaceutical compositions before administration to patients. Therefore, according to another aspect of the present invention, a pharmaceutical composition is provided, comprising a compound of the present invention as defined above or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, diluents or carriers.

[0354] The pharmaceutical composition of the present invention can be prepared and packaged in bulk form, wherein a safe and effective amount of the compound of the present invention can be extracted and then administered to the patient in the form of a powder or syrup. Alternatively, the pharmaceutical composition of the present invention can be prepared and packaged in a unit dosage form, wherein each physically discrete unit contains a safe and effective amount of the compound of the present invention. When prepared in a unit dosage form, the pharmaceutical composition of the present invention typically contains 1 mg to 1000 mg.

[0355] The compositions of the present invention may be in a form suitable for oral use (e.g., as tablets, capsules, caplets, pills, lozenges, powders, syrups, elixirs, suspensions, solutions, emulsions, sachets and cachets), in a form suitable for topical use (e.g., as creams, ointments, lotions, solutions, pastes, sprays, foams and gels), in a form suitable for transdermal administration, for example, via a transdermal patch, in a form suitable for administration by inhalation (e.g., as dry powders, aerosols, suspensions and solutions), for administration by insufflation (e.g., as a fine powder) or for parenteral administration (e.g., as a sterile aqueous or oily solution for intravenous, subcutaneous, intramuscular, intraperitoneal or intramuscular administration, or as a suppository for rectal administration).

[0356] As used herein, "pharmaceutically acceptable excipient" refers to a pharmaceutically acceptable material, composition or carrier that is involved in giving a pharmaceutical composition its form or consistency. Each excipient must be compatible with the other ingredients of the pharmaceutical composition when mixed, thereby avoiding interactions that would significantly reduce the efficacy of the compounds of the invention when administered to a patient and interactions that would render the pharmaceutical composition unpharmaceutically acceptable. In addition, each excipient must be of sufficiently high purity to make it pharmaceutically acceptable.

[0357] Suitable pharmaceutically acceptable excipients will vary depending on the particular dosage form selected. In addition, suitable pharmaceutically acceptable excipients may be selected for specific functions in the composition. For example, certain pharmaceutically acceptable excipients may be selected because they can promote the production of uniform dosage forms. Certain pharmaceutically acceptable excipients may be selected based on their ability to promote the production of stable dosage forms. Certain pharmaceutically acceptable excipients may be selected because they can promote the administration of one or more compounds of the present invention from one organ or part of the body to another organ or part of the body. Certain pharmaceutically acceptable excipients may be selected based on their ability to enhance patient compliance.

[0358] Suitable pharmaceutically acceptable excipients include excipients of the following types: diluents, fillers, adhesives, disintegrating agents, lubricants, glidants, granulating agents, coating agents, wetting agents, solvents, cosolvents, suspending agents, emulsifiers, sweeteners, flavoring agents, taste masking agents, coloring agents, anticaking agents, wetting agents, chelating agents, plasticizers, tackifiers, antioxidants, preservatives, stabilizers, surfactants and buffers. It will be appreciated by those skilled in the art that some pharmaceutically acceptable excipients can perform more than one function, and can perform alternative functions according to the amount of the excipient present in the preparation and other components present in the preparation.

[0359] The knowledge and skills possessed by those skilled in the art enable them to select suitable pharmaceutically acceptable excipients of appropriate amounts for use in the present invention. In addition, those skilled in the art have access to many resources describing pharmaceutically acceptable excipients that can be used to select suitable pharmaceutically acceptable excipients. Examples include Remington's Pharmaceutical Sciences (Mack Publishing Company), The Handbook of Pharmaceutical Additives (Gower Publishing Limited), and The Handbook of Pharmaceutical Excipients (the American Pharmaceutical Association and the Pharmaceutical Press).

[0360] The pharmaceutical compositions of the present invention are prepared using techniques and methods known to those skilled in the art. Some methods commonly used in the art are described in Remington's Pharmaceutical Sciences (Mack Publishing Company).

[0361] The amount of active ingredient combined with one or more excipients to produce a single dosage form will necessarily vary depending on the host being treated and the particular route of administration. For example, a formulation for oral administration to humans typically contains, for example, 0.5 mg to 0.5 g of active agent (more suitably 0.5 to 100 mg, such as 1 to 30 mg), mixed with an appropriate and convenient amount of excipients, which may comprise from about 5% to about 98% by weight of the total composition.

[0362] According to well-known medical principles, the size of the dose of the compound of formula I for therapeutic or preventive purposes will naturally vary depending on the nature and severity of the disease, the age and sex of the animal or patient and the route of administration.

[0363] When the compound of the present invention is used for treatment or prevention purposes, the compound is usually administered so as to obtain a daily dose (if necessary, in divided doses) within the range of, for example, 0.1 mg / kg to 75 mg / kg body weight. In general, when a parenteral route is adopted, a lower dose will be administered. Therefore, for example, for intravenous or intraperitoneal administration, a dose within the range of 0.1 mg / kg to 30 mg / kg body weight is usually used. Similarly, for inhalation administration, a dose within the range of, for example, 0.05 mg / kg to 25 mg / kg body weight will be used. Oral administration is also suitable, especially in tablet form. Typically, a unit dosage form will contain about 0.5 mg to 0.5 g of the compound of the present invention.

[0364] Route of administration

[0365] The compounds of the invention or pharmaceutical compositions comprising the active compounds may be administered to the subject by any convenient route of administration, whether systemically / peripherally or locally (ie, at the site of desired action).

[0366] Routes of administration include, but are not limited to, oral (e.g., by ingestion); buccal; sublingual; transdermal (including, for example, by patch, plaster, etc.); transmucosal (including, for example, by patch, plaster, etc.); intranasal (e.g., by nasal spray); ocular (e.g., by eye drops); pulmonary (e.g., using, for example, an aerosol, by inhalation or insufflation therapy, such as through the mouth or nose); rectal (e.g., by suppository or enema); vaginal (e.g., by vaginal suppository); parenteral, such as by injection, including subcutaneous, intradermal, intramuscular, intravenous, intraarterial, intracardiac, intrathecal, intraspinal, intracapsular, subcapsular, intraorbital, intraperitoneal, intratracheal, subcutaneous, intraarticular, subarachnoid, and intrasternal; by implantation of a reservoir or depot, such as subcutaneously or intramuscularly.

[0367] In a preferred embodiment, the compound of the invention as defined herein, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition as defined herein, is administered orally or by injection, for example conveniently by oral administration.

[0368] Therapeutic uses and applications

[0369] The compounds of the present invention are inhibitors of MALT1. Therefore, they are potentially useful therapeutic agents for treating diseases or conditions mediated by MALT1.

[0370] Thus, in one aspect, the invention relates to a compound of the invention as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in therapy.

[0371] In another aspect, the invention relates to a compound of the invention as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein, for use in the treatment of a disease or condition mediated by MALT1.

[0372] In another aspect, the present invention relates to a method of treating a disease or condition mediated by MALT1, said method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of the present invention as defined herein, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as defined herein.

[0373] Examples of specific diseases or conditions that compounds of formula (I) and their pharmaceutically acceptable salts can be used to treat include, but are not limited to:

[0374] i) Lymphomas, leukemias, carcinomas and sarcomas; e.g. non-Hodgkin lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenstrom's macroglobulinemia, lymphoblastic T-cell leukemia, chronic myeloid leukemia (CML), hairy cell leukemia, acute lymphoblastic T

[0375] leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal cancer / colon cancer, prostate cancer, including non-small cell lung cancer, stomach cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, Ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial carcinoma, vulvar cancer, esophageal cancer, salivary gland cancer, nasopharyngeal cancer, cheek cancer, oral cancer, or GIST (gastrointestinal stromal tumor);

[0376] and

[0377] ii) immune diseases, including autoimmune diseases and inflammatory diseases; for example, arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatitis, Crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allogeneic transplant rejection, acute or chronic graft-versus-host disease, dermatitis including atopic dermatitis, dermatomyositis, psoriasis, Behcet's disease, uveitis, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Sjögren's syndrome, vesicular disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic diseases, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, lung disease, including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, berylliosis or polymyositis.

[0378] In particular, the compounds of the present invention (including pharmaceutically acceptable salts) can be used to treat lymphomas, such as non-Hodgkin's lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

[0379] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition for use in the treatment of non-Hodgkin's lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Macroglobulinemia, lymphoblastic T-cell leukemia, chronic myeloid leukemia (CML), hairy cell leukemia, acute lymphoblastic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal cancer / colon cancer, prostate cancer, including non-small cell lung cancer, gastric cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, Ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial carcinoma, vulvar cancer, esophageal cancer, salivary gland cancer, nasopharyngeal cancer, cheek cancer, oral cancer, GIST (gastrointestinal stromal tumor), Arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatitis, Crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, dermatitis including atopic dermatitis, dermatomyositis, psoriasis, Behcet's disease, uveitis, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Sjögren's syndrome, vesicular disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic disease, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, lung disease including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, berylliosis, or polymyositis.

[0380] In another aspect, the present invention provides a compound as defined herein or a pharmaceutically acceptable salt thereof or a pharmaceutical composition for use in the treatment of non-Hodgkin lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

[0381] In another aspect, the present invention provides a method for treating the following diseases: non-Hodgkin lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Macroglobulinemia, lymphoblastic T-cell leukemia, chronic myeloid leukemia (CML), hairy cell leukemia, acute lymphoblastic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal cancer / colon cancer, prostate cancer, including non-small cell lung cancer, gastric cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, Ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial carcinoma, vulvar cancer, esophageal cancer, salivary gland cancer, nasopharyngeal cancer, cheek cancer, oral cancer, GIST (gastrointestinal stromal tumor), Arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatitis, Crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, dermatitis including atopic dermatitis, dermatomyositis, psoriasis, Behcet's disease, uveitis, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Sjögren's syndrome, vesicular disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic disease, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, lung disease including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, berylliosis, or polymyositis. The method comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound as defined herein, or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0382] In another aspect, the present invention provides a method for treating non-Hodgkin lymphoma (IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound as defined herein or a pharmaceutically acceptable salt or pharmaceutical composition thereof.

[0383] In another aspect, the present invention provides a method for inhibiting MALT1 in vitro, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt thereof.

[0384] In another aspect, the present invention provides a method for inhibiting MALT1 in vivo, comprising administering an effective amount of a compound or a pharmaceutically acceptable salt thereof.

[0385] In another aspect, the present invention provides a method of inhibiting MALT1 in vitro and / or in vivo, the method comprising contacting a cell with an effective amount of a compound as defined herein, or a pharmaceutically acceptable salt thereof.

[0386] Combination therapy

[0387] The compounds of the invention may be administered alone as a monotherapy, or may be administered in combination with one or more additional therapeutic agents. The choice of one or more additional therapeutic agents will of course vary depending on the disease or condition to be treated and its severity.

[0388] It is common to use combination therapies to treat certain medical conditions.

[0389] According to a specific aspect of the present invention, there is provided a combination suitable for the treatment of a disease or condition involving MALT1, comprising a compound of the present invention as defined above, or a pharmaceutically acceptable salt thereof, and another therapeutic agent.

[0390] According to this aspect of the invention, there is provided a combination suitable for the prevention or treatment of the following diseases: non-Hodgkin's lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Macroglobulinemia, lymphoblastic T-cell leukemia, chronic myeloid leukemia (CML), hairy cell leukemia, acute lymphoblastic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal cancer / colon cancer, prostate cancer, including non-small cell lung cancer, stomach cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, Ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial carcinoma, vulvar cancer, esophageal cancer, salivary gland cancer, nasopharyngeal cancer, cheek cancer, oral cancer, GIST (gastrointestinal stromal tumor), arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcer ulcerative colitis, pancreatitis, Crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allogeneic transplant rejection, acute or chronic graft-versus-host disease, dermatitis including atopic dermatitis, dermatomyositis, psoriasis, Behcet's disease, uveitis, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Sjögren's syndrome, vesicular disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic diseases, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, lung diseases including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, berylliosis or polymyositis, the combination comprising a compound of the invention as defined above or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents.

[0391] In another aspect of the present invention, there is provided a compound of the present invention or a pharmaceutically acceptable salt thereof in combination with one or more additional therapeutic agents.

[0392] In this article, when the term "combination" is used, it should be understood to refer to simultaneous, separate or sequential administration. In one aspect of the invention, "combination" refers to simultaneous administration. In another aspect of the invention, "combination" refers to separate administration. In another aspect of the invention, "combination" refers to sequential administration. When administered sequentially or separately, delayed administration of the second component should not result in loss of the beneficial effects of the combination.

[0393] According to another aspect of the present invention, there is provided a pharmaceutical composition comprising a compound of the present invention or a pharmaceutically acceptable salt thereof in combination with one or more additional therapeutic agents, and a pharmaceutically acceptable diluent or carrier.

[0394] The one or more additional therapeutic agents may comprise additional compounds of the invention.Thus, in one embodiment, there is provided a pharmaceutical composition comprising two compounds of the invention or pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable diluent or carrier.

[0395] According to a specific aspect of the present invention, there is provided a combination suitable for preventing or treating non-Hodgkin lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

[0396] Examples of other therapeutic agents that can be used as part of a combination therapy with a compound of the invention (e.g., one of two or more active agents as part of a dual or triple combination) include, but are not limited to, the following:

[0397] (i) BTK (Bruton's tyrosine kinase) inhibitors, such as ibrutinib, acalabrutinib, zanubrutinib, tirabrutinib, orelabrutinib, ivotinib, fennibrutinib, rizabrutinib, tolebrutinib, MK1026 (ARQ-531), LOXO-305, elsubrutinib, bosertinib, branebrutinib, spebrutinib, luxetinib, DTRM-555, JnJ64264681, BGB-3959, AS-1763, and ribrutinib.

[0398] (ii) SYK inhibitors, such as fotatinib, entostatinib, HMPL-523, IC-265, SKI-O-703, cerutinib, PRT-2761, GSK-264264, SYHX-1901, MK-8457, HM-43239, R-348 and PUR-1800;

[0399] (iii) PKC inhibitors, such as darovasertib, MS-553, enzastaurin, safingol, rubustadine, and AR-13503;

[0400] (iv) PI3K pathway inhibitors, such as apelisib, dovilisib, cupanisib, idelalisib, erbulisib, sebelisib, CHF-6523, BDP-681, zandelisib, ART-001, bupanisib, OP-11, HMPL-689, dezapelisib, selelisib, ipilimumab, IOA-244, SHC-014748M, LX-086, inavolisib, ME N-1611, eganelisib, lenilisib, ACP-319, BGB-10188, CYH-33, HS-10352, CMX-2043, ZX-101A, KA-2237, VS-5584, ASN-003, TQ-B325, AL-58805, gidalisib, HEC-68498, CLL-442, tenalisib, daclisib, GSK-2126458, and bimiralisib;

[0401] (v) BCL family inhibitors, such as BCL-201, AZD-0466, navitoclax, pelcitoclax, LP-118, FCN-338, BGB-11417, UBX-1325, LP-108, VOB-560, lisaftoclax, venetoclax, ZN-d5, and ABBV-167;

[0402] (vi) JAK inhibitors, such as gusacitinib, digotinib, tofacitinib, abrocitinib, ruxolitinib, baricitinib, fuzotinib, upadacitinib, filgotinib, peftinib, TD-8236, TD-0903, CEE-321, lorpucitinib, WXSH-0150, SYHX-1901, selenotinib, izencitinib, KL-130008, WP-1066, gusacitinib, INCB-52793, AC-1101, ATI -1777, SHR-0302, CPL-409116, molotinib, brigatinib, TTL-018, TD-5202, LP-0184, INCB-054707, jaktinib, TQ-05105, itatinib, AZD-0449, GLPG-0555, LW-104, ARQ-252, WXFL-10203614, golixitinib, deuruxolitinib, CJ-15314, CS-12192, rituximab, R-348, ATI-2138, and igatinib;

[0403] (vii) PIM kinase inhibitors, such as uzansertib, TP-3654, MEN-1703, ETH-155008, abemaciclib, and SF-1126;

[0404] (viii) mTORC inhibitors, such as rapamycin, sirolimus, novolimus, umimos, zotarolimus, temsirolimus, everolimus, merimolimus, irapa, and redalimus;

[0405] (ix) rituximab or other B cell antigen-binding antibodies and immune cell redirecting agents (e.g., blinatumomab or CAR-T cells);

[0406] (x) anti-PD-1 antibodies, such as nivolumab, pembrolizumab, lambrolizumab, pidilzumab, BGB-A317;

[0407] (xi) Anti-PD-L1 antibodies, such as atezolizumab, afolumab, durvalumab, MEDI-4736, and MPDL3280A

[0408] (xii) Antibodies that inhibit 4-1BB-ligand interactions, such as utolumab and

[0409] (xiii) Antibodies that inhibit the interaction of CTLA-4 with its ligands, such as ipilimumab, tesimumab, or those disclosed in WO2014 / 207063.

[0410] The combinations described above may conveniently be presented for use in the form of a pharmaceutical formulation and thus pharmaceutical formulations comprising a combination as defined above together with a pharmaceutically acceptable diluent or carrier represent a further aspect of the invention.

[0411] Such combined / combination therapy may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment. In one embodiment, the separate compounds will be administered simultaneously in a combined pharmaceutical preparation.

[0412] Such combination therapies employ the compounds of this invention within the dosage range described herein and the other pharmaceutically active agent within the dosage range approved and / or described in the relevant publications referenced.

[0413] Example

[0414] General procedure:

[0415] Methods for preparing the compounds of the invention are illustrated in the following examples. Starting materials are prepared according to procedures known in the art or as described herein, or are commercially available. Commercial reagents are used without further purification. Where reaction temperatures are not included, reactions are carried out at ambient temperature, typically 17–27° C.

[0416] Those skilled in the art will appreciate that reaction temperatures, reaction times, and amounts of reagents may vary from those described herein.

[0417] When the compounds described in the present invention were characterized by 1H NMR spectroscopy, the spectra were recorded on a 400 MHz Bruker instrument. In the absence of temperature, the spectra were recorded at ambient temperature. Chemical shift values ​​are expressed in parts per million (ppm). The following abbreviations are used for the multiplicity of NMR signals: s = singlet, br = broad, t = triplet, q = quadruplet, m = multimodal, d = doublet.

[0418] When the compounds described in the present invention were characterized by LCMS data, retention times and molecular weights were determined using the conditions listed below.

[0419] Method 1: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 0.1% formic acid in water [eluent A], 0.1% formic acid in MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 5–95% B in 2.2min, hold at 95% for 1.2min; column temperature 40°C.

[0420] Method 2: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Luna Omega C18, 1.6μm, 50x 2.1mm. Conditions: 0.05% formic acid in water [eluent A], 0.05% formic acid in MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 5–95% B in 2.2min, hold at 95% for 1.2min; column temperature 40°C.

[0421] Method 3: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 0.05% formic acid in water [eluent A], 0.05% formic acid in MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 5–95% B in 6.7min, hold at 95% for 1.2min; column temperature 40°C.

[0422] Method 4: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 0.05% formic acid in water [eluent A], 0.05% formic acid in MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 5–95% B in 2.2min, hold at 95% for 1.2min; column temperature 40°C.

[0423] Method 5: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 0.1% formic acid in water [eluent A], 0.1% formic acid in MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 5–95% B in 1.7min, hold at 95% for 1.5min; column temperature 40°C.

[0424] Method 6: Dionex Ultima 3000 (Avalon PDA 210–400 nm and Thermo Scientific LCQIon Trap detector). Column: Luna Omega PS C18, 3μm, 50x 2.1mm. Conditions: 95:5 10mM ammonium formate aqueous solution / MeCN [eluent A], 5:95 10mM ammonium formate aqueous solution / MeCN [eluent B] (flow rate 1.0mL / min). Gradient: 2–98% B in 3min, hold at 98% for 0.5min; column temperature 40°C.

[0425] Method 7: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 10mM ammonium acetate aqueous solution [eluent A], MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 2-98% B in 2.9min, hold at 98% for 1.2min; column temperature 40℃.

[0426] Method 8: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 10mM ammonium acetate aqueous solution [eluent A], MeCN [eluent B] (flow rate 0.5mL / min). Gradient: 2-98% B in 2.9min, hold at 98% for 1.2min; column temperature 45°C.

[0427] Method 9: Dionex Ultima 3000 (Avalon PDA 210–400 nm and Thermo Scientific LCQIon Trap detector). Column: Luna Omega PS C18, 3μm, 50x 2.1mm. Conditions: 95:5 10mM ammonium formate aqueous solution / MeCN [eluent A], 5:95 10mM ammonium formate aqueous solution / MeCN [eluent B] (flow rate 1.0mL / min). Gradient: 2–98% B in 1.9min, hold at 98% for 2.2min; column temperature 40°C.

[0428] Method 10: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 10mM ammonium acetate aqueous solution [eluent A], MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 2-98% B in 2.9min, hold at 98% for 1.2min; column temperature 45°C.

[0429] Method 11: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 10mM NH 4HCO 3 Aqueous solution [eluent A], MeCN [eluent B] (flow rate 0.5 mL / min). Gradient: 3–100% B in 6.7 min, hold at 100% for 1.2 min; column temperature 40°C.

[0430] Method 12: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 10mM NH 4 HCO 3 Aqueous solution [eluent A], MeCN [eluent B] (flow rate 0.5 mL / min). Gradient: 5–95% B in 2.2 min, hold at 95% for 1.2 min; column temperature 40°C.

[0431] Method 13: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 10mM ammonium acetate aqueous solution [eluent A], MeCN [eluent B] (flow rate 0.5mL / min). Gradient: 5–95% B in 2.9min, hold at 95% for 1.2min; column temperature 40°C.

[0432] Method 14: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 0.1% formic acid in water [eluent A], MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 5–95% B in 2.2min, hold at 95% for 1.2min; column temperature 40°C.

[0433] Method 15: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 10mM ammonium acetate aqueous solution [eluent A], MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 2-65% B in 7.7min, hold at 65% for 1min, 65-90% in 1min, hold at 90% for 1min; column temperature 40℃.

[0434] Method 16: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 2.5μm, 50x 3.5mm. Conditions: 5mM NH 4 HCO 3 Aqueous solution [eluent A], MeCN [eluent B] (flow rate 1.0 mL / min). Gradient: 5–95% B in 1.7 min, hold at 95% for 2 min; column temperature 40°C.

[0435] Method 17: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 3.5μm, 50x 4.6mm. Conditions: 5mM NH 4 HCO 3 Aqueous solution [eluent A], MeCN [eluent B] (flow rate 1.0 mL / min). Gradient: 5–95% B in 1.7 min, hold at 95% for 2 min; column temperature 40°C.

[0436] Method 18: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity BEH C18, 1.7μm, 50x 2.1mm. Conditions: 0.1% TFA aqueous solution [eluent A], MeCN [eluent B] (flow rate 0.6mL / min). Gradient: 5-95% B in 2.2min, hold at 95% for 1.2min; column temperature 40℃.

[0437] Method 19: Agilent 1260 (Waters Acquity PDA 210–400 nm and Waters Acquity SQ detector). Column: Waters Acquity XBridge C18, 3.5μm, 50x 4.6mm. Conditions: 0.1% formic acid in water [eluent A], MeCN [eluent B] (flow rate 1.0mL / min). Gradient: 5–95% B in 2.2min, hold at 95% for 1.2min; column temperature 40°C.

[0438] Preparative HPLC was performed using Shimadzu SIL 10AP.

[0439] abbreviation:

[0440]

[0441]

[0442]

[0443] Intermediate synthesis

[0444] Intermediate 1: 8-Bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carbonitrile

[0445]

[0446] To a stirred solution of 2-amino-6-bromophenol (1.00 g, 5.32 mmol, CAS 28165-50-6) in DMSO (15 mL) was added potassium carbonate (1.47 g, 10.6 mmol). The reaction mixture was cooled to 0 ° C, and 2-chloroacrylonitrile (0.70 g, 7.95 mmol, CAS 920-37-6) was added dropwise. The mixture was then heated at 80 ° C for 16 h. The mixture was diluted with ice-cold water and extracted with ethyl acetate. The combined organic layers were purified by anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 20-30% ethyl acetate in hexanes) to give the title compound (0.30 g). LCMS (Method 1): 2.00 min, 239.1 [M+H] + .

[0447] Intermediate 2: tert-Butyl 5-(pyridin-3-yl)-3,4-dihydroquinoline-1(2H)-carboxylate

[0448]

[0449] To a stirred solution of tert-butyl 5-bromo-3,4-dihydroquinoline-1(2H)-carboxylate (0.2 g, 0.64 mmol, CAS 1706449-47-9) in THF:water (3:1, 5 mL) were added pyridin-3-ylboronic acid (79 mg, 0.64 mmol, CAS 1692-25-7), Cs 2 CO 3 (0.29 g, 0.96 mmol), the resulting reaction mass was heated to N 2 Purge for 10 min. 2 (PPh 3 ) 2 (0.021 g, 0.035 mmol), Xanthphos (17 mg, 0.035 mmol), and purged with nitrogen for 10 minutes. The mixture was heated at 90 ° C for 16 h. The mixture was diluted with water and extracted with EtOAc. The combined organic layers were washed with saturated NaHCO 3 solution, washed with brine, and passed through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh, eluting with 10-25% ethyl acetate in petroleum ether) to give the title compound (0.17 g). LCMS (Method 1): 1.73 min, 311.4 [M+H] + .

[0450] Intermediate 3: 5-(Pyridin-3-yl)-1,2,3,4-tetrahydroquinoline hydrochloride

[0451]

[0452] A stirred solution of intermediate 2 (0.17 g, 0.54 mmol) in dioxane (2 mL) was cooled to 0 °C, 4M HCl in dioxane (10 mL) was added, and stirred at room temperature for 16 h. The mixture was concentrated under reduced pressure and triturated with n-pentane to give the title compound (0.11 g). LCMS (Method 1): 1.06 min, 211.2 [M+H] + .

[0453] Intermediate 4: 2-(Quinolin-5-yl)oxazole

[0454]

[0455] 2-bromooxazole (1.28 g, 8.67 mmol, CAS 125533-82-6) and potassium carbonate (1.60 g, 11.6 mmol) were added to a stirred solution of quinolin-5-ylboronic acid (1.00 g, 5.78 mmol, CAS 355386-94-6) in dioxane: water (5: 1 ratio, 20 mL), and the mixture was purged with argon for 15 min. Tetrakis (triphenylphosphine) palladium (0) (0.34 g, 0.29 mmol) was added and purged with argon for 10 min. The reaction mixture was heated at 80 ° C for 4 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was purified by anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh, eluting with 20-40% ethyl acetate in hexane) to give the title compound (0.8 g). LCMS (Method 1): 1.20 min, 197.6 [M+H] + .

[0456] Intermediate 5: 2-(1,2,3,4-tetrahydroquinolin-5-yl)oxazole

[0457]

[0458] To a stirred solution of intermediate 4 (0.50 g, 2.55 mmol) in MeOH (10 mL) in a steel pressure vessel was added platinum (IV) oxide (29 mg, 0.13 mmol) and stirred at room temperature under hydrogen pressure (50 psi) for 16 h. The reaction mixture was passed through a pad of celite, washed with MeOH, and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh silica gel, eluted with 15-25% ethyl acetate in petroleum ether) to give the title compound (0.15 g). LCMS (Method 1): 1.28 min, 201.2 [M+H] + .

[0459] Intermediate 6: 2-(Quinolin-5-yl)thiazole

[0460]

[0461] The title compound (0.75 g) was prepared in a similar manner to Intermediate 4 from quinolin-5-ylboronic acid (1.00 g, 5.78 mmol, CAS 355386-94-6), 2-bromothiazole (1.42 g, 8.67 mmol, CAS 3034-53-5), potassium carbonate (1.60 g, 11.6 mmol), tetrakis(triphenylphosphine)palladium(0) (0.34 g, 0.29 mmol) in dioxane:water (4:1 ratio, 20 mL); purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 25-40% ethyl acetate in hexanes). LCMS (Method 1): 1.26 min, 213.0 [M+H] + .

[0462] Intermediate 7: 2-(1,2,3,4-Tetrahydroquinolin-5-yl)thiazole

[0463]

[0464] To a stirred solution of intermediate 6 (0.50 g, 2.35 mmol) in MeOH (10 mL) in a steel pressure vessel was added IrCl 2 (COD) (79 mg, 0.12 mmol) and stirred at room temperature under hydrogen pressure (50 psi) for 48 h. The reaction mixture was passed through a diatomaceous earth pad, washed with MeOH, and the filtrate was concentrated under reduced pressure. The crude product was purified by rapid column chromatography (silica gel, 100-200 mesh silica gel, eluted with 20-35% ethyl acetate in petroleum ether) to give the title compound (0.20 g). LCMS (Method 1): 1.40 min, 217.2 [M+H] + .

[0465] Intermediate 8: (E)-N-(3-bromophenyl)-2-methylbut-2-enamide

[0466]

[0467] To a stirred solution of 3-bromoaniline (10 g, 58.1 mmol, CAS 591-19-5) in DMF (100 mL) was added (E)-2-methylbut-2-enoic acid (5.8 g, 58.1 mmmol, CAS 13201-46-2), followed by HATU (33 g, 87.2 mmol) and DIPEA (30 mL, 174 mmol), and the mixture was stirred at RT for 16 h. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was purified by anhydrous Na 2 SO 4Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh silica gel, eluted with 15% ethyl acetate in petroleum ether) to give the title compound (7.5 g). LCMS (Method 1): 1.90 min, 254.2 [M+H] + .

[0468] Intermediate 9: 5-bromo-3,4-dimethyl-3,4-dihydroquinolin-2(1H)-one

[0469]

[0470] Intermediate 8 (7.5 g, 58.1 mmol) and aluminum chloride (7.88 g, 59.0 mmol) were heated at 180°C for 2 h. The mixture was cooled at 0°C, then quenched with 1.5 M hydrochloric acid, diluted with water, and extracted with DCM. The organic layer was washed with anhydrous Na 2 SO 4 The crude product was purified by preparative SFC (Chiralpak IE, 30 x 250 mm x 5 μm, flow rate: 90 g / min, 80% CO 2 , 20% MeOH, containing 0.2% diethylamine, back pressure 100 bar, temperature 35°C) to give the title compound (0.60 g). LCMS (Method 1): 1.85 min, 254.1 [M+H] + .

[0471] Intermediate 10: 5-Bromo-3,4-dimethyl-1,2,3,4-tetrahydroquinoline

[0472]

[0473] To a solution of intermediate 9 (0.3 g, 1.2 mmol) in THF (5 mL) cooled at 0°C was added a solution of borane in THF (1 M, 7.2 mL, 7.2 mmol), and the mixture was placed at RT for 16 h. The mixture was quenched by the addition of MeOH at 0°C and then concentrated under reduced pressure. The residue was partitioned between water and EtOAc, the organic layer was washed with brine, and the residue was purified by HPLC. 2 SO 4 Dry, filter and concentrate under reduced pressure to give the title compound (0.27 g). LCMS (Method 1): 2.31 min, 240.1 [M+H] + .

[0474] Intermediate 11: 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinoline-1 (2H)-tert-Butyl formate

[0475]

[0476] To a stirred solution of tert-butyl 5-bromo-1,2,3,4-tetrahydroquinoline-1-carboxylate (2.5 g, 8.02 mmol, CAS 1706449-47-9) and bis(pinacolato)diboron (2.03 g, 8.02 mmol) in 1,4-dioxane (50 mL) was added potassium acetate (1.57 g, 16.0 mmol). The reaction mixture was degassed with argon for 10 min. Pd(dppf)Cl was added 2 (0.29 g, 0.40 mmol) and degassed with argon for 5 min. The mixture was then heated at 110 °C for 16 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organic layers were purified by anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh, eluting with 5-7% ethyl acetate in hexanes) to give the title compound (1.80 g). LCMS (Method 1): 2.64 min, 260.5 [M-Boc+H] + .

[0477] Intermediate 12: tert-Butyl 5-(1,3,4-thiadiazol-2-yl)-3,4-dihydroquinoline-1(2H)-carboxylate

[0478]

[0479] To a stirred solution of intermediate 11 (1.8 g, 5.01 mmol) 2-bromo-1,3,4-thiadiazole (0.99 g, 6.01 mmol, CAS 61929-24-6) in THF (40 mL) was added K 3 PO 4 (3.32 g, 15.0 mmol). The reaction mixture was degassed with argon for 10 min, then palladium acetate (0.06 g, 0.25 mmol) and yellow phosphorus (0.14 g, 0.25 mmol) were added and degassed for 5 min. The mixture was stirred at 110 ° C for 16 h. The mixture was cooled, diluted with water, and extracted with ethyl acetate. The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh, eluting with 10-15% ethyl acetate in hexanes) to give the title compound (0.35 g). LCMS (Method 1): 2.33 min, 318.3 [M+H] + .

[0480] Intermediate 13: 2-(1,2,3,4-tetrahydroquinolin-5-yl)-1,3,4-thiadiazole

[0481]

[0482] To a stirred solution of intermediate 12 (0.35 g, 1.10 mmol) in DCM (10 mL) at 0°C was added 4M HCl in dioxane (5 mL). The mixture was stirred at room temperature for 6 h. The mixture was concentrated under reduced pressure and the residue was then taken up in saturated NaHCO 3 The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh, eluting with 30-35% ethyl acetate in hexane) to give the title compound (0.15 g). LCMS (Method 1): 1.16 min, 218.4 [M+H] + .

[0483] Intermediate 14: 4-bromo-2,2-dimethyl-2,3-dihydroquinolin-1H-inden-1-one

[0484]

[0485] To a stirred solution of 4-bromo-1-indanone (5.0 g, 23.7 mmol, CAS 15115-60-3) in DMF (50 mL) was added sodium hydride (60% dispersion in mineral oil, 1.25 g, 52.1 mmol), and the mixture was stirred at RT for 1 hour. The mixture was cooled at 0 ° C, then methyl iodide (10.3 mL, 166 mmol) was added, and the mixture was stirred at RT for 2 h. The mixture was quenched with water and extracted with EtOAc. The combined organic layers were purified by anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 230-400 mesh, eluting with 5-10% ethyl acetate in hexanes) to give the title compound (2.70 g). LCMS (Method 1): 2.14 min, 239.2 [M+H] + .

[0486] Intermediate 15: 5-bromo-3,3-dimethyl-3,4-dihydroquinolin-2(1H)-one

[0487]

[0488] To a stirred solution of intermediate 14 (2.7 g, 11.3 mmol) in benzene (40 mL) was added 18 M sulfuric acid (0.9 mL, 16.9 mmol) dropwise at room temperature. Sodium azide (3.67 g, 56.4 mmol) was added and the mixture was stirred at 70 °C for 30 min. The mixture was cooled and concentrated under reduced pressure. The residue was partitioned between water and EtOAc. The combined organic layers were washed with brine, purified by anhydrous Na 2 SO 4Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 230-400 mesh, eluting with 5-10% ethyl acetate in hexanes) to give the title compound (0.70 g). LCMS (Method 1): 2.21 min, 254.1 [M+H] + .

[0489] Intermediate 16: 5-Bromo-3,3-dimethyl-1,2,3,4-tetrahydroquinoline

[0490]

[0491] To a solution of intermediate 15 (0.70 g, 2.75 mmol) in THF (20 mL) cooled at 0°C was added borane dimethyl sulfide complex (2M in THF, 6.9 mL, 13.8 mmol), and the mixture was placed at RT for 16 h. The mixture was quenched by the addition of MeOH and then concentrated under reduced pressure. The residue was partitioned with water and EtOAc, the organic layer was washed with brine, and the residue was purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 230-400 mesh, eluting with 5-10% ethyl acetate in hexanes) to give the title compound (0.48 g). LCMS (Method 1): 2.33 min, 240.3 [M+H] + . Intermediate 17: 8-Bromo-1-methyl-1,2,3,4-tetrahydroquinoxaline

[0492]

[0493] To a stirred solution of 6-bromo-N1-methylbenzene-1,2-diamine (0.5 g, 2.49 mmol, CAS 1150102-47-8) in DMA (15 mL) was added NaHCO 3 (2.09 g, 24.9 mmol) and stirred for 30 min. Then 1,2-dibromoethane (0.56 g, 2.98 mmol) was added and the mixture was heated to reflux for 16 h. The mixture was cooled and diluted with brine and EtOAc. The aqueous phase was extracted with ethyl acetate, followed by washing the organic layer with brine and then filtered through Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh, eluting with 15-20% ethyl acetate in hexane) to give the title compound (0.3 g). LCMS (Method 1): 1.21 min, 227.1 [M+H] + .

[0494] Intermediate 18: tert-Butyl 8-bromo-2-cyano-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate

[0495]

[0496] To a stirred solution of intermediate 1 (0.89 g, 3.63 mmol) and triethylamine (0.55 g, 5.44 mmol) in THF (10 mL) was added di-tert-butyl dicarbonate (1.58 g, 7.26 mmol) and DMAP (44 mg, 0.36 mmol) and stirred at RT for 14 h. The solvent was removed under reduced pressure and the residue was partitioned with water and EtOAc. The organic layer was filtered through Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the title compound (0.69 g). LCMS (Method 1): 2.19 min, 337.1 [MH] - .

[0497] Intermediate 19: 8-Bromo-2-cyano-2-methyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylic acid tert-butyl ester

[0498]

[0499] To a stirred solution of intermediate 18 (0.69 g, 2.03 mmol) in DMF (7 mL) was added sodium hydride (60% dispersion in mineral oil, 0.25 g, 6.15 mmol) and the mixture was stirred at RT for 15 min. Methyl iodide (2.9 g, 20.3 mmol) was then added and the mixture was stirred at RT for 5 h. The solvent was removed under reduced pressure and the residue was partitioned with water and EtOAc. The organic layer was washed with brine and purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the title compound (0.62 g). LCMS (Method 1): 2.26 min, 253.1 [M-Boc+H] + .

[0500] Intermediate 20: 8-Bromo-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carbonitrile hydrochloride

[0501]

[0502] Intermediate 19 (0.35 g, 1.10 mmol) was cooled at 0°C and then a 4M solution of HCl in dioxane (6 mL) was added. The mixture was stirred at RT for 3 h. The mixture was concentrated under reduced pressure to give the title compound (0.46 g). LCMS (Method 1): 1.84 min, 253.1 [M+H] + .

[0503] Intermediate 21: 3-Amino-5-bromopyridin-4-ol

[0504]

[0505] To a solution of 3-bromo-5-nitropyridine-4-ol (10.0 g, 45.6 mmol, CAS 31872-65-8) in ethanol: water (4: 1, 100 mL) was added iron powder (12.7 g, 228 mmol) followed by ammonium chloride (12.2 g, 228 mmol). The mixture was stirred at 80 ° C for 16 h. The mixture was concentrated under reduced pressure and the crude product was purified by flash column chromatography (neutral alumina, eluted with 20-30% MeOH in DCM) to give the title compound (8 g). LCMS (Method 1): 0.33 min, 188.9 [M+H] + .

[0506] Intermediate 22: 8-Bromo-2,2-dimethyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0507]

[0508] To a solution of intermediate 21 (8.0 g, 42.3 mmol) in acetonitrile (80 mL) cooled at 0°C was added potassium carbonate (35.1 g, 254 mmol) and 2-bromo-2-methylpropanoyl bromide (11.7 g, 50.8 mmol) in a sealed tube. The mixture was stirred at 80°C for 16 h. The mixture was cooled, quenched with water, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 45-50% EtOAC in hexanes) to give the title compound (5.0 g). LCMS (Method 1): 1.44 min, 257.0 [M+H] + .

[0509] Intermediate 23: 8-Bromo-2,2-dimethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0510]

[0511] To a solution of intermediate 22 (5.0 g, 19.5 mmol) in THF (50 mL) cooled at 0°C was added a solution of borane in THF (1 M, 17.5 mL, 17.5 mmol), and the mixture was placed at RT for 2 h. The mixture was quenched by the addition of MeOH, then heated at 80°C for 6 h, and then concentrated under reduced pressure. The residue was partitioned with water and EtOAc, and the organic layer was then washed with water and 4% paraffin. 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 230-400 mesh, eluting with 15-20% EtOAC in hexanes) to give the title compound (3.5 g). LCMS (Method 1): 1.10 min, 243.1 [M+H] + .

[0512] Intermediate 24: 4-(tert-Butyl)2-ethyl 8-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazine-2,4-dicarboxylic acid ester

[0513]

[0514] To a solution of 8-bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine-2-carboxylic acid ethyl ester (3.70 g, 12.9 mmol, CAS 1021859-84-6) and triethylamine (4.5 mL, 32.3 mmol) in THF (35 mL) were added di-tert-butyl dicarbonate (8.47 g, 38.8 mmol) and DMAP (0.16 g, 1.29 mmol). The mixture was stirred at RT for 14 h. The mixture was diluted with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 2-5% EtOAC in petroleum ether) to give the title compound (4.4 g). LCMS (Method 1): 2.31 min, 286.2 [M-Boc+H] + .

[0515] Intermediate 25: tert-Butyl 8-bromo-2-(hydroxymethyl)-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylate

[0516]

[0517] To a solution of intermediate 24 (4.35 g, 11.3 mmol) in ethanol (40 mL) at 0°C was added sodium borohydride (1.28 g, 33.8 mmol). The mixture was stirred at room temperature for 14 h. The mixture was diluted with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 5-7% EtOAC in petroleum ether) to give the title compound (3.8 g). LCMS (Method 1): 2.00 min, 244.1 [M-Boc+H] + .

[0518] Intermediate 26: 8-bromo-2-formyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylic acid tert-butyl ester

[0519]

[0520] To a solution of oxalyl chloride (1.0 mL, 11.7 mmol) in DCM (10 mL) cooled at -78 °C was added DMSO (1.65 mL, 23.24 mmol) dropwise, and the mixture was stirred for 1 h. A solution of intermediate 25 (1.0 g, 2.91 mmol) in DCM (3 mL) was then added dropwise at -78 °C and stirred for 1 h. Triethylamine (4.05 mL, 29.1 mmol) was added at -78 °C and then left at RT for 1 h. The mixture was diluted with water and extracted with DCM. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (1.07 g). LCMS (Method 1): 1.81 min, 242.1 [M-Boc+H] + .

[0521] Intermediate 27: 8-Bromo-2-ethynyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxylic acid tert-butyl ester

[0522]

[0523] To a solution of intermediate 26 (1.0 g, 2.92 mmol) in MeOH (10 mL) was added dimethyl (1-diazo-2-oxopropyl)phosphonate (10% in MeCN, 0.67 g, 3.50 mmol) and potassium carbonate (0.81 g, 5.84 mmol). The mixture was stirred at 60 °C for 45 min under microwave irradiation. The mixture was concentrated under reduced pressure, the residue was diluted with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 2-4% EtOAC in petroleum ether) to give the title compound (0.30 g). LCMS (Method 1): 2.25 min, 238.2 [M-Boc+H] + .

[0524] Intermediate 28: 8-Bromo-2-ethynyl-3,4-dihydro-2H-benzo[b][1,4]oxazine hydrochloride

[0525]

[0526] Intermediate 27 (0.29 g, 0.86 mmol) was cooled at 0°C and then a 4M solution of HCl in dioxane (3 mL) was added. The mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure to give the title compound (0.22 g). LCMS (Method 1): 1.80 min, 238.2 [M+H] + .

[0527] Intermediate 29: 5-Cyclopropyl-1,7-naphthyridine

[0528]

[0529] To a solution of 5-bromo-1,7-naphthyridine (0.2 g, 0.96 mmol, CAS 17965-76-3) and cyclopropylboronic acid (82 mg, 0.95 mmol) in 1,4-dioxane: water (8:1, 4.5 mL) was added potassium carbonate (0.4 g, 2.87 mmol) and the mixture was degassed with nitrogen for 10 min. PdCl was added 2 A solution of (dppf) in DCM (78 mg, 0.095 mmol) was prepared and the mixture was degassed with nitrogen for 15 min and then stirred at 90 °C for 16 h. The mixture was diluted with ethyl acetate and filtered through celite. The filtrate was washed with water, washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 50% EtOAC in petroleum ether) to give the title compound (0.15 g). LCMS (Method 1): 1.04 min, 171.2 [M+H] + .

[0530] Intermediate 30: 5-Cyclopropyl-1,2,3,4-tetrahydro-1,7-naphthyridine

[0531]

[0532] To a stirred solution of intermediate 29 (0.15 g, 0.88 mmol) in ethanol (20 mL) was added platinum (IV) oxide (20 mg, 0.09 mmol) and stirred for 16 h at RT under a hydrogen atmosphere. The reaction mixture was concentrated under reduced pressure, diluted with EtOAc, and filtered through celite. The filtrate was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (0.14 g). LCMS (Method 1): 1.09 min, 175.3 [M+H] + .

[0533] Intermediate 31: 8-Cyclopropyl-2,2-dimethyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0534]

[0535] To a solution of intermediate 22 (1.5 g, 5.84 mmol) and 2-cyclopropyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (1.47 g, 8.75 mmol) in 1,4-dioxane:water (4:1, 15 mL) was added potassium carbonate (2.01 g, 14.6 mmol) and the mixture was degassed with nitrogen for 5 min. PdCl was added 2(dppf) DCM (0.71 g, 0.88 mmol) and stirred at 80 °C for 16 h. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The residue was diluted with EtOAc and washed with water, washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 30-40% EtOAC in petroleum ether) to give the title compound (0.65 g). LCMS (Method 2): 0.96 min, 219.2 [M+H] + .

[0536] Intermediate 32: 8-Cyclopropyl-2,2-dimethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0537]

[0538] To a solution of intermediate 31 (0.6 g, 2.75 mmol) in THF (10 mL) at 0°C was added lithium aluminum hydride (2M THF solution, 4.12 mL, 8.25 mmol). The mixture was stirred at RT for 3 h. The mixture was concentrated under reduced pressure, the residue was diluted with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The product was purified by preparative HPLC (XSELECT C18, 25 x 150 mm x 10 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 The crude product was purified by HPLC (HPLC: 500 μg / mL, MeCN from 35% to 65% in 8 min, maintained at 65% for 1.7 min) to give the title compound (0.10 g). LCMS (Method 1): 1.36 min, 205.1 [M+H] + .

[0539] Intermediate 33: (3-bromo-5-nitropyridin-4-yl)-L-proline

[0540]

[0541] To a solution of 3-bromo-4-chloro-5-nitropyridine (2.0 g, 8.43 mmol, CAS 31872-63-6) and L-proline (1.26 g, 10.9 mmol) in acetonitrile (20 mL) at 0°C was added triethylamine (3.65 mL, 25.3 mmol). The mixture was stirred at RT for 2 h. The mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 5-10% MeOH in DCM) to give the title compound (2.1 g). LCMS (Method 2): 1.43 min, 316.2 [M+H] + .

[0542] Intermediate 34: (S)-1-Bromo-6a,7,8,9-tetrahydropyrido[3,4-e]pyrrolo[1,2-a]pyrazine-6(5H)- ketone

[0543]

[0544] To a solution of intermediate 33 (2.0 g, 6.34 mmol) in acetic acid (8 mL) was added iron powder (1.06 g, 19.0 mmol). The mixture was stirred at 80 °C for 4 h. The mixture was concentrated under reduced pressure, then the residue was diluted with water, basified with sodium bicarbonate, and then extracted with 10% MeOH in DCM. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (1.1 g). LCMS (Method 1): 0.99 min, 268.2 [M+H] + .

[0545] Intermediate 35: (S)-1-Bromo-5,6,6a,7,8,9-hexahydropyrido[3,4-e]pyrrolo[1,2-a]pyrazine

[0546]

[0547] To a solution of intermediate 34 (1.1 g, 4.10 mmol) in THF (10 mL) cooled at 0°C was added a THF solution of borane (1 M, 12.3 mL, 12.3 mmol), and the mixture was stirred at 80°C for 3 h. The mixture was quenched by the addition of MeOH and then heated at 80°C for 3 h. The mixture was allowed to cool, and then a 1 M aqueous solution of HCl (5 mL) was added and heated at 80°C for 3 hours. The mixture was concentrated under reduced pressure. The residue was basified with aqueous sodium bicarbonate solution and extracted with 10% MeOH in DCM. The organic layer was washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 230-400 mesh, eluting with 50-100% EtOAC in hexanes) to give the title compound (0.5 g). LCMS (Method 1): 1.16 min, 254.1 [M+H] + .

[0548] Intermediate 36: N-(3-bromo-5-nitropyridin-4-yl)-N-methyl-D-alanine

[0549]

[0550] To a solution of 3-bromo-4-chloro-5-nitropyridine (2.0 g, 8.42 mmol, CAS 31872-63-6) and N-methyl-D-alanine (1.30 g, 12.6 mmol) in 1,4-dioxane:water (2:1, 20 mL) at 0°C was added sodium carbonate (1.34 g, 12.6 mmol). The reaction mixture was stirred at room temperature for 16 h. The mixture was quenched with water and washed with EtOAc. The aqueous phase was acidified with aqueous sodium bisulfate solution and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 50% EtOAC in hexane) to give the title compound (1.25 g). LCMS (Method 1): 1.54 min, 304.3 [M+H] + .

[0551] Intermediate 37: (R)-8-Bromo-1,2-dimethyl-1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one

[0552]

[0553] To a solution of intermediate 36 (1.25 g, 4.11 mmol) in acetic acid (25 mL) was added iron powder (0.69 g, 12.3 mmol). The mixture was stirred at 80 °C for 4 h. The mixture was concentrated under reduced pressure, then the residue was diluted with water, basified with sodium bicarbonate, and then extracted with 10% MeOH in DCM. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (0.6 g). LCMS (Method 2): 0.80 min, 256.1 [M+H] + .

[0554] Intermediate 38: (R)-8-Bromo-1,2-dimethyl-1,2,3,4-tetrahydropyrido[3,4-b]pyrazine

[0555]

[0556] To a solution of intermediate 37 (0.6 g, 2.34 mmol) in THF (12 mL) cooled at 0°C was added a THF solution of borane (1 M, 7.02 mL, 7.02 mmol), and the mixture was stirred at 80°C for 3 h. The mixture was quenched by the addition of MeOH and then heated at 60°C for 16 h. The mixture was concentrated under reduced pressure. The residue was basified with aqueous sodium bicarbonate solution and extracted with 10% MeOH in DCM. The organic layer was washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the title compound (0.5 g). LCMS (Method 1): 1.10 min, 242.1 [M+H] + .

[0557] Intermediate 39: 8'-bromo-4,5-dihydro-2H-spiro[furan-3,2'-pyrido[4,3-b][1,4]oxazine]-3'(4' H)-Keto

[0558]

[0559] A solution of 3-hydroxytetrahydrofuran-3-carboxylic acid (0.6 g, 4.55 mmol, CAS 183162-36-9) in thionyl chloride (6 mL) was stirred at 80 ° C for 12 h. The mixture was concentrated under reduced pressure and then flushed with nitrogen to give acyl chloride A. In addition, a mixture of 3-amino-5-bromopyridine-4-ol (0.6 g, 3.17 mmol) and potassium carbonate (2.63 g, 19.0 mmol) in DMF:THF (1:1, 6 mL) was stirred at 0 ° C for 30 min. Acyl chloride A was added, and the mixture was stirred at RT for 1 hour, and then at 100 ° C for 16 hours. The mixture was cooled and concentrated under reduced pressure. It was diluted with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 20-30% EtOAC in hexanes) to give the title compound (0.24 g). LCMS (Method 1): 1.35 min, 285.3 [M+H] + .

[0560] Intermediate 40: 8'-Bromo-3',4,4',5-tetrahydro-2H-spiro[furan-3,2'-pyrido[4,3-b][1,4]oxazine]

[0561]

[0562] To a solution of intermediate 39 (0.24 g, 0.84 mmol) in THF (10 mL) cooled at 0°C was added a solution of borane in THF (1 M, 2.53 mL, 2.53 mmol), and the mixture was stirred at 70°C for 3 h. The mixture was quenched by the addition of MeOH and then heated at 70°C for 3 h. The mixture was concentrated under reduced pressure. The residue was diluted with aqueous sodium bicarbonate and extracted with 10% MeOH in DCM. The organic layer was washed with Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the title compound (0.2 g). LCMS (Method 1): 0.98 min, 271.2 [M+H] + .

[0563] Intermediate 41: 1-(3-bromo-5-nitropyridin-4-yl)piperidine-2-carboxylic acid

[0564]

[0565] To a solution of pipecolic acid (1.63 g, 12.6 mmol, CAS 535-75-1) in 1,4-dioxane: water (2:1, 40 mL) at 0°C was added sodium carbonate (1.34 g, 12.6 mmol) and stirred for 5 min, followed by the addition of 3-bromo-4-chloro-5-nitropyridine (2.0 g, 8.42 mmol, CAS 31872-63-6). The mixture was stirred at room temperature for 16 h. The mixture was acidified with aqueous sodium bisulfate solution and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 30-35% EtOAC in hexanes) to give the title compound (1.5 g). LCMS (Method 1): 1.77 min, 330.2 [M+H] + .

[0566] Intermediate 42: 1-Bromo-7,8,9,10-tetrahydro-5H-bipyrido[1,2-a:3',4'-e]pyrazin-6(6aH)-one

[0567]

[0568] To a solution of intermediate 41 (1.25 g, 4.11 mmol) in acetic acid (14.5 mL) was added iron powder (0.74 g, 13.2 mmol). The mixture was stirred at 85 °C for 5 h. The mixture was carefully basified with aqueous sodium bicarbonate solution and then extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (0.50 g). LCMS (Method 2): 1.17 min, 282.1 [M+H] + .

[0569] Intermediate 43: 1-Bromo-6,6a,7,8,9,10-hexahydro-5H-bipyrido[1,2-a:3',4'-e]pyrazine

[0570]

[0571] To a solution of intermediate 42 (0.45 g, 1.60 mmol) in THF (5 mL) cooled at 0°C was added a THF solution of borane (1 M, 4.79 mL, 4.79 mmol), and the mixture was stirred at 80°C for 3 h. The mixture was quenched by the addition of MeOH and then heated at 80°C for 6 h. The mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 30-35% EtOAC in hexanes) to give the title compound (0.16 g). LCMS (Method 1): 1.31 min, 268.3 [M+H] + .

[0572] Intermediate 44: N-(3-bromo-5-nitropyridin-4-yl)-N-methylglycine

[0573]

[0574] To a solution of N-methylglycine methyl ester hydrochloride (2.20 g, 15.8 mmol, CAS 13515-93-0) in acetonitrile (25 mL) at 0°C was added triethylamine (443 mL, 31.6 mmol) and stirred for 5 min, followed by the addition of 3-bromo-4-chloro-5-nitropyridine (2.5 g, 10.5 mmol, CAS 31872-63-6). The mixture was stirred at RT for 16 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 35-40% EtOAC in petroleum ether) to give the title compound (2.0 g). LCMS (Method 1): 1.76 min, 290.9 [M+H] + .

[0575] Intermediate 45: 8-Bromo-1-methyl-1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one

[0576]

[0577] To a solution of intermediate 44 (2.0 g, 6.89 mmol) in acetic acid (20 mL) was added iron powder (1.15 g, 20.7 mmol). The mixture was stirred at 80 °C for 16 h. The mixture was carefully basified with aqueous sodium bicarbonate solution and then filtered through celite. The filtrate was extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (1.50 g). LCMS (Method 3): 0.73 min, 242.2 [M+H] + .

[0578] Intermediate 46: 8-Bromo-1-methyl-1,2,3,4-tetrahydropyrido[3,4-b]pyrazine

[0579]

[0580] To a solution of intermediate 45 (1.50 g, 6.19 mmol) in THF (15 mL) cooled at 0°C was added a solution of borane in THF (1 M, 18.5 mL, 18.5 mmol), and the mixture was stirred at 80°C for 2 h. The mixture was cooled to 0°C and then quenched by the addition of MeOH, and then heated at 80°C for 16 h. The mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 5-10% MeOH in DCM) to give the title compound (0.35 g). LCMS (Method 4): 0.93 min, 228.2 [M+H] + .

[0581] Intermediate 47: Methyl 2-((3-bromo-5-nitropyridin-4-yl)oxy)propanoate

[0582]

[0583] To a suspension of sodium hydride (60% dispersion in mineral oil, 1.01 g, 25.3 mmol) in THF (25 mL) stirred at 0°C was added methyl 2-hydroxypropionate (1.31 g, 12.6 mmol, CAS 547-64-8), and the mixture was stirred at RT for 30 min. A solution of 3-bromo-4-chloro-5-nitropyridine (2.0 g, 8.42 mmol, CAS 31872-63-6) in THF (25 mL) was then added, and the mixture was stirred at 80°C for 2 h. The mixture was cooled, diluted with water and extracted with EtOAc. The organic layer was washed with brine, filtered through Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 230-400 mesh, eluting with 30-35% EtOAC in petroleum ether) to give the title compound (1.0 g). LCMS (Method 4): 1.73 min, 305.2 [M+H] + .

[0584] Intermediate 48: 8-Bromo-2-methyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0585]

[0586] To a solution of intermediate 47 (1.0 g, 3.28 mmol) in acetic acid (10 mL) was added iron powder (0.55 g, 9.84 mmol). The mixture was stirred at 80 °C for 2 h. The mixture was concentrated under reduced pressure, then diluted with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was triturated with ether, filtered and dried in vacuo to give the title compound (0.60 g). LCMS (Method 4): 1.30 min, 243.1 [M+H] + .

[0587] Intermediate 49: 8-Bromo-2-methyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0588]

[0589] To a solution of intermediate 48 (0.60 g, 2.47 mmol) in THF (6 mL) cooled at 0° C., a THF solution of borane (1 M, 7.41 mL, 7.41 mmol) was added, and the mixture was then stirred at 80° C. for 2 h. The mixture was cooled to 0° C., then quenched by the addition of MeOH, and then heated at 80° C. for 2 h. The mixture was concentrated under reduced pressure, then diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 40-45% EtOAC in petroleum ether) to give the title compound (0.50 g). 1 HNMR (400 MHz; CDCl 3 )δ:8.01(s,1H),7.82(s,1H),4.39-4.43(m,1H),3.88(br s,1H),3.41-3.46(m,1H),3.11-3.16(m,1H),1.45-1.47(m,3H).

[0590] Intermediate 50: (R)-8-bromo-1,2-dimethyl-4-((2-(trimethylsilyl)ethoxy)methyl)-1,4- Dihydropyrido[3,4-b]pyrazin-3(2H)-one

[0591]

[0592] To a stirred solution of intermediate 37 (1.0 g, 3.90 mmol) in THF (20 mL) at 0°C was added sodium hydride (60% dispersion in mineral oil, 0.46 g, 11.7 mmol) and the mixture was stirred for 15 min. (Trimethylsilyl)ethoxymethyl chloride (1.3 g, 7.81 mmol) was added and the mixture was stirred at RT for 2 h. The mixture was quenched with ice-cold water and extracted with EtOAc. The organic layer was washed with water, brine, purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 230-400 mesh, eluted with 10% EtOAC in petroleum ether) to give the title compound (0.75 g). LCMS (Method 1): 2.18 min, 386.2 [M+H] + .

[0593] Intermediate 51: 8-Bromo-1,2,2-trimethyl-4-((2-(trimethylsilyl)ethoxy)methyl)-1,4-dimethoxy Hydropyrido[3,4-b]pyrazin-3(2H)-one

[0594]

[0595] To a stirred solution of intermediate 50 (0.75 g, 1.94 mmol) in THF (15 mL) at -40 °C was added LDA (1 M in THF, 5.82 mL, 5.82 mmol) and the mixture was stirred for 15 min. Iodomethane (0.83 g, 5.82 mmol) was added thereto and the mixture was stirred at -40 °C for 2 h. The mixture was quenched with ice-cold water and extracted with EtOAc. The organic layer was washed with water, brine, filtered through Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 8% EtOAc in petroleum ether) to give the title compound (0.41 g). LCMS (Method 1): 2.51 min, 400.2 [M+H] + .

[0596] Intermediate 52: 8-Bromo-1,2,2-trimethyl-1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one

[0597]

[0598] Intermediate 51 (0.40 g, 0.99 mmol) was dissolved in concentrated HCl (37% aqueous solution, 8 mL) and stirred at 60 °C for 3 h. The mixture was carefully basified with saturated aqueous sodium bicarbonate solution and extracted with EtOAc. The organic layer was washed with brine and purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the title compound (0.23 g). LCMS (Method 1): 1.29 min, 270.0 [M+H] + .

[0599] Intermediate 53: 8-Bromo-1,2,2-trimethyl-1,2,3,4-tetrahydropyrido[3,4-b]pyrazine

[0600]

[0601] To a solution of intermediate 52 (0.23 g, 0.85 mmol) in THF (2.3 mL) cooled at 0 °C was added a THF solution of borane (1 M, 4.25 mL, 4.25 mmol), and the mixture was stirred at 80 °C for 3 h. The mixture was quenched by the addition of MeOH and then heated at 60 °C for 16 h. The mixture was concentrated under reduced pressure, then diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (0.23 g). LCMS (Method 1): 1.13 min, 256.1 [M+H] + .

[0602] Intermediate 54: 3-Amino-5-chloropyridin-4-ol

[0603]

[0604] To a solution of 3-chloro-5-nitropyridine-4-ol (2.0 g, 11.5 mmol) in ethanol: water (2: 1, 20 mL) was added iron powder (3.2 g, 57.3 mmol) followed by ammonium chloride (3.07 g, 57.3 mmol). The mixture was stirred at 80 ° C for 16 h. The mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (neutral alumina, eluted with 20-30% MeOH in DCM) to give the title compound (1.0 g). LCMS (Method 1): 0.28 min, 145.2 [M+H] + .

[0605] Intermediate 55: 8-Chloro-2,2-dimethyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0606]

[0607] To a solution of intermediate 54 (1.0 g, 6.92 mmol) in acetonitrile (10 mL) at 0°C was added potassium carbonate (5.74 g, 41.5 mmol) and stirred at RT for 30 min. The mixture was cooled at 0°C and then 2-bromo-2-methylpropanoyl bromide (1.91 g, 8.30 mmol) was added and stirred at RT for 1 h. The mixture was concentrated under reduced pressure and then diluted with water and extracted with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (0.6 g). LCMS (Method 1): 1.51 min, 212.9 [M+H] + .

[0608] Intermediate 56: 8-Chloro-2,2-dimethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0609]

[0610] To a solution of intermediate 55 (0.60 g, 2.82 mmol) in THF (10 mL) cooled at 0 ° C was added a THF solution of borane (1 M, 14.1 mL, 14.1 mmol), and the mixture was stirred at RT for 2 h. The mixture was quenched by the addition of MeOH and then heated at 80 ° C for 8 h. The mixture was concentrated under reduced pressure, then diluted with water and extracted with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (0.45 g). LCMS (Method 1): 1.17 min, 199.0 [M+H] + .

[0611] Intermediate 57: 3-Bromo-5-nitro-N-(tetrahydro-2H-pyran-4-yl)pyridin-4-amine

[0612]

[0613] To a solution of 4-aminotetrahydropyran (2.55 g, 25.3 mmol, CAS 38041-19-9) in 1,4-dioxane: water (2: 1, 40 mL) at 0 ° C was added sodium carbonate (3.57 g, 33.7 mmol) followed by 3-bromo-4-chloro-5-nitropyridine (4.0 g, 16.8 mol, CAS 31872-63-6). The mixture was stirred at RT for 16 h. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (4.3 g). LCMS (Method 1): 1.66 min, 302.0 [M+H] + .

[0614] Intermediate 58: 5-Bromo-N4-(tetrahydro-2H-pyran-4-yl)pyridine-3,4-diamine

[0615]

[0616] To a solution of intermediate 57 (4.3 g, 14.2 mmol) in ethanol: water (4: 1, 43 mL) was added iron powder (3.97 g, 71.2 mmol) followed by ammonium chloride (3.80 g, 71.2 mmol). The mixture was stirred at 80 °C for 16 h. The mixture was concentrated under reduced pressure, filtered through celite and washed with 10% MeOH in DCM. The filtrate was concentrated and the crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 5% MeOH in DCM) to give the title compound (3.4 g). LCMS (Method 1): 0.85 min, 271.9 [M+H] + .

[0617] Intermediate 59: 8-Bromo-1-(tetrahydro-2H-pyran-4-yl)-1,2,3,4-tetrahydropyrido[3,4-b]pyrazine

[0618]

[0619] To a solution of intermediate 58 (3.4 g, 12.5 mmol) in ethanol (68 mL) was added acetaldehyde (0.87 g, 15.0 mmol), and the mixture was then stirred at 100 ° C for 16 h. The mixture was concentrated under reduced pressure, extracted with ethyl acetate, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was suspended in THF (68 mL) at 0 ° C, and TFA (34 mL) and sodium borohydride (1.65 g, 43.7 mmol) were then added. The mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure and purified by preparative HPLC (X-Bridge C18, 25 x 150 mm x 10 μm, flow rate: 19 mL / min, 10 mM NH4 HCO 3 The crude product was purified by HPLC (HPLC: HPLC: HPLC: HPLC: HPLC: HPLC: HPLC: 1.09 min, 298.1 [M+H] + .

[0620] Intermediate 60: (R)-methyl 2-((3-bromo-5-nitropyridin-4-yl)(methyl)amino)butanoate

[0621]

[0622] To a solution of 3-bromo-4-chloro-5-nitropyridine (2.0 g, 8.42 mmol, CAS 31872-63-6) in 1,4-dioxane: water (2: 1, 430 mL) was added sodium carbonate (3.57 g, 25.3 mmol) and stirred at RT for 10 min. Then 4-(R)-methyl 2-(methylamino)butanoate (2.55 g, 25.3 mmol, CAS 745759-46-0) was added and the mixture was stirred at RT for 16 h. The mixture was quenched with water and extracted with EtOAc. The organic layer was concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 60-120 mesh, eluted with 20% EtOAC in petroleum ether) to give the title compound (0.35 g). LCMS (Method 1): 1.97 min, 332.5 [M+H] + .

[0623] Intermediate 61: (R)-8-Bromo-2-ethyl-1-methyl-1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one

[0624]

[0625] To a solution of intermediate 60 (0.35 g, 1.06 mmol) in acetic acid (3.5 mL) was added iron powder (0.34 g, 6.04 mmol). The mixture was stirred at 80 °C for 2 h. The mixture was concentrated under reduced pressure, dissolved in 10% MeOH in DCM, and then filtered through celite. The filtrate was washed with aqueous sodium bicarbonate. The combined organic layers were concentrated under reduced pressure to give the title compound (0.32 g). LCMS (Method 4): 1.06 min, 270.2 [M+H] + .

[0626] Intermediate 62: (R)-8-Bromo-2-ethyl-1-methyl-1,2,3,4-tetrahydropyrido[3,4-b]pyrazine

[0627]

[0628] To a solution of intermediate 61 (0.32 g, 1.19 mmol) in THF (3.2 mL) cooled at 0 °C was added a solution of borane in THF (1 M, 5.9 mL, 5.9 mmol), and the mixture was stirred at RT for 2 h. The mixture was quenched by the addition of MeOH and then heated at 80 °C for 16 h. The mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (neutral alumina, eluted with 30-40% EtOAc in hexanes) to give the title compound (0.1 g). LCMS (Method 1): 1.23 min, 256.1 [M+H] + .

[0629] Intermediate 63: N-(3-bromo-5-nitropyridin-4-yl)-N-methyl-D-valine methyl ester

[0630]

[0631] To a solution of N-methyl-D-valine methyl ester (2.50 g, 17.2 mmol, CAS 769890-37-1) in 1,4-dioxane:water (4:1, 25 mL) at 0°C was added sodium carbonate (3.57 g, 33.7 mmol). It was stirred for 10 min followed by the addition of 3-bromo-4-chloro-5-nitropyridine (2.86 g, 12.1 mmol, CAS 31872-63-6). The mixture was stirred at 80°C for 16 h. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 5-10% EtOAC in hexanes) to give the title compound (0.16 g). LCMS (Method 1): 2.13 min, 346.2 [M+H] + .

[0632] Intermediate 64: (R)-8-Bromo-2-isopropyl-1-methyl-1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one

[0633]

[0634] To a solution of intermediate 63 (0.16 g, 0.46 mmol) in acetic acid (2.0 mL) was added iron powder (0.08 g, 1.39 mmol). The mixture was stirred at 80 °C for 4 h. The mixture was filtered through celite, washed with EtOAc, and the filtrate was concentrated under reduced pressure to give the title compound (0.16 g). LCMS (Method 1): 1.15 min, 284.5 [M+H] + .

[0635] Intermediate 65: (R)-8-Bromo-2-isopropyl-1-methyl-1,2,3,4-tetrahydropyrido[3,4-b]pyrazine

[0636]

[0637] To a solution of intermediate 64 (0.16 g, 0.56 mmol) in THF (3 mL) cooled at 0°C was added a THF solution of borane (1 M, 2.8 mL, 2.8 mmol), and the mixture was stirred at RT for 16 h. The mixture was quenched by the addition of MeOH and then heated at 60°C for 5 h. The mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 50-100% EtOAC in hexanes) to give the title compound (55 mg). LCMS (Method 1): 1.32 min, 270.1 [M+H] + .

[0638] Intermediate 66: 3-Bromo-4-chloro-5-nitropyridin-2-amine

[0639]

[0640] 3-Bromo-4-chloropyridin-2-amine (4 g, 19.28 mmol, CAS 221297-82-1) was added portionwise to concentrated sulfuric acid (98%, 40 mL) cooled at 0°C, followed by nitric acid (48%, 2 mL), and the mixture was stirred at RT for 1 h. The mixture was poured into ice water, the resulting solid was filtered, washed with water, and the solid was dried under reduced pressure to give the title compound (2.6 g). LCMS (Method 1): 1.59 min, 252.1 [M+H] + .

[0641] Intermediate 67: Methyl 2-((2-amino-3-bromo-5-nitropyridin-4-yl)oxy)propanoate

[0642]

[0643] To a stirred solution of methyl 2-hydroxyacetate (1.85 g, 20.60 mmol) in DMF (25 mL) at 0°C was added sodium hydride (60% dispersion in mineral oil, 0.82 g, 20.6 mmol) and the mixture was stirred for 30 min. Intermediate 66 (2.6 g, 10.3 mmol) was added portionwise and the mixture was stirred at RT for 16 h. The mixture was quenched with ice-cold water and extracted with EtOAc. The organic layer was purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (neutral alumina, eluting with 5-10% MeOH in DCM) to give the title compound (0.65 g). LCMS (Method 1): 1.36 min, 306.2 [M+H] + .

[0644] Intermediate 68: 7-amino-8-bromo-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0645]

[0646] To a solution of intermediate 67 (0.65 g, 2.12 mmol) in acetic acid (10 mL) was added iron powder (0.34 g, 6.09 mmol). The mixture was stirred at 80 °C for 2 h. The mixture was filtered through celite, washed with EtOAc, and the filtrate was concentrated under reduced pressure to give the title compound (1.0 g). LCMS (Method 1): 0.55 min, 244.3 [M+H] + .

[0647] Intermediate 69: 8-Bromo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazin-7-amine

[0648]

[0649] To a solution of intermediate 68 (1.0 g, 4.10 mmol) in THF (10 mL) cooled at 0°C was added a THF solution of borane (1 M, 24.6 mL, 24.6 mmol), and the mixture was stirred at 80°C for 2 h. The mixture was cooled to 0°C and then quenched by the addition of MeOH and then heated at 80°C for 6 h. The mixture was concentrated under reduced pressure. The residue was purified by preparative HPLC (X SELECT C18, 19x 250mm x 5μm, flow rate: 18mL / min, 10mM NH 4 HCO 3 The crude product was purified by HPLC (5% MeCN in water, 10% to 30% MeCN over 10 min, kept at 30% for 1.25 min, then increased to 98% over 0.01 min and kept for 0.1 min) to give the title compound (0.1 g). 1 H NMR (400 MHz; DMSO-d 6 )δ:7.32(s,1H),5.23(br s,3H),4.25(t,2H),3.18(t,2H).

[0650] Intermediate 70: 2-((3-bromo-5-nitropyridin-4-yl)amino)-3,3,3-trifluoropropionic acid

[0651]

[0652] To a solution of 2-amino-3,3,3-trifluoropropionic acid (0.5 g, 3.49 mmol, CAS 17463-43-3) in acetonitrile (10 mL) was added 3-bromo-4-chloro-5-nitropyridine (0.86 g, 3.67 mmol, CAS 31872-63-6) and DIPEA (1.92 g, 10.5 mmol) and stirred at RT for 16 h. The mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 5-10% MeOH in DCM) to give the title compound (0.70 g). LCMS (Method 1): 1.31 min, 344.0 [M+H] + .

[0653] Intermediate 71: 8-Bromo-2-(trifluoromethyl)-1,4-dihydropyrido[3,4-b]pyrazin-3(2H)-one

[0654]

[0655] To a solution of intermediate 70 (0.70 g, 2.04 mmol) in acetic acid (7 mL) was added iron powder (0.34 g, 6.09 mmol). The mixture was stirred at 80 °C for 4 h. The mixture was concentrated under reduced pressure, basified with aqueous sodium bicarbonate solution and extracted with 10% MeOH in DCM. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 5-10% MeOH in DCM) to give the title compound (0.45 g). LCMS (Method 1): 0.90 min, 296.0 [M+H] + .

[0656] Intermediate 72: 8-Bromo-2-(trifluoromethyl)-1,2,3,4-tetrahydropyrido[3,4-b]pyrazine

[0657]

[0658] To a solution of intermediate 71 (0.45 g, 1.52 mmol) in THF (10 mL) cooled at 0°C was added a THF solution of borane (1 M, 4.57 mL, 4.57 mmol), and the mixture was stirred at RT for 3 h. The mixture was quenched by the addition of MeOH and then heated at 80°C for 16 h. The mixture was concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 5-10% MeOH in DCM) to give the title compound (0.12 g). LCMS (Method 1): 0.95 min, 282.0 [M+H] + .

[0659] Intermediate 73: 3-((2,4-dimethoxybenzyl)amino)-1,1,1-trifluoropropan-2-ol

[0660]

[0661] To a solution of 3-amino-1,1,1-trifluoropropan-2-ol (10 g, 77.5 mmol, CAS 431-38-9) in MeOH (100 mL) was added acetic acid (4.6 mL, 77.5 mmol), followed by 2,4-dimethoxybenzaldehyde (14.2 g, 85.2 mmol) and stirred at RT for 30 min. The mixture was cooled to 0 ° C, and sodium cyanoborohydride (14.6 g, 232 mmol) was added in batches, keeping the temperature between 15 ° C and 25 ° C. The mixture was stirred at RT for 16 h. The mixture was concentrated under reduced pressure and then quenched by adding water. It was extracted with EtOAc, and the organic layer was then washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (neutral alumina, eluted with 15-20% EtOAc in petroleum ether) to give the title compound (11 g). LCMS (method 1): 1.10 min, 280.2 [M+H] + .

[0662] Intermediate 74: tert-butyl (2,4-dimethoxybenzyl)(3,3,3-trifluoro-2-hydroxypropyl)carbamate

[0663]

[0664] To a stirred solution of intermediate 73 (11 g, 39.4 mmol) and triethylamine (12.0 mL, 118 mmol) in DCM (10 mL) at 0°C was added di-tert-butyl dicarbonate (10.3 g, 47.3 mmol) and stirred at RT for 16 h. The mixture was quenched with water and extracted with DCM. The organic layer was washed with brine and filtered through Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh, eluted with 20-25% EtOAC in petroleum ether) to give the title compound (8.0 g). LCMS (Method 1): 2.17 min, 324.1 [M-tBu+H] + .

[0665] Intermediate 75: (2-((3,5-dibromopyridin-4-yl)oxy)-3,3,3-trifluoropropyl)(2,4-dimethoxybenzyl tert-Butyl)carbamate

[0666]

[0667] To intermediate 74 (8.0 g, 21.1 mmol) Cs 2 CO 33,5-dibromo-4-chloropyridine (5.72 g, 21.1 mmol, CAS 13626-17-0) was added to a suspension of (20.6 g, 63.3 mmol) in DMF (80 mL), and the mixture was stirred at RT for 16 h. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 10-15% EtOAC in petroleum ether) to give the title compound (11 g). LCMS (Method 1): 2.65 min, 615.2 [M+H] + .

[0668] Intermediate 76: 2-((3,5-dibromopyridin-4-yl)oxy)-N-(2,4-dimethoxybenzyl)-3,3,3-trifluoro Propane-1-amine hydrochloride

[0669]

[0670] To a stirred solution of intermediate 75 (4.0 g, 6.5 mmol) in EtOAc (20 mL) at 0°C was added 4M HCl in 1,4-dioxane (40 mL) and stirred at RT for 3 h. The mixture was concentrated under reduced pressure to give the title compound (3.5 g). LCMS (Method 1): 2.20 min, 515.3 [M+H] + .

[0671] Intermediate 77: 8-Bromo-4-(2,4-dimethoxybenzyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrido[4, 3-b][1,4]oxazine

[0672]

[0673] To a solution of intermediate 76 (1.7 g, 3.08 mmol) in toluene (12.5 mL) was added sodium tert-butoxide (2.01 g, 20.9 mmol) and the mixture was degassed with nitrogen for 5 min. 2 (dba) 3 (0.28 g, 0.31 mmol) and BINAP (0.39 g, 0.62 mmol) were added and the mixture was stirred in a sealed tube at 110 °C for 16 h. The mixture was allowed to cool, then diluted with water and extracted with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 20-25% EtOAC in petroleum ether) to give the title compound (0.30 g). LCMS (Method 1): 2.06 min, 433.2 [M+H] + .

[0674] Intermediate 78: 8-Bromo-2-(trifluoromethyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0675]

[0676] To a stirred solution of intermediate 77 (0.30 g, 0.69 mmol) in EtOAc (1.5 mL) at 0 °C was added 4M HCl in 1,4-dioxane (3 mL), which was then stirred at 60 °C for 2 h. The mixture was concentrated under reduced pressure, and the residue was then basified with saturated aqueous sodium bicarbonate solution and extracted with EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 35-40% EtOAC in petroleum ether) to give the title compound (0.19 g). LCMS (Method 1): 1.39 min, 283.1 [M+H] + .

[0677] Intermediate 79: 3,5-Dibromo-2-methylpyridin-4-ol hydrobromide

[0678]

[0679] To a stirred solution of 2-methylpyridine-4-ol (20 g, 183 mmol, CAS 18615-86-6) in hydrobromic acid (48% aqueous solution, 70 mL) at 0°C was added a solution of bromine (18.6 mL, 367 mmol) in acetic acid (80 mL). The mixture was then stirred at RT for 3 h. The mixture was poured into ice water, the solid was filtered and washed with cold water. The solid was dried under reduced pressure to give the title compound (22 g). 1 H NMR (400 MHz; DMSO-d 6 )δ:12.31(br s,1H),8.19(s,1H),3.57(br s,1H),2.39(s,3H).

[0680] Intermediate 80: 3,5-Dibromo-4-chloro-2-methylpyridine

[0681]

[0682] To a stirred suspension of intermediate 79 (17 g, 48.9 mmol) in DCM (170 mL) at 0°C was added thionyl chloride (13.9 mL, 191 mmol) and DMF (1.7 mL). The mixture was then stirred at 60°C for 4 h. The mixture was allowed to cool and then poured into cold saturated aqueous sodium bicarbonate solution. It was extracted with DCM, the layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (18 g). LCMS (Method 1): 2.19 min, 285.9 [M+H] + .

[0683] Intermediate 81: 2-((3,5-dibromo-2-methylpyridin-4-yl)oxy)-N-(2,4-dimethoxybenzyl)ethane- 1-Amine

[0684]

[0685] To a stirred solution of 2-((2,4-dimethoxybenzyl)amino)ethane-1-ol (9.98 g, 47.3 mmol, CAS 40171-89-9) in DMF (100 mL) at 0°C was added sodium hydride (60% dispersion in mineral oil, 2.52 g, 62.1 mmol) and the mixture was stirred for 30 min. Intermediate 80 (9.0 g, 31.5 mmol) was added and the mixture was stirred at RT for 16 h. The mixture was quenched with ice-cold water and extracted with EtOAc. The organic layer was purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (neutral alumina, eluted with 50% EtOAc in petroleum ether) to give the title compound (3.6 g). LCMS (Method 1): 1.40 min, 461.3 [M+H] + .

[0686] Intermediate 82: 8-Bromo-4-(2,4-dimethoxybenzyl)-7-methyl-3,4-dihydro-2H-pyrido[4,3-b] [1,4]Oxazine

[0687]

[0688] To a solution of intermediate 81 (2.5 g, 5.43 mmol) in toluene (25 mL) was added sodium tert-butoxide (1.56 g, 16.3 mmol) and the mixture was degassed with nitrogen for 5 min. 2 (dba) 3 (0.50 g, 0.54 mmol) and X-Phos (0.39 g, 0.62 mmol) were added and the mixture was stirred in a sealed tube at 100 °C for 4 h. The mixture was cooled and then filtered through celite and washed with EtOAc. The filtrate was washed with water, washed with brine and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 15% EtOAC in petroleum ether) to give the title compound (0.28 g). LCMS (Method 1): 1.50 min, 379.2 [M+H] + .

[0689] Intermediate 83: 8-Bromo-7-methyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine hydrochloride

[0690]

[0691] To a stirred solution of intermediate 82 (0.28 g, 0.74 mmol) in EtOAc (3 mL) at 0°C was added 4M HCl in 1,4-dioxane (3 mL) and stirred at 80°C for 6 h. The mixture was concentrated under reduced pressure, the crude product was triturated with ether, and the solid was filtered to give the title compound (0.15 g). LCMS (Method 1): 0.98 min, 229.0 [M+H] + .

[0692] Intermediate 84: (2-((3,5-dibromo-2-methylpyridin-4-yl)oxy)-3,3,3-trifluoropropyl)(2,4-dimethyl tert-Butyl (2-(2-(2-oxybenzyl)carbamate)

[0693]

[0694] To intermediate 74 (4.5 g, 11.9 mmol) Cs 2 CO 3 3,5-dibromo-4-chloro-2-methylpyridine (3.37 g, 11.9 mmol, CAS 1188024-01-2) was added to a suspension of (11.6 g, 35.7 mmol) in DMF (45 mL) and the mixture was stirred at RT for 16 h. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 30% EtOAC in petroleum ether) to give the title compound (5.1 g). LCMS (Method 1): 2.71 min, 629.2 [M+H] + .

[0695] Intermediate 85: 2-((3,5-dibromo-2-methylpyridin-4-yl)oxy)-N-(2,4-dimethoxybenzyl)-3,3, 3-Trifluoropropane-1-amine hydrochloride

[0696]

[0697] To a stirred solution of intermediate 84 (3.5 g, 5.57 mmol) in EtOAc (25 mL) at 0°C was added 4M HCl in 1,4-dioxane (50 mL) and stirred at RT for 3 h. The mixture was concentrated under reduced pressure to give the title compound (2.7 g). LCMS (Method 1): 2.24 min, 529.2 [M+H] + .

[0698] Intermediate 86: 8-Bromo-4-(2,4-dimethoxybenzyl)-7-methyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrrolidone Irido[4,3-b][1,4]oxazine

[0699]

[0700] To a solution of intermediate 85 (2.7 g, 4.78 mmol) in toluene (27 mL) was added sodium tert-butoxide (1.37 g, 14.3 mmol) and the mixture was degassed with nitrogen for 5 min. 2 (db)a 3 (0.44 g, 0.48 mmol) and BINAP (0.59 g, 0.95 mmol) were added and the mixture was stirred in a sealed tube at 110 °C for 5 h. The mixture was allowed to cool, then diluted with water and extracted with EtOAc. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 20% EtOAC in petroleum ether) to give the title compound (0.60 g). LCMS (Method 16): 3.35 min, 448.7 [M+H] + .

[0701] Intermediate 87: 8-Bromo-7-methyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine Hydrochloride

[0702]

[0703] To a stirred solution of intermediate 86 (0.60 g, 1.34 mmol) in EtOAc (3 mL) at 0°C was added 4M HCl in 1,4-dioxane (6 mL), which was then stirred at 80°C for 2 h. The mixture was concentrated under reduced pressure, and the solid residue was triturated with ether and filtered to give the title compound (0.42 g). LCMS (Method 1): 1.26 min, 297.2 [M+H] + .

[0704] Intermediate 88: 8-Bromo-2-ethyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0705]

[0706] To a solution of 3-amino-5-bromopyridin-4-ol (3.42 g, 17.6 mmol, CAS 13073-25-1) in MeCN (35 mL) at 0°C, potassium carbonate (7.28 g, 52.7 mmol) was added, and the mixture was stirred at RT for 30 min. 2-Bromo-butyryl bromide (2.55 mL, 21.1 mmol) was added dropwise at 0°C, and the mixture was stirred at RT for 30 min, and then heated at 80°C for 16 h. The mixture was concentrated under reduced pressure, and the crude product was then purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 0-100% EtOAC in petroleum ether) to give the title compound (1.32 g). 1 H NMR (400 MHz; DMSO-d 6)δ:11.06(br s,1H),8.26(s,1H),8.02(s,1H),4.87(dd,1H),1.88–1.78(m,2H),1.00(t,3H).

[0707] Intermediate 89: 8-Bromo-2-ethyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0708]

[0709] To a solution of intermediate 88 (1.31 g, 4.38 mmol) in THF (13 mL) cooled at 0°C was added a THF solution of borane (1 M, 21.9 mL, 21.9 mmol), and the mixture was placed at room temperature for 2 h. The mixture was quenched by adding MeOH at 0°C and then heated at 60°C for 16 h. The mixture was concentrated under reduced pressure. The residue was partitioned with water and EtOAc, the organic layer was washed with brine, and the residue was purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. Purify the crude product by flash column chromatography (silica gel, 100-200 mesh, eluting with 0-100% EtOAC in petroleum ether) to give the title compound (0.50 g). LCMS (Method 1): 1.12 min, 243.1 [M+H] + .

[0710] Intermediate 90: Methyl 2-((3-bromo-5-nitropyridin-4-yl)oxy)-3-methylbutanoate

[0711]

[0712] To a stirred solution of methyl 2-hydroxy-3-methylbutanoate (1.31 g, 12.6 mmol, CAS 17417-00-4) and 3-bromo-4-chloro-5-nitropyridine (2.0 g, 8.42 mmol, CAS 31872-63-6) in DMF (25 mL) was added Cs 2 CO 3 (11.0 g, 33.7 mmol), and the mixture was stirred at RT for 2 h. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine and purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (40 g silica gel, eluted with 2-5% EtOAC in petroleum ether) to give the title compound (1.8 g). LCMS (Method 17): 3.13 min, 333.1 [M+H] + .

[0713] Intermediate 91: 8-Bromo-2-isopropyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0714]

[0715] To a solution of intermediate 90 (1.75 g, 5.25 mmol) in acetic acid (17.5 mL) was added iron powder (1.5 g, 26.7 mmol). The mixture was stirred at 80 °C for 2 h. The mixture was carefully basified with aqueous sodium bicarbonate solution and then extracted with DCM. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (1.0 g). LCMS (Method 1): 1.54 min, 271.1 [M+H] + .

[0716] Intermediate 92: 8-Bromo-2-isopropyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0717]

[0718] To a solution of intermediate 91 (1.0 g, 2.58 mmol) in THF (10 mL) cooled at 0°C was added a THF solution of borane (1 M, 5 mL, 5.0 mmol), and the mixture was then placed at RT for 2 h. The mixture was quenched by adding MeOH (5 mL) at 0°C and then heated at 60°C for 16 h. The mixture was concentrated under reduced pressure. The residue was partitioned with water and EtOAc, the organic layer was washed with brine, and the residue was purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (silica gel, eluting with 2-5% MeOH in DCM) to give the title compound (0.65 g). LCMS (Method 1): 1.25 min, 257.1 [M+H] + .

[0719] Intermediate 93: Ethyl 2-((3-bromo-5-nitropyridin-4-yl)oxy)-2-cyclopropylacetate

[0720]

[0721] To a stirred solution of ethyl 2-cyclopropyl-2-hydroxyacetate (1.56 g, 7.58 mmol, CAS 1185387-66-9) and 3-bromo-4-chloro-5-nitropyridine (1.5 g, 6.32 mmol, CAS 31872-63-6) in DMF (25 mL) was added Cs 2 CO 3 (1.03 g, 3.16 mmol), and the mixture was stirred at RT for 16 h. The mixture was quenched with water and extracted with EtOAc. The organic layer was washed with brine and purified by Na 2 SO 4Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (40 g silica gel, eluting with 15% EtOAc in isohexane) to give the title compound (0.4 g). LCMS (Method 1): 1.92 min, 345.2 [M+H] + .

[0722] Intermediate 94: 8-Bromo-2-cyclopropyl-2H-pyrido[4,3-b][1,4]oxazin-3(4H)-one

[0723]

[0724] To a solution of intermediate 93 (0.4 g, 0.75 mmol) in acetic acid (4 mL) was added iron powder (0.21 g, 3.77 mmol). The mixture was stirred at 80 °C for 3 h. The mixture was concentrated under reduced pressure, dissolved in EtOAc and carefully basified with aqueous sodium bicarbonate solution. The organic layer was washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (0.2 g). LCMS (Method 1): 1.38 min, 269.1 [M+H] + .

[0725] Intermediate 95: 8-Bromo-2-cyclopropyl-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0726]

[0727] To a solution of intermediate 94 (0.2 g, 0.56 mmol) in THF (3 mL) cooled at 0°C was added a solution of borane in THF (1 M, 0.56 mL, 0.56 mmol) and the mixture was then placed at RT for 2 h. The mixture was quenched by the addition of MeOH at 0°C and then heated at 60°C for 16 h. The mixture was concentrated under reduced pressure. The crude product was purified by automated flash chromatography (10-BiotageSnap neutral alumina, eluted with 50% EtOAc in isohexane) to give the title compound (60 mg). LCMS (Method 1): 1.19 min, 255.1 [M+H] + .

[0728] Intermediate 96: 8-Bromo-7-methyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0729]

[0730] To a stirred solution of intermediate 86 (0.49 g, 1.03 mmol) in EtOAc (3 mL) at 0 °C was added 4 M HCl in 1,4-dioxane (5 mL), which was then stirred at 60 °C for 3 h. The mixture was concentrated under reduced pressure, and the residue was then basified with saturated aqueous sodium bicarbonate solution and extracted with EtOAc. The organic layer was washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 0-70% EtOAC in petroleum ether) to give the title compound (0.21 g). LCMS (Method 1): 1.22 min, 299.1 [M+H] + .

[0731] Intermediate 97: 7-Methyl-2-(trifluoromethyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine-8-carbonitrile

[0732]

[0733] To a solution of intermediate 96 (0.17 g, 0.44 mmol) in 1,4-dioxane (0.5 mL) was added zinc (II) cyanide (0.10 g, 0.88 mmol), and the mixture was purged with nitrogen for 10 min. 2 CO 3 (0.43 g, 1.32 mmol) and Pd(dppf)Cl 2 (32 mg, 0.04 mmol), the mixture was stirred in a sealed container at 130 ° C for 16 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 0-40% EtOAC in petroleum ether) to give the title compound (0.12 g). LCMS (Method 1): 1.36 min, 244.1 [M+H] + .

[0734] Intermediate 98: 4-(2,4-dimethoxybenzyl)-2-(trifluoromethyl)-3,4-dihydro-2H-pyrido[4,3-b] [1,4]Oxazine-8-carbonitrile

[0735]

[0736] A mixture of intermediate 77 (0.50 g, 0.84 mmol), sodium carbonate (89 mg, 0.84 mol) and potassium hexacyanoferrate (II) (71 mg, 0.17 mmol) in DMF (5 mL) was degassed with argon for 15 min. Palladium acetate (19 mg, 0.08 mmol) was added thereto and the mixture was stirred at 125 °C in a sealed container for 16 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 0-100% EtOAC in petroleum ether) to give the title compound (0.17 g). LCMS (Method 1): 1.98 min, 380.2 [M+H] + .

[0737] Intermediate 99: 2-(Trifluoromethyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine-8-carbonitrile

[0738]

[0739] To a stirred solution of intermediate 98 (0.21 g, 0.53 mmol) in EtOAc (1 mL) at 0 °C was added 4M HCl in 1,4-dioxane (2 mL), which was then stirred at 60 °C for 3 h. The mixture was concentrated under reduced pressure, and the residue was then basified with saturated aqueous sodium bicarbonate solution and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 30-40% EtOAC in petroleum ether) to give the title compound (0.21 g). LCMS (Method 1): 1.35 min, 230.1 [M+H] + .

[0740] Intermediate 100: 4-(2,4-dimethoxybenzyl)-8-methoxy-2-(trifluoromethyl)-3,4-dihydro-2H-pyridine 4-[4,3-b][1,4]oxazine

[0741]

[0742] A solution of intermediate 77 (1.40 g, 2.20 mmol) in toluene (15 mL) was degassed with argon for 10 min. tBuBrettPhos Pd G3 (0.02 g, 0.02 mmol) and sodium methoxide (30% in methanol, 0.47 g, 8.79 mmol) were added and the mixture was stirred at 80 °C for 16 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 0-30% EtOAC in petroleum ether) to give the title compound (0.38 g). LCMS (Method 1): 1.50 min, 385.3 [M+H] + .

[0743] Intermediate 101: 8-methoxy-2-(trifluoromethyl)-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine

[0744]

[0745] To a stirred solution of intermediate 100 (0.35 g, 0.88 mmol) in EtOAc (1.8 mL) at 0 °C was added 4M HCl in 1,4-dioxane (0.88 mL), which was then stirred at 60 °C for 3 h. The mixture was concentrated under reduced pressure, and the residue was then basified with saturated aqueous sodium bicarbonate solution and extracted with EtOAc. The organic layer was washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 0-35% EtOAC in petroleum ether) to give the title compound (0.20 g). LCMS (Method 1): 0.99 min, 235.1 [M+H] + .

[0746] Intermediate 102: 3-(3-bromo-5-nitropyridin-4-yl)-2-cyanopropionic acid ethyl ester

[0747]

[0748] To a solution of ethyl 2-cyanoacetate (3.1 mL, 29.1 mmol, CAS 105-56-6) in THF (50 mL) was added LDA (2M in THF, 19.4 mL, 38.8 mmol) at 0°C and the mixture was stirred for 30 min. A solution of 3-bromo-4-(bromomethyl)-5-nitropyridine (7.0 g, 19.4 mmol, CAS 1807024-35-6) in THF (20 mL) was added and the mixture was stirred at 80°C for 2 h. The mixture was diluted with saturated aqueous ammonium chloride solution and extracted into EtOAc. The organic layer was washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-200 mesh, eluted with 0-10% EtOAC in petroleum ether) to give the title compound (4.8 g). LCMS (method 1): 1.81 min, 330.2 [M+H] + .

[0749] Intermediate 103: 5-Bromo-2-oxo-1,2,3,4-tetrahydro-1,7-naphthyridine-3-carbonitrile

[0750]

[0751] To a solution of intermediate 102 (1.8 g, 4.28 mmol) in ethanol (30 mL) and water (12 mL) were added iron powder (1.21 g, 21.7 mmol) and ammonium chloride (1.16 g, 21.7 mmol) and the mixture was stirred at 80 °C for 6 h. The mixture was filtered through celite and washed with MeOH. The filtrate was concentrated under reduced pressure, dissolved in EtOAc and washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (2.1 g). LCMS (Method 1): 1.25 min, 254.1 [M+H] + .

[0752] Intermediate 104: 5-Bromo-1,2,3,4-tetrahydro-1,7-naphthyridine-3-carbonitrile

[0753]

[0754] To a solution of intermediate 103 (1.6 g, 2.22 mmol) in THF (10 mL) cooled at 0°C was added borane dimethyl sulfide complex (2M in THF, 2.78 mL, 5.56 mmol), and the mixture was placed at RT for 2 h. The mixture was quenched by adding MeOH at 0°C and then heated at 60°C for 16 h. The mixture was concentrated under reduced pressure, then dissolved in DCM, washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The product was purified by preparative HPLC (X-Select C18, 19 x 250 mm x 5 μm, flow rate: 18 mL / min, 10 mM NH4 HCO 3 The crude product was purified by aqueous solution of 1% MeCN (30% to 38% MeCN in 7 min, increasing to 100% over 0.5 min and maintaining for 3.5 min) to give the title compound (1.2 g). LCMS (Method 1): 0.95 min, 240.0 [M+H] + .

[0755] Intermediate 105: 5-Bromo-N-cyclopropyl-3-(difluoromethyl)-N-methylpicolinamide

[0756]

[0757] To a solution of 5-bromo-3-(difluoromethyl)pyridine-2-carboxylic acid (0.50 g, 1.98 mmol, CAS 1404337-672-7) in THF (5 mL) cooled at 0°C was added DIPEA (1.72 mL, 9.92 mmol), then after 5 minutes T3P (1.79 mL, 5.95 mmol) and N-methylcyclopropylamine (0.21 g, 2.98 mmol; CAS 5163-20-2), and the mixture was stirred at RT for 3 h. The mixture was poured into water and extracted with EtOAc. The organics were purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (silica gel, eluting with 0-100% EtOAC in hexanes) to give the title compound (0.35 g). LCMS (Method 4): 1.80 min, 305.3 [M+H] + .

[0758] Intermediate 106: N-cyclopropyl-3-(difluoromethyl)-5-((benzhydryl)amino)-N-methylpicolinamide

[0759]

[0760] To a solution of intermediate 105 (0.50 g, 1.49 mmol) in toluene (10 mL) was added Cs 2 CO 3 (1.46 g, 4.47 mmol), the mixture was degassed with argon for 20 min. Pd 2 (db) a3 (0.14 g, 0.15 mmol) and X-Phos (0.14 g, 0.30 mmol) were added and the mixture was stirred at 110 °C for 16 h. The mixture was cooled, diluted with water and extracted with EtOAc. The organics were washed with water, brine, and purified by Na 2 SO 4Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 0-100% EtOAC in petroleum ether) to give the title compound (0.50 g). LCMS (Method 4): 2.22 min, 406.4 [M+H] + .

[0761] Intermediate 107: 5-amino-N-cyclopropyl-3-(difluoromethyl)-N-methylpicolinamide

[0762]

[0763] To a solution of intermediate 106 (0.70 g, 1.57 mmol) in DCM (10 mL) at 0°C was added TFA (0.36 mL, 4.71 mmol), and the mixture was stirred at RT for 3 h. The mixture was poured into water and extracted with DCM. The organics were purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 0-100% EtOAC in petroleum ether) to give the title compound (0.20 g). LCMS (Method 19): 2.34 min, 242.0 [M+H] + .

[0764] Synthesis Example

[0765] Example 1: 5-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,4-dihydroquinoline-1 (2H)-Formamide

[0766]

[0767] To a stirred solution of 5-bromo-1,2,3,4-tetrahydroquinoline (0.25 g, 1.17 mmol, CAS114744-50-2) in DCM (10 mL) was added 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.25 g, 1.28 mmol, CAS1832583-43-3) and triphosgene (0.24 g, 0.82 mmol) at 0°C and stirred for 15 min at 0°C. Triethylamine (0.33 mL, 2.35 mmol) was added dropwise and the mixture was stirred at room temperature for 3 h. The mixture was diluted with DCM, washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (Sunfire C18, 19 x 150 mm x 5 μm, flow rate: 20 mL / min, 0.1% TFA in water, MeCN from 10% to 60% in 9 min, kept at 60% for 5 min, then increased to 100% in 0.01 min and kept for 1.9 min) to give the title compound (39 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.69(br s,1H),8.61(d,1H),8.36(d,1H),8.15(s,2H),7.44(dd,1H),7.38(dd,1H),7.13(t, 1H),3.76(dd,2H),2.78(t,2H),1.94-2.00(m,2H).LCMS(Method 5):2.22min,431.1[MH] - .

[0768] Example 2: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-bromo-3,4-dihydro- Hydroquinoline-1(2H)-carboxamide

[0769]

[0770] To a stirred solution of 5-bromo-1,2,3,4-tetrahydroquinoline (0.25 g, 1.17 mmol, CAS114744-50-2) in DCM (10 mL) was added 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.30 g, 1.29 mmol, CAS1832582-59-8) and triphosgene (0.24 g, 0.82 mmol) at 0°C and stirred for 15 min at 0°C. Triethylamine (0.33 mL, 2.35 mmol) was added dropwise and the mixture was stirred at room temperature for 3 h. The mixture was diluted with DCM, washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X SELECT C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 0.1% TFA aqueous solution, MeCN from 30% to 80% in 9 min, maintained at 80% for 1 min, then increased to 100% in 0.1 min and maintained for 2.9 min) to give the title compound (57 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.82(br s,1H),8.92(d,1H),8.60(d,1H),8.16(s,2H),7.47(dd,1H),7.40(dd,1H),7.13(t, 1H),3.77(dd,2H),2.79(t,2H),1.95-2.01(m,2H).LCMS(Method 5):2.29min,465.1[MH] - .

[0771] Example 3: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-methoxy-3,4-dihydroquinoline Phospholine-1(2H)-carboxamide

[0772]

[0773] To a stirred solution of 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.18 g, 0.92 mmol, CAS1832583-43-3) in DCM (2 mL) was added triethylamine (0.25 mL, 1.84 mmol) and triphosgene (0.19 g, 0.64 mmol) at 0°C and stirred at 0°C for 30 min. 5-Methoxy-1,2,3,4-tetrahydroquinoline (0.25 g, 1.17 mmol, CAS30389-37-8) was added and the mixture was stirred at room temperature for 16 h. The mixture was diluted with DCM, washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X TERRAC18, 19×250 mm×10 μm, flow rate: 18 mL / min, 0.1% TFA aqueous solution, MeCN from 20% to 70% in 9 min, maintained at 70% for 5 min, then increased to 100% in 0.1 min and maintained for 1.9 min) to give the title compound (26 mg). 1 HNMR (400 MHz; DMSO-d 6 )δ:9.60(br s,1H),8.62(d,1H),8.36(d,1H),8.14(s,2H),7.15(t,1H),7.02(d,1H),6.74(d,1H),3.8 1(s,3H),3.72(dd,2H),2.66(t,2H),1.88–1.95(m,2H).LCMS(Method 6):3.45min,385.3[M+H] + .

[0774] Example 4: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2,3-dihydro- Hydrogen-4H-benzo[b][1,4]oxazine-4-carboxamide

[0775]

[0776] To a stirred solution of 8-bromo-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.25 g, 1.16 mmol, CAS 625394-65-2) in DCM (2 mL) was added triphosgene (0.34 g, 1.16 mmol) and triethylamine (0.32 mL, 2.32 mmol) at 0°C and stirred at 0°C for 15 min. Then 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.26 g, 1.16 mmol, CAS 1832582-59-8) was added and the mixture was stirred at room temperature for 16 h. The mixture was diluted with saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X TERRA C18, 19×250 mm×10 μm, flow rate: 20 mL / min, 0.1% TFA aqueous solution, MeCN from 20% to 70% in 9 min, maintained at 70% for 5 min, then increased to 100% in 0.1 min and maintained for 2.9 min) to give the title compound (40 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.01(br s,1H),8.94(d,1H),8.61(d,1H),8.17(s,2H),7.61(dd,1H),7.34(dd,1H),6.85(t,1H)4.43(t,2H),3.95(t,2H).LCMS(Method 1):2.01min,467.2[MH] - .

[0777] Example 5: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2-methyl- 2,3-Dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide

[0778]

[0779] To a stirred solution of 8-bromo-2-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.20 g, 0.87 mmol, CAS1267095-78-2) in THF (5 mL) was added 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.20 g, 0.87 mmol, CAS1832582-59-8) and triphosgene (0.13 g, 0.44 mmol) at 0°C and stirred at 0°C for 15 min. Triethylamine (0.25 mL, 1.75 mmol) was then added dropwise and the mixture was stirred at room temperature for 16 h. The mixture was diluted with DCM, washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 25% to 50% in 7 min, held at 50% for 6.1 min, then increased to 100% in 0.1 min and held for 3.8 min) to give the title compound (37 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.02(s,1H),8.94(d,1H),8.60(d,1H),8.17(s,2H),7.60(dd,1H),7.34(dd,1H),6.85(t,1H ),4.48-4.52(m,1H),4.18(dd,1H),3.45(dd,1H),1.38(d,3H).LCMS(Method 7):2.47min,483.1[M+H] + .

[0780] Example 6: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2-cyano- 2,3-Dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide

[0781]

[0782] To a stirred solution of intermediate 1 (0.30 g, 1.25 mmol) in DCM (2 mL) was added 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.29 g, 1.25 mmol, CAS 1832582-59-8) and triphosgene (0.19 g, 0.63 mmol) at 0 °C and stirred at 0 °C for 15 min. Triethylamine (0.35 g, 3.50 mmol) was then added dropwise and the mixture was stirred at room temperature for 4 h. The mixture was diluted with DCM, washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 20 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 50% in 4 min, kept at 50% for 16 min, then increased to 100% in 0.1 min and kept for 2.9 min) to give the title compound (50 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.29(s,1H),8.95(br s,1H),8.60(d,1H),8.17(s,2H),7.63(br d,1H),7.45(dd,1H),7.01(t,1H),5.94(t,1H),4.66(dd,1H),3.93(dd,1H).LCMS(Method 1):1.94min,492.1[MH] - .

[0783] Example 7: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-cyano-3,4-dihydroquinoline- 1(2H)-Formamide

[0784]

[0785] To a stirred solution of 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.20 g, 1.02 mmol, CAS 1832583-43-3) in DCM (2 mL) was added triethylamine (0.28 mL, 2.04 mmol) and triphosgene (0.37 g, 1.02 mmol) at 0°C and stirred at 0°C for 30 min. 1,2,3,4-tetrahydroquinoline-5-carbonitrile (0.17 g, 1.02 mmol, CAS 939758-72-2) was added and the mixture was stirred at room temperature for 16 h. The mixture was diluted with DCM, washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X TERRAC18, 19×250 mm×10 μm, flow rate: 20 mL / min, 0.1% TFA aqueous solution, MeCN from 20% to 70% in 9 min, maintained at 70% for 5 min, then increased to 100% in 0.1 min and maintained for 1.9 min) to give the title compound (39 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.76(s,1H),8.64(d,1H),8.37(d,1H),8.15(s,2H),7.81(dd,1H),7.55(dd,1H),7. 35(t,1H),3.81(t,2H),2.95(t,2H),1.98–2.06(m,2H).LCMS(Method 1):1.75min,378.3[MH] - .

[0786] Example 8: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(pyridine-3-yl) 1-(2H)-3,4-dihydroquinolinecarboxamide

[0787]

[0788] To a stirred solution of intermediate 3 (0.10 g, 0.47 mmol) in DCM (10 mL) at 0°C, 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.11 g, 0.47 mmol, CAS 1832582-59-8), triphosgene (75 mg, 0.23 mmol) and triethylamine (0.1 mL, 0.72 mmol) were added, and the mixture was stirred at room temperature for 2 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with saturated sodium bicarbonate aqueous solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge Phenyl, 19×250 mm×5 μm, flow rate: 18 mL / min, 0.1% TFA aqueous solution, MeCN from 10% to 40% in 7 min, maintained at 40% for 4.5 min, then increased to 100% in 0.1 min and maintained for 2.4 min) to give the title compound (22 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.76(br s,1H),8.99(d,1H),8.66-8.69(m,3H),8.17(s,2H),7.96(d,1H),7.63(dd,1H),7.57(d,1H),7.33( t,1H),7.09(d,1H),3.79(t,2H),2.62(t,2H),1.87-1.91(m,2H).LCMS(Method 8):2.23min,466.4[M+H] + .

[0789] Example 9: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(oxazole-2-yl)- 1-(2H)-3,4-dihydroquinolinecarboxamide

[0790]

[0791] To a stirred solution of intermediate 5 (0.13 g, 0.65 mmol) in DCM (5 mL) at 0 °C were added 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.15 g, 0.65 mmol, CAS 1832582-59-8) and triphosgene (135 mg, 0.45 mmol) and stirred at 0 °C for 15 min. Triethylamine (0.27 mL, 1.95 mmol) was added dropwise and the mixture was stirred at room temperature for 16 h. The mixture was diluted with DCM and then washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X SELECT C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH4 HCO 3 Aqueous solution, MeCN from 35% to 65% in 4 min, kept at 65% for 12 min, then increased to 100% in 1 min and kept for 5 min) to give the title compound (46 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.76(br s,1H),8.93(d,1H),8.62(d,1H),8.27(d,1H),8.16(s,2H),7.68(dd,1H),7.61(d,1H),7.44(d, 1H),7.35(t,1H),3.80(t,2H),3.32(t,2H),1.94-1.99(m,2H).LCMS(Method 1):2.63min,454.0[MH] - .

[0792] Example 10: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(thiazole-2-yl) 1-(2H)-3,4-dihydroquinolinecarboxamide

[0793]

[0794] To a stirred solution of intermediate 7 (0.15 g, 0.69 mmol) in DCM (5 mL) at 0 °C were added 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.15 g, 0.65 mmol, CAS 1832582-59-8) and triphosgene (0.14 g, 0.48 mmol) and stirred at 0 °C for 15 min. Triethylamine (0.29 mL, 2.08 mmol) was added dropwise and the mixture was stirred at room temperature for 16 h. The mixture was diluted with DCM, then washed with saturated aqueous sodium bicarbonate solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X SELECT C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 in water with MeCN,30%to 55%over 4min,held at 55%for 8.52min then ramped to 100%over 0.1min and held for 3.4min) to provide the title compound(45mg). 1 H NMR (400 MHz; DMSO-d 6)δ:9.77(br s,1H),8.95(d,1H),8.63(d,1H),8.16(s,2H),8.01(d,1H),7.89(d,1H),7.59(dd,1H),7.44(dd, 1H),7.33(t,1H),3.79(t,2H),3.03(t,2H),1.89-1.96(m,2H).LCMS(Method 8):2.38min,472.3[M+H] + .

[0795] Example 11: cis-N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-bromo- 3,4-Dimethyl-3,4-dihydroquinoline-1(2H)-carboxamide

[0796]

[0797] To a stirred solution of intermediate 10 (0.27 g, 1.10 mmol) in DCM (10 mL) at 0 °C were added 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.25 g, 1.10 mmol, CAS 1832582-59-8) and triphosgene (0.24 g, 0.82 mmol) and stirred at 0 °C for 15 min. Triethylamine (0.22 mL, 1.65 mmol) was added dropwise and the mixture was stirred at room temperature for 2 h. The mixture was diluted with DCM and then washed with saturated sodium bicarbonate aqueous solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 40% to 70% in 5 min, kept at 70% for 8 min, then increased to 100% in 0.1 min and kept for 2.9 min) to give the title compound (60 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.67(brs,1H),8.99(d,1H),8.63(d,1H),8.16(s,2H),7.55(d,1H),7.34(dd,1H),7.12(t,1H),3.90(dd,1H ),3.37(d,1H),3.10-3.18(m,1H),2.01-2.12(m,1H),1.12(d,3H),0.96(d,3H).LCMS(Method 1):2.36min,493.2[MH] - .

[0798] Example 12: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-phenyl-3,4- Dihydroquinoline-1(2H)-carboxamide

[0799]

[0800] To a stirred solution of Example 2 (0.27 g, 1.10 mmol) in 1,4-dioxane:water (4:1 10 mL) was added Cs 2 CO 3 (0.39 g, 1.2 mmol) and phenylboronic acid (70 mg, 0.64 mmol, CAS 98-80-6), the mixture was degassed with nitrogen for 10 min. PdCl was added 2 (PPh 3 ) 2 (21 mg, 0.03 mmol) and X-Phos (17 mg, 0.03 mmol), the mixture was degassed with nitrogen for 10 min. The mixture was stirred at 90 ° C for 16 h. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with saturated sodium bicarbonate aqueous solution, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X SELECT C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 40% to 60% in 4 min, held at 60% for 16.5 min, then increased to 100% in 0.1 min and held for 3.4 min) to give the title compound (21 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.71(br s,1H),8.98(d,1H),8.65(d,1H),8.16(s,2H),7.48(t,3H),7.41(d,1H),7.37(d,2H),7.27(t,1 H),7.04(dd,1H),3.76(t,2H),2.61(t,2H),1.83-1.90(m,2H).LCMS(Method 1):2.29min,463.3[MH] - .

[0801] Example 13: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2, 3-Dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide

[0802]

[0803] To a stirred solution of 5-chloro-6-(2H-1,2,3-triazol-2-yl)nicotinic acid (0.25 g, 1.03 mmol, CAS 2244109-97-3) in toluene (10 mL) were added triethylamine (0.28 mL, 2.04 mmol) and DPPA (0.3 mL, 1.24 mmol), and the mixture was stirred at 100 ° C for 30 min. 8-bromo-2,2-dimethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.20 g, 0.83 mmol, CAS 853683-76-8) was added, and the mixture was stirred at 100 ° C for 16 h. The mixture was cooled, quenched with water, and then extracted with ethyl acetate. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 10% to 67% in 1.14 min, held at 75% for 8.44 min, then increased to 100% in 1.5 min and held for 2 min) to give the title compound (45 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.95(s,1H),8.63(d,1H),8.36(d,1H),8.15(s,2H),7.52(dd,1H),7.35(dd ,1H),6.85(t,1H),3.73(s,2H),1.36(s,6H).LCMS(Method 9):3.71min,463.5[M+H] + .

[0804] Example 14: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(1,3,4-thiophene oxadiazole-2-yl)-3,4-dihydroquinoline-1(2H)-carboxamide

[0805]

[0806] To a stirred solution of intermediate 13 (0.13 g, 0.58 mmol) in DCM (10 mL) was added DIPEA (0.22 g, 1.73 mmol) and 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.13 g, 0.58 mmol, CAS 1832582-59-8) at 0°C, and the mixture was stirred at 0°C for 15 min. Phosgene (0.28 g, 0.57 mmol) was added at 0°C, and the mixture was stirred at room temperature for 5 h. The mixture was quenched with water and extracted with DCM. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X SELECT C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 45% to 85% in 9 min, kept at 90% for 5 min, and increased to 100% in 0.1 min and kept for 2.9 min) to give the title compound (16 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.81(br s,1H),9.75(s,1H),8.95(d,1H),8.63(d,1H),8.16(s,2H),7.67(dd,1H),7.43(dd,1H),7. 36(t,1H),3.81(t,2H),2.94(t,2H),1.91-1.98(m,2H).LCMS(Method 10):2.12min,473.3[M+H] + .

[0807] Example 15: 5-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,3-dimethyl-3, 4-Dihydroquinoline-1(2H)-carboxamide

[0808]

[0809] To a stirred solution of intermediate 16 (0.30 g, 1.25 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.15 g, 0.75 mmol, CAS 1832583-43-3) in DCM (10 mL) at 0°C was added triethylamine (0.28 mL, 2.04 mmol). Triphosgene (0.28 g, 0.94 mmol) was added and the mixture was stirred at room temperature for 3 h. The mixture was diluted with DCM, washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×150 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO3 Aqueous solution, MeCN from 40% to 75% in 4 min, hold at 75% for 6 min) to give the title compound (56 mg). 1 H NMR (400 MHz; CDCl 3 )δ:8.51(d,1H),8.26(d,1H),7.91(s,2H),7.47(dd,1H),7.30(d,2H),7.17(t ,1H),3.62(s,2H),2.66(s,2H),1.09(s,6H).LCMS(Method 14):2.24min,459.1[MH] - .

[0810] Example 16: 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-4-methyl-3,4-dihydro- Hydroquinoxaline-1(2H)-carboxamide

[0811]

[0812] To a stirred solution of intermediate 17 (0.30 g, 1.32 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.18 g, 0.92 mmol, CAS 1832583-43-3) in DCM (10 mL) at 0°C was added triethylamine (0.53 g, 5.28 mmol). Triphosgene (0.27 g, 0.92 mmol) was added and the mixture was stirred at room temperature for 3 h. The mixture was diluted with DCM, washed with water, brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 100-22 mesh, eluted with 15-20% ethyl acetate in hexanes) followed by preparative HPLC (X-Bridge C18, 19x250 mm x 5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 25% to 55% in 4 min, maintained at 55% for 6.8 min, then increased to 100% in 4 min) to give the title compound (30 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.78(s,1H),8.65(d,1H),8.39(d,1H),8.15(s,2H),7.57(dd,1H),7.30(dd,1H),6 .87(t,1H),3.84(dd,2H),3.20(dd,2H),2.87(s,3H).LCMS(Method 1):1.97min,446.2[MH] - .

[0813] Example 17: 5-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,4-dihydro-1,7- Naphthyridine-1(2H)-carboxamide

[0814]

[0815] To a stirred solution of 5-bromo-1,2,3,4-tetrahydro-1,7-naphthyridine (95 mg, 0.44 mmol, CAS351457-97-1) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (51 mg, 0.26 mmol, CAS1832583-43-3) in DCM (2 mL) was added triethylamine (0.18 mL, 1.32 mmol) at 0 °C. Triphosgene (91 mg, 0.31 mmol) was added and the mixture was stirred at room temperature for 16 h. The mixture was quenched with water and extracted with 10% methanol in DCM. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 20% to 60% in 7 min, kept at 60% for 4.8 min, increased to 100% in 0.2 min, and kept at 100% for 5 min) to give the title compound (9 mg). 1 HNMR (400 MHz; CDCl 3 )δ:8.59(s,1H),8.54(s,1H),8.47(d,1H),8.31(d,1H),7.92(s,2H),7.15(s,1H),3.89(t,2H),2.90(t,2H),2.06-2.13(m,2H).LCMS(Method 1):1.66min,434.2[M+H] + .

[0816] Example 18: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-cyano-2-methyl- 2,3-Dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide

[0817]

[0818] To a stirred solution of intermediate 20 (0.30 g, 1.18 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.16 g, 0.83 mmol, CAS 1832583-43-3) in DCM (7 mL) at 0°C was added triethylamine (0.36 g, 3.54 mmol). Triphosgene (0.25 g, 0.83 mmol) was added and the mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge Phenyl, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 35% to 50% in 4 min, maintained at 50% for 10 min) to give the title compound (50 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.19(s,1H),8.65(d,1H),8.35(d,1H),8.16(s,2H),7.60(d,1H),7.46(dd,1H),7 .01(t,1H),4.89(d,1H),3.60(d,1H),1.88(s,3H).LCMS(Method 11):2.38min,474.1[M+H] + .

[0819] Example 19: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2, 3-Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0820]

[0821] To a stirred solution of intermediate 23 (1.50 g, 6.17 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (1.20 g, 6.17 mmol, CAS 1832583-43-3) in DCM (15 mL) was added triethylamine (3.44 mL, 24.7 mmol) at 0°C, and the mixture was allowed to react at room temperature for 30 min. The mixture was cooled to 0°C again, a solution of triphosgene (1.83 g, 6.17 mmol) in DCM (10 mL) was added dropwise, and the mixture was stirred at room temperature for 2 h. The solvent was removed under reduced pressure. The crude product was purified by preparative HPLC (Symmetry C18, 19×250 mm×5 μm, flow rate: 17 mL / min, water and MeCN, isocratic 50:50) to give the title compound (0.51 g). 1 H NMR (400 MHz; DMSO-d6 )δ:10.08(br s,1H),8.67(s,1H),8.61(s,1H),8.37(d,1H),8.35(s,1H),8.15(s,2H),3.82(s,2H),1.39(s,6H).LCMS(Method 4):1.78min,464.4[M+H] + .

[0822] Example 20: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethynyl-2,3- Dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide

[0823]

[0824] To a stirred solution of intermediate 28 (0.19 g, 0.67 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (92 mg, 0.47 mmol, CAS 1832583-43-3) in DCM (7 mL) at 0°C was added triethylamine (0.28 mL, 2.01 mmol). Triphosgene (0.14 g, 0.47 mmol) was added and the mixture was stirred at room temperature for 1 h. The mixture was diluted with DCM, washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 30×150 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 50% in 6 min, kept at 50% for 5 min, increased to 100% in 0.1 min, kept at 100% for 5.9 min) to give the title compound (10 mg). 1 HNMR (400 MHz; DMSO-d 6 )δ:9.97(br s,1H),8.65(s,1H),8.36(d,1H),8.15(s,2H),7.55(d,1H),7.38(d,1H),6.91(t,1H),5 .47(s,1H),4.24(dd,1H),3.83(d,1H),3.76(d,1H).LCMS(Method 12):2.05min,459.3[M+H] + .

[0825] Example 21: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,3-dihydro-4H-pyridin- Irido[4,3-b][1,4]oxazine-4-carboxamide

[0826]

[0827] To a stirred solution of 8-bromo-3,4-dihydro-2H-pyrido[4,3-b][1,4]oxazine (0.13 g, 0.58 mmol, CAS1379320-13-4) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (79 mg, 0.40 mmol, CAS1832583-43-3) in DCM (5 mL) at 0°C was added triethylamine (0.24 g, 1.74 mmol). Triphosgene (0.12 g, 0.40 mmol) was added and the mixture was stirred at room temperature for 16 h. The mixture was quenched with water and extracted with 10% methanol in DCM. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 20% to 60% in 7 min, kept at 60% for 4.8 min, increased to 100% in 0.2 min, kept at 100% for 5 min) to give the title compound (30 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.01(br s,1H),8.84(s,1H),8.50(s,1H),8.39(d,1H),8.27(s,1H),8.13(s,2H),4.48(t,2H),4.03(t,2H).LCMS(Method 13):1.94min,436.1[M+H] + .

[0828] Example 22: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-cyclopropyl-3,4-dihydro- 1,7-Naphthyridine-1(2H)-carboxamide

[0829]

[0830] To a stirred solution of intermediate 30 (0.17 g, 0.97 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.19 g, 0.97 mmol, CAS 1832583-43-3) in DCM (10 mL) at 0°C was added triethylamine (0.30 g, 2.92 mmol). Triphosgene (0.22 g, 0.73 mmol) was added and the mixture was stirred at room temperature for 3 h. The mixture was quenched with saturated aqueous sodium bicarbonate solution and extracted with DCM. The combined organic layers were washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4HCO 3 Aqueous solution, MeCN from 10% to 70% in 14 min, increased to 100% in 0.1 min, maintained at 100% for 1.9 min) to give the title compound (10 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.75(br s,1H),8.62(d,1H),8.51(s,1H),8.38(d,1H),8.14(s,2H),7.94(s,1H),3.80(t,2H),2.91(t,2H),1.97 -2.01(m,2H),1.84-1.88(m,1H),0.94-0.98(m,2H),0.70-0.73(m,2H).LCMS(Method 1):1.30min,396.2[M+H] + .

[0831] Example 23: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2,2-di Methyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide

[0832]

[0833] Triethylamine (0.43 mL, 3.09 mmol) and triphosgene (0.21 g, 0.72 mmol) were added to a stirred solution of 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.19 g, 0.82 mmol, CAS1832582-59-8) and 8-bromo-2,2-dimethyl-3,4-dihydro-2H-benzo[b][1,4]oxazine (0.25 g, 1.03 mmol, CAS853683-76-8) in DCM (15 mL) at 0 ° C. The mixture was stirred at room temperature for 1 h. The mixture was diluted with water and then extracted with DCM. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 10% to 67% in 1.14 min, held at 75% for 8.44 min, then increased to 100% in 1.5 min and held for 2 min) to give the title compound (50 mg). 1 H NMR (400 MHz; DMSO-d 6)δ:10.08(s,1H),8.94(d,1H),8.59(d,1H),8.16(s,2H),7.55(dd,1H),7.36(d d,1H),6.86(t,1H),3.75(s,2H),1.36(s,6H).LCMS(Method 1):2.21min,495.2[MH] - .

[0834] Example 24: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyclopropyl-2,2-dimethoxy 2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0835]

[0836] Pyridine (0.12 mL, 1.47 mmol) was added to a stirred solution of intermediate 32 (0.10 g, 0.49 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (67 mg, 0.34 mmol, CAS 1832583-43-3) in DCM (5 mL) at 0°C. A solution of triphosgene (0.22 g, 0.73 mmol) in DCM (1 mL) was added and the reaction was stirred at 0°C for 15 min and then at room temperature for 16 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 17 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 50% in 8 min, increased to 98% in 0.1 min, maintained at 98% for 1.9 min) to give the title compound (39 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.03(br s,1H),8.60(br s,1H),8.48(br s,1H),8.37(d,1H),8.12(s,2H),7.72(s,1H),3.79(s,2H),1.93-2.00(m,1H),1.3 5(s,6H),0.91-0.94(m,2H),0.74-0.77(m,2H).LCMS(Method 14):1.52min,426.5[M+H] + .

[0837] Example 25: (S)-1-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-6a,7,8,9- Tetrahydropyrido[3,4-e]pyrrolo[1,2-a]pyrazine-5(6H)-carboxamide

[0838]

[0839] To a stirred solution of intermediate 35 (0.30 g, 1.18 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.18 g, 0.92 mmol, CAS 1832583-43-3) in DCM (5 mL) at 0°C was added pyridine (0.29 mL, 3.54 mmol). A solution of triphosgene (0.35 g, 1.18 mmol) in DCM (1 mL) was added and stirred at 0°C for 15 min, then at room temperature for 3 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Select C18, 25×150 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 25% to 45% in 6 min, kept at 45% for 8 min, increased to 98% in 0.1 min, kept at 98% for 1.9 min) to give the title compound (50 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.75(br s,1H),8.58(s,1H),8.35(d,1H),8.33(s,1H),8.18(s,1H),8.14(s,2H),4.43(d,1H),4.17-4.23(m,1H),3.40-3.5 4(m,2H),2.70(dd,1H),2.11-2.20(m,1H),1.83-1.90(m,2H),1.69-1.69(m,1H).LCMS(Method 14):1.41min,475.5[M+H] + .

[0840] Example 26: (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1,2-dimethoxy 2,3-Dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide

[0841]

[0842] To a stirred solution of intermediate 38 (0.25 g, 1.03 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.14 g, 0.72 mmol, CAS 1832583-43-3) in DCM (5 mL) at 0°C was added triethylamine (0.43 mL, 3.09 mmol). A solution of triphosgene (0.33 g, 1.13 mmol) in DCM (1 mL) was added and stirred at 0°C for 15 min, then at room temperature for 3 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4HCO 3 Aqueous solution, MeCN from 20% to 45% in 7 min, kept at 45% for 7.5 min, increased to 98% in 0.1 min, kept at 98% for 2.4 min) to give the title compound (28 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.82(br s,1H),8.60(d,1H),8.40(s,1H),8.37(d,1H),8.22(s,1H),8.14(s,2H),3.94(q,1 H),3.52-3.57(m,2H),3.14(s,3H),1.09(d,3H).LCMS(Method 14):1.62min,463.3[M+H] + .

[0843] Example 27: 8'-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-4,5-dihydro-2H- Spiro[furan-3,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-carboxamide

[0844]

[0845] To a stirred solution of intermediate 40 (0.14 g, 0.52 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.18 g, 0.94 mmol, CAS 1832583-43-3) in DCM (5 mL) at 0°C was added triethylamine (0.22 mL, 1.55 mmol). A solution of triphosgene (0.35 g, 1.18 mmol) in DCM (1 mL) was added and stirred at 0°C for 15 min, then at room temperature for 3 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Select C18, 25×150 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 25% to 45% in 6 min, kept at 45% for 8 min, increased to 98% in 0.1 min, kept at 98% for 1.9 min) to give the title compound (24 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.11(br s,1H),8.75(s,1H),8.58(s,1H),8.35-8.39(m,2H),8.14(s,2H),3.90-4.1 2(m,4H),3.78(s,2H),2.02-2.17(m,2H).LCMS(Method 14):1.65min,492.1[M+H] + .

[0846] Example 28: 1-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-6,6a,7,8,9,10- Hexahydro-5H-bipyrido[1,2-a:3',4'-e]pyrazine-5-carboxamide

[0847]

[0848] To a stirred solution of intermediate 43 (50 mg, 0.19 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (29 mg, 0.15 mmol, CAS 1832583-43-3) in DCM (2 mL) was added triethylamine (0.08 mL, 0.56 mmol) at 0°C. Triphosgene (39 mg, 0.13 mmol) was added and the mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge Phenyl, 19×250 mm×5 μm, flow rate: 17 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 60% in 9 min, maintained at 60% for 5 min, increased to 100% in 0.1 min, and maintained at 100% for 2.9 min). Chiral preparative SFC (Chiralcel-OJ-H, 30×250 mm×5 μm, flow rate: 100 g / min, 60% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS) with 40% MeOH:MeCN (1:1), back pressure 100 bar, temperature 30°C) to isolate peak 1. The title compound (10 mg) was isolated. 1 H NMR (400 MHz; DMSO-d 6 )δ:9.70(s,1H),8.63(s,1H),8.37(d,1H),8.30(s,1H),8.23(s,1H),8.14(s,2H),4.55(d,1H),4.31(dd,1H),3.40- 3.49(m,1H)3.17-3.23(m,1H),2.93(t,1H),1.52–1.90(m,5H),1.20-1.35(m,1H).LCMS(Method 14):1.50min,489.1[M+H] + .

[0849] Example 29: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-methyl-2,3-triazol-2-yl Hydropyrido[3,4-b]pyrazine-4(1H)-carboxamide

[0850]

[0851] To a stirred solution of intermediate 46 (150 mg, 0.66 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (103 mg, 0.53 mmol, CAS 1832583-43-3) in DCM (2 mL) was added triethylamine (0.28 mL, 1.98 mmol) at 0°C and stirred at 0°C for 5 min. Triphosgene (137 mg, 0.46 mmol) was added and the mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 25% to 40% in 4 min, kept at 40% for 7.6 min, increased to 98% in 0.1 min, kept at 98% for 2.3 min) to give the title compound (45 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.79(s,1H),8.60(s,1H),8.42(s,1H),8.37(d,1H),8.22(s,1H),8.14(s,2H),3.89(t,2H),3.37(t,2H),3.18(s,3H).LCMS(Method 14):1.26min,449.1[M+H] + .

[0852] Example 30: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-methyl-2,3-triazol-2-yl Hydrogen-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0853]

[0854] To a stirred solution of intermediate 49 (0.30 g, 1.31 mmol) in DCM (6 mL) at 0°C were added triethylamine (0.54 mL, 3.93 mmol) and triphosgene (312 mg, 1.05 mmol) and stirred at 0°C for 15 min. 5-Chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.21 g, 1.05 mmol, CAS 1832583-43-3) was added and the mixture was stirred at room temperature for 2 h. The mixture was diluted with DCM, washed with brine, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 60-65% ethyl acetate in petroleum ether) and subsequently by preparative HPLC (X-Bridge C18, 19 x 250 mm x 5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3Aqueous solution, MeCN from 10% to 75% in 14 min, hold at 75% for 1 min) to give the title compound (31 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.01(s,1H),8.72(s,1H),8.62(s,1H),8.38(d,1H),8.33(s,1H),8.15(s,2H),4. 61(t,1H),4.25(d,1H),3.50(dd,1H),1.41(t,3H).LCMS(Method 14):1.61min,450.2[M+H] + .

[0855] Example 31: 8-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1,2,2-trimethyl- 2,3-Dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide

[0856]

[0857] To a stirred solution of intermediate 53 (0.23 g, 0.89 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.12 g, 0.61 mmol, CAS 1832583-43-3) in DCM (7 mL) at 0°C was added triethylamine (0.50 mL, 3.59 mmol) and stirred at 0°C for 15 min. A solution of triphosgene (0.26 g, 0.89 mmol) in DCM (1 mL) was added, and the mixture was stirred at room temperature for 2 h, and the mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (Symmetry C18, 19×300 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 40% to 50% in 5 min, kept at 50% for 7.6 min, increased to 98% in 0.1 min, kept at 98% for 5.3 min) to give the title compound (24 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.92(br s,1H),8.53(br s,1H),8.44(br s,1H),8.36(d,1H),8.17(s,1H),8.13(s,2H),3.70(s,2H),3.05(s,3H),1.23(s,6H).LCMS(Method 14):1.42min,477.1[M+H] + .

[0858] Example 32: 8-Chloro-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2, 3-Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0859]

[0860] To a stirred solution of intermediate 56 (0.25 g, 1.26 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.17 g, 0.88 mmol, CAS 1832583-43-3) in DCM (5 mL) at 0°C was added triethylamine (0.70 mL, 5.03 mmol) and stirred at 0°C for 15 min. A solution of triphosgene (0.37 g, 1.26 mmol) in DCM (1 mL) was added and the mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Select C18, 19×250 mm×5 μm, flow rate: 16 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 20% to 55% in 7 min, kept at 55% for 5.5 min, increased to 98% in 0.1 min, kept at 98% for 5.4 min) to give the title compound (53 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.09(br s,1H),8.68(s,1H),8.60(s,1H),8.37(d,1H),8.26(s,1H),8.15(s,2H),3.83(s,2H),1.39(s,6H).LCMS(Method 14):1.76min,418.1[MH] - .

[0861] Example 33: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-(tetrahydro-2H-pyridin-2-yl)- pyran-4-yl)-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide

[0862]

[0863] To a stirred solution of intermediate 59 (0.10 g, 0.33 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (66 mg, 0.37 mmol, CAS 1832583-43-3) in DCM (2 mL) at 0°C was added triethylamine (0.18 mL, 1.34 mmol) and stirred at 0°C for 15 min. A solution of triphosgene (50 mg, 0.16 mmol) in DCM (0.5 mL) was added and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×150 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3Aqueous solution, MeCN from 25% to 50% in 8 min, kept at 50% for 3 min, increased to 100% in 0.1 min, kept at 100% for 2.9 min) to give the title compound (38 mg). 1 HNMR (400 MHz; DMSO-d 6 )δ:9.75(s,1H),8.63(d,1H),8.45(s,1H),8.37(d,1H),8.28(s,1H),8.15(s,2H),4.15-4.24(m,1H),3.95( dd,2H),3.79(t,2H),3.37-3.40(m,4H),1.86-1.91(m,2H),1.67(d,2H).LCMS(Method 14):1.35min,519.4[M+H] + .

[0864] Example 34: (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethyl-1- Methyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide

[0865]

[0866] To a stirred solution of intermediate 62 (0.10 g, 0.27 mmol) in DCM (1 mL) at 0°C was added triethylamine (0.16 mL, 1.17 mmol), followed by triphosgene (60 mg, 0.20 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (60 mg, 0.31 mmol, CAS 1832583-43-3), and the mixture was stirred at 0°C for 1 hour. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Select C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 50% to 80% in 7 min, kept at 80% for 5 min, increased to 98% in 0.1 min, kept at 98% for 4.9 min) to give the title compound (100 mg). 1 H NMR (400 MHz; DMSO-d 6)δ:9.88(s,1H),8.63(d,1H),8.41(s,1H),8.36(d,1H),8.24(s,1H),8.15(s,2H),3.76( dd,1H),3.70(dd,1H),3.11(s,3H),1.38-1.47(m,1H),1.29-1.38(m,1H),0.89(t,3H)–1H obscured bywater signal.LCMS(Method 14):1.47min,477.4[M+H] + .

[0867] Example 35: (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-isopropyl- 1-Methyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide

[0868]

[0869] To a stirred solution of intermediate 65 (55 mg, 0.20 mmol) in DCM (1 mL) was added triethylamine (0.16 mL, 1.17 mmol) followed by 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (28 mg, 0.20 mmol, CAS 1832583-43-3) at 0° C. and the mixture was stirred for 15 min at 0° C. A solution of triphosgene (60 mg, 0.20 mmol) in DCM (0.5 mL) was added and the mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure, and then DCM (1 mL) was added, followed by triethylamine (0.16 mL, 1.17 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (28 mg, 0.20 mmol, CAS1832583-43-3), and the mixture was stirred at room temperature for 16 hours. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (Gemini NX C18, 21×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 70% in 7 min, hold at 70% for 5.5 min) to give the title compound (31 mg). 1 H NMR (400 MHz; DMSO-d 6)δ:10.00(br s,1H),8.60(br s,1H),8.44(br s,1H),8.35(d,1H),8.16(s,1H),8.11(s,2H),4.22(br s,1H),3.39-3.43(m,1H),3.06(s,3H),2.94(br s,1H),1.38-1.47(m,1H),0.97(d,3H),0.84(d,3H).LCMS(Method 14):1.59min,491.4[M+H] + .

[0870] Example 36: 7-amino-8-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,3-triazol-2-yl Hydrogen-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0871]

[0872] To a stirred solution of intermediate 69 (100 mg, 0.43 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (85 mg, 0.43 mmol, CAS 1832583-43-3) in DCM (2 mL) was added triethylamine (0.15 mL, 1.09 mmol) at 0°C, and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (60 mg, 0.20 mmol) in DCM (0.5 mL) was added, and the mixture was stirred at room temperature for 16 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 15% to 40% in 11 min, increased to 98% in 0.1 min, maintained at 98% for 2.9 min) to give the title compound (5 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.69(br s,1H),8.60(br s,1H),8.36(d,1H),8.13(s,3H),5.96(s,2H),4.42(t,2H),3.92(t,2H).LCMS(Method 14):1.31min,451.3[M+H] + .

[0873] Example 37: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)- 2,3-Dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide

[0874]

[0875] To a stirred solution of intermediate 72 (20 mg, 0.07 mmol) in DCM (2 mL) was added triethylamine (0.03 mL, 0.21 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (11 mg, 0.06 mmol, CAS 1832583-43-3) at 0°C, and the mixture was stirred at 0°C for 15 min. A solution of triphosgene (20 mg, 0.07 mmol) in DCM (0.5 mL) was added, and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 50% in 7 min, kept at 50% for 3.3 min, increased to 98% in 0.1 min, kept at 98% for 3.6 min) to give the title compound (8 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.85(br s,1H),8.46(br s,2H),8.33(d,1H),8.16(brs,1H),8.11(s,2H),7.25(br s,1H),4.98(br s,1H),4.49(s,1H),3.10(d,1H).LCMS(Method 15):4.47min,503.2[M+H] + .

[0876] Example 38: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)- 2,3-Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0877]

[0878] To a stirred solution of intermediate 78 (0.10 g, 0.35 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (69 mg, 0.35 mmol, CAS 1832583-43-3) in DCM (2 mL) was added triethylamine (0.30 mL, 2.10 mmol) at 0°C, and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (0.10 g, 0.35 mmol) in DCM (0.5 mL) was added, and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (Gemini NX C18, 21×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3Aqueous solution, MeCN from 20% to 60% in 7 min, kept at 60% for 6.5 min, increased to 98% in 5.5 min, kept at 98% for 2.5 min) to give the title compound (41 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.10(br s,1H),8.76(br s,1H),8.60(br s,1H),8.44(s,1H),8.36(d,1H),8.15(s,2H),5.57(br s,1H),4.31(d,1H),4.18(d,1H).LCMS(Method 14):1.85min,504.3[M+H] + .

[0879] Example 39: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)- 2,3-Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide;

[0880] Example 40: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)- 2,3-Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0881] Chiral preparative SFC (Chiralcel-OJ-H, 46 x 250 mm x 5 μm, flow rate: 100 g / min, 70% CO 2 and 30% MeOH, back pressure 100 bar, temperature 30° C.) to purify Example 38 (35 mg): Peak 1 provided Example 39 (13 mg), Peak 2 provided Example 40 (13 mg).

[0882] Embodiment 39: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.13(br s,1H),8.87(br s,1H),8.48(brs,1H),8.36(d,2H),8.12(s,2H),5.50(br s,1H),4.49(br s,1H),4.15(dd,1H).LCMS(Method 14):1.85min,504.3[M+H] + .

[0883] Embodiment 40: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.17(br s,1H),8.93(br s,1H),8.38(d,2H),8.34(br s,1H),8.11(s,2H),5.46(br s,1H),4.44(br s,1H),4.13(dd,1H).LCMS(Method 14):1.85min,504.4[M+H]+ .

[0884] Example 41: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2,3-triazol-2-yl Hydrogen-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0885]

[0886] To a stirred solution of intermediate 83 (0.20 g, 0.75 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.13 g, 0.68 mmol, CAS 1832583-43-3) in DCM (5 mL) was added triethylamine (0.42 mL, 3.10 mmol) at 0°C, and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (0.22 g, 0.75 mmol) in DCM (1 mL) was added, and the mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 50% in 7 min, kept at 50% for 5 min, increased to 98% in 0.1 min, kept at 98% for 1.9 min) to give the title compound (52 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:9.92(br s,1H),8.61(s,2H),8.38(d,1H),8.14(s,2H),4.50(t,2H),3.98(t,2H),2.54(s,3H).LCMS(Method 1):1.36min,450.2[M+H] + .

[0887] Example 42: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2-(trifluoro methyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0888] Example 43: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2-(trifluoro methyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0889]

[0890] To a stirred solution of intermediate 87 (0.42 g, 1.26 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.24 g, 1.26 mmol, CAS 1832583-43-3) in DCM (5 mL) was added triethylamine (0.53 mL, 3.78 mmol) at 0°C, and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (0.37 g, 1.26 mmol) in DCM (1 mL) was added, and the mixture was stirred at room temperature for 1 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 17 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 45% to 70% in 13 min, kept at 70% for 2 min, increased to 98% in 0.1 min, kept at 98% for 1.9 min) to give a racemic compound (94 mg). Chiral preparative SFC (Chiralpak-AD-H, 30×250 mm×5 μm, flow rate: 100 g / min, 73% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 42 (36 mg) and Peak 2 provided Example 43 (32 mg).

[0891] Embodiment 42: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.02(br s,1H),8.62(br s,2H),8.36(d,1H),8.15(s,2H),5.56(br s,1H),4.21(dd,2H),2.58(s,3H).LCMS(Method 18):1.66min,520.1[M+H] + .

[0892] Embodiment 43: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.02(br s,1H),8.66(br s,1H),8.57(brs,1H),8.37(d,1H),8.14(s,2H),5.54(br s,1H),4.23(dd,2H),2.57(s,3H).LCMS(Method 18):1.66min,520.2[M+H] + .

[0893] Example 44: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-methyl-2,3-triazol-2-yl Hydrogen-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0894] Example 45: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-methyl-2,3-triazol-2-yl Hydrogen-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0895]

[0896] Chiral preparative SFC (Chiralpak-AS-H, 30 x 250 mm x 5 μm, flow rate: 100 g / min, 60% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 44 (12 mg), Peak 2 provided Example 45 (12 mg).

[0897] Embodiment 44: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.01(br s,1H),8.71(br s,1H),8.62(brs,1H),8.37(d,1H),8.33(s,1H),8.15(br s,2H),4.62(t,1H),4.24(d,1H)3.50(dd,1H),1.40(d,3H).LCMS(Method 14):1.55min,452.1[M+H] + .

[0898] Embodiment 45: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.01(br s,1H),8.73(br s,1H),8.60(brs,1H),8.37(br d,1H),8.32(br s,1H),8.15(br s,2H),4.61(t,1H),4.24(d,1H)3.50(dd,1H),1.39(d,3H).LCMS(Method 14):1.55min,452.1[M+H] + .

[0899] Example 46: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethyl-2,3-triazol-2-yl Hydrogen-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0900] Example 47: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethyl-2,3-triazol-2-yl Hydrogen-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0901]

[0902] To a stirred solution of intermediate 89 (0.27 g, 1.10 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.34 g, 1.65 mmol, CAS1832583-43-3) in DCM (3 mL) at 0°C was added 4-nitrophenyl chloroformate (0.33 g, 1.65 mmol) and stirred at room temperature for 15 min. The mixture was cooled to 0°C, then triethylamine (0.46 mL, 3.30 mmol) was added dropwise, and the mixture was stirred at room temperature for 5 hours. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and washed with Na 2 SO 4 The crude product was purified by preparative HPLC (X-Bridge Phenyl, 19×250 mm×5 μm, flow rate: 17 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 60% in 10 min, then increased to 65% in 3.5 min, increased to 100% in 0.1 min, maintained at 100% for 2.4 min) to give a racemic compound (310 mg). Chiral preparative SFC (Chiralpak-AS-H, 30×250 mm×5 μm, flow rate: 100 g / min, 70% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 46 (127 mg), Peak 2 provided Example 47 (150 mg).

[0903] Embodiment 46: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.00(br s,1H),8.69(br s,1H),8.64(d,1H),8.37(d,1H),8.35(s,1H),8.16(s,2H),4.41–4.47(m,1H),4.18–4.24 (m,1H),3.59(dd,1H),1.75–1.66(m,2H),1.05(t,3H).LCMS(Method 14):1.72min,466.2[M+H] + .

[0904] Embodiment 47: 1 H NMR (400 MHz; DMSO-d 6)δ:10.00(br s,1H),8.69(br s,1H),8.63(d,1H),8.37(d,1H),8.35(s,1H),8.16(s,2H),4.41–4.47(m,1H),4.18–4.24 (m,1H),3.59(dd,1H),1.75–1.66(m,2H),1.05(t,3H).LCMS(Method 14):1.72min,466.2[M+H] + .

[0905] Example 48: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-isopropyl-2,3- Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0906] Example 49: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-isopropyl-2,3- Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0907]

[0908] To a stirred solution of intermediate 92 (0.30 g, 0.99 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.21 g, 0.99 mmol, CAS 1832583-43-3) in DCM (10 mL) was added triethylamine (0.55 mL, 3.97 mmol) at 0°C, and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (0.21 g, 0.69 mmol) in DCM (1 mL) was added, and the mixture was stirred at room temperature for 2 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 35% to 60% in 9 min, maintained at 60% for 2 min, increased to 100% in 0.1 min, maintained at 100% for 3.9 min) to give a racemic compound (120 mg). Chiral preparative SFC (Chiralpak-AD-H, 30×250 mm×5 μm, flow rate: 100 g / min, 60% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 48 (32 mg), Peak 2 provided Example 49 (40 mg).

[0909] Embodiment 48: 1 H NMR (400 MHz; DMSO-d 6)δ:9.98(br s,1H),8.70(br s,1H),8.62(brs,1H),8.39(d,1H),8.35(s,1H),8.15(s,2H),4.18–4.28(m,2H),3.59( dd,1H),1.90–1.98(m,1H),1.08(d,3H),1.02(d,3H).LCMS(Method 18):1.65min,480.2[M+H] + .

[0910] Embodiment 49: 1 H NMR (400 MHz; DMSO-d 6 )δ:9.99(br s,1H),8.70(br s,1H),8.62(brs,1H),8.39(d,1H),8.34(s,1H),8.15(s,2H),4.18–4.28(m,2H),3.59( dd,1H),1.90–1.98(m,1H),1.07(d,3H),1.03(d,3H).LCMS(Method 18):1.65min,480.2[M+H] + .

[0911] Example 50: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-cyclopropyl-2,3- Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0912] Example 51: 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-cyclopropyl-2,3- Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0913]

[0914] To a stirred solution of intermediate 95 (0.10 g, 0.33 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.10 g, 0.50 mmol, CAS1832583-43-3) in DCM (2 mL) at 0°C was added 4-nitrophenyl chloroformate (67 mg, 0.33 mmol) and stirred at room temperature for 30 min. The mixture was cooled to 0°C, and triethylamine (0.28 mL, 1.99 mmol) was then added dropwise, and the mixture was stirred at room temperature for 4 hours. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and washed with Na 2 SO 4 The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 17 mL / min, 10 mM NH 4 HCO 3Aqueous solution, MeCN from 20% to 40% in 8 min, increased to 98% in 2.1 min, maintained at 98% for 1.9 min) to give a racemic compound (65 mg). Chiral preparative SFC (Chiralpak-AS-H, 30×250 mm×5 μm, flow rate: 100 g / min, 60% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 50 (24 mg), Peak 2 provided Example 51 (24 mg).

[0915] Embodiment 50: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.00(br s,1H),8.69(br s,1H),8.64(brd,1H),8.37(d,1H),8.34(s,1H),8.16(s,2H),4.22(d,1H),3.91–3.98(m,1 H),3.72(dd,1H),1.15–1.06(m,1H),0.68–0.48(m,4H).LCMS(Method 14):1.77min,478.2[M+H] + .

[0916] Embodiment 51: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.00(br s,1H),8.69(br s,1H),8.64(brd,1H),8.37(d,1H),8.34(s,1H),8.15(s,2H),4.22(d,1H),3.91–3.98(m,1 H),3.72(dd,1H),1.15–1.06(m,1H),0.68–0.48(m,4H).LCMS(Method 14):1.77min,478.2[M+H] + .

[0917] Example 52: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyano-7-methyl-2-( ... (fluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0918] Example 53: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyano-7-methyl-2-( ... (fluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0919]

[0920] To a stirred solution of intermediate 97 (0.10 g, 0.37 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.12 g, 0.56 mmol, CAS1832583-43-3) in DCM (1 mL) at 0°C was added 4-nitrophenyl chloroformate (0.11 g, 0.56 mmol) and stirred at room temperature for 30 min. The mixture was cooled to 0°C, then triethylamine (0.15 mL, 1.11 mmol) was added dropwise, and the mixture was stirred at room temperature for 5 hours. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and washed with Na 2 SO 4 The crude product was purified by preparative HPLC (X-Bridge C18, 19×250 mm×5 μm, flow rate: 17 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 40% to 45% in 8 min, maintained at 45% for 3 min, increased to 98% in 0.1 min, maintained at 98% for 1.9 min) to give a racemic compound (54 mg). Chiral preparative SFC (Chiralcel-OJ-H, 30×250 mm×5 μm, flow rate: 100 g / min, 65% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 52 (15 mg), Peak 2 provided Example 53 (15 mg).

[0921] Embodiment 52: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.09(br s,1H),8.89(br s,1H),8.63(brs,1H),8.36(d,1H),8.16(s,2H),5.71–5.63(m,1H),4.35–4.20(m,2H),2.64(s,3H).LCMS(Method 14):1.77min,465.2[M+H] + .

[0922] Embodiment 53: 1 H NMR (400 MHz; DMSO-d 6)δ:10.10(br s,1H),8.90(br s,1H),8.62(brs,1H),8.36(d,1H),8.16(s,2H),5.71–5.63(m,1H),4.35–4.20(m,2H),2.64(s,3H).LCMS(Method 14):1.77min,465.2[M+H] + .

[0923] Example 54: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyano-2-(trifluoromethyl)pyridin-3-yl)- 2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0924] Example 55: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyano-2-(trifluoromethyl)pyridin-3-yl)- 2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0925]

[0926] To a stirred solution of intermediate 99 (0.16 g, 0.57 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (0.17 g, 0.86 mmol, CAS1832583-43-3) in DCM (2 mL) at 0°C was added 4-nitrophenyl chloroformate (0.17 g, 0.86 mmol) and stirred at room temperature for 5 min. The mixture was cooled to 0°C, and triethylamine (0.24 mL, 1.72 mmol) was added dropwise, and the mixture was stirred at room temperature for 5 hours. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and washed with Na 2 SO 4 The crude product was purified by preparative HPLC (X-Bridge C18, 19×150 mm×5 μm, flow rate: 17 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 40% to 45% in 8 min, maintained at 45% for 3 min, increased to 98% in 0.1 min, maintained at 98% for 1.9 min) to give a racemic compound (95 mg). Chiral preparative SFC (Chiralpak-IJ-H, 30×250 mm×5 μm, flow rate: 100 g / min, 70% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 54 (15 mg), Peak 2 provided Example 55 (15 mg).

[0927] Embodiment 54: 1 H NMR (400 MHz; DMSO-d 6)δ:10.18(br s,1H),9.04(br s,1H),8.72(brs,1H),8.62(br s,1H),8.36(d,1H),8.16(s,2H),5.71–5.63(m,1H),4.39–4.20(m,2H).LCMS(Method 18):1.73min,451.2[M+H] + .

[0928] Embodiment 55: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.18(br s,1H),9.05(br s,1H),8.71(brs,1H),8.62(br s,1H),8.36(d,1H),8.16(s,2H),5.71–5.63(m,1H),4.39–4.20(m,2H).LCMS(Method 18):1.73min,451.2[M+H] + .

[0929] Example 56: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-methoxy-2-(trifluoromethyl)- 2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0930] Example 57: N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-methoxy-2-(trifluoromethyl)- 2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0931]

[0932] To a stirred solution of intermediate 101 (0.18 g, 0.46 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (96 mg, 0.46 mmol, CAS1832583-43-3) in DCM (2 mL) at 0°C was added 4-nitrophenyl chloroformate (93 mg, 0.46 mmol) and stirred at room temperature for 15 min. The mixture was cooled to 0°C, and triethylamine (0.19 mL, 1.38 mmol) was added dropwise, and the mixture was stirred at room temperature for 5 hours. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with water and washed with Na 2 SO 4 The crude product was purified by preparative HPLC (X-Bridge Phenyl, 19×250 mm×5 μm, flow rate: 17 mL / min, 10 mM NH 4 HCO 3Aqueous solution, MeCN from 20% to 50% in 9 min, maintained at 50% for 4 min, increased to 100% in 0.1 min, maintained at 100% for 2.9 min) to give a racemic compound (240 mg). Chiral preparative SFC (Chiralpak-IC, 30×250 mm×5 μm, flow rate: 100 g / min, 60% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 56 (46 mg), Peak 2 provided Example 57 (53 mg).

[0933] Embodiment 56: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.04(br s,1H),8.65(br d,1H),8.42(brs,1H),8.36(d,1H),8.16(s,2H),8.12(s,1H),5.49–5.42( m,1H),4.23–4.10(m,2H),3.93(s,3H).LCMS(Method 14):1.41min,456.2[M+H] + .

[0934] Embodiment 57: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.04(br s,1H),8.65(br d,1H),8.42(brs,1H),8.36(d,1H),8.16(s,2H),8.12(s,1H),5.49–5.42( m,1H),4.23–4.10(m,2H),3.93(s,3H).LCMS(Method 14):1.41min,456.2[M+H] + .

[0935] Example 58: 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-cyano-3,4-dihydro- Hydrogen-1,7-naphthyridine-1(2H)-carboxamide

[0936]

[0937] To a stirred solution of intermediate 104 (55 mg, 0.22 mmol) and 5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-amine (44 mg, 0.22 mmol, CAS 1832583-43-3) in DCM (2.8 mL) was added triethylamine (0.09 mL, 0.64 mmol) at 0°C, and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (70 mg, 0.24 mmol) in DCM (1 mL) was added, and the mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure. The crude product was purified by preparative HPLC (X-Select C18, 19×250 mm×5 μm, flow rate: 18 mL / min, 10 mM NH 4 HCO 3 Aqueous solution, MeCN from 30% to 45% in 8 min, kept at 45% for 2.2 min, increased to 100% in 0.2 min) to give the title compound (13 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.16(br s,1H),8.72(br s,1H),8.58(br s,1H),8.47(br s,1H),8.34(d,1H),8.15(s,2H),4.30(dd,1H),3.94(d,1H),3.72–3.66(m,1H),3.21(dd,1H),3.07(dd,1H).LCMS(Method 14):1.55min,461.1[M+H] + .

[0938] Example 59: 8-cyano-7-methyl-2-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-2,3-difluoromethyl Hydrogen-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0939]

[0940] To a stirred solution of intermediate 97 (0.10 g, 0.36 mmol) and 2-(trifluoromethyl)pyridin-4-amine (70 mg, 0.43 mmol, CAS 147149-98-2) in DCM (2.8 mL) was added triethylamine (0.24 mL, 1.73 mmol) at 0°C and the mixture was stirred at 0°C for 15 min. A solution of triphosgene (137 mg, 0.43 mmol) in DCM (1 mL) was added and the mixture was stirred at room temperature for 5 h. The mixture was diluted with water and extracted with EtOAc. The combined organics were washed with water, brine and washed with anhydrous Na 2 SO 4The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 0-30% ethyl acetate in hexane) to give a racemic compound (78 mg). The product was purified by chiral preparative SFC (Lux Cellulose, 30×250 mm×5 μm, flow rate: 100 g / min, 80% CO 2 The racemic compound was purified by HPLC-MS / MS (compound 50:1:1) and 20% MeOH, back pressure 100 bar, temperature 30° C.): Peak 2 afforded Example 59 (29 mg). 1 H NMR (400 MHz; DMSO-d 6 )δ:10.14(br s,1H),8.83(s,1H),8.58(d,1H),7.98(d,1H),7.72(d,1H),5.69–5.61(m,1H),4.28–4.20(m,2H),2.63(s,3H).LCMS(Method 14):1.80min,432.3[M+H] + .

[0941] Example 60: N-(5-chloro-6-(difluoromethoxy)pyridin-3-yl)-8-cyano-7-methyl-2-(trifluoromethyl)- 2,3-Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0942] Example 61: N-(5-chloro-6-(difluoromethoxy)pyridin-3-yl)-8-cyano-7-methyl-2-(trifluoromethyl)- 2,3-Dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0943]

[0944] To a stirred solution of intermediate 97 (0.12 g, 0.38 mmol) and 5-chloro-6-(difluoromethoxy)pyridin-3-amine (92 mg, 0.45 mmol, CAS 1832583-48-8) in DCM (1.2 mL) at 0°C was added triethylamine (0.16 mL, 1.13 mmol) and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (0.11 g, 0.38 mmol) in DCM (1 mL) was added and the mixture was stirred at room temperature for 1 h. The mixture was diluted with water and extracted with ethyl acetate. The combined organics were washed with water, brine and washed with anhydrous Na 2 SO 4 The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 0-100% ethyl acetate in petroleum ether) to give a racemic compound (45 mg). The product was purified by chiral preparative SFC (LuxCellulose, 30×250 mm×5 μm, flow rate: 100 g / min, 75% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 60 (11 mg), Peak 2 provided Example 61 (11 mg).

[0945] Embodiment 60: 1 H NMR (400 MHz; DMSO-d 6 )δ:9.74(br s,1H),8.85(br s,1H),8.24(brs,1H),8.19(br d,1H),7.67(t,1H),5.68–5.59(m,1H),4.28–4.18(m,2H),2.62(s,3H).LCMS(Method 14):1.98min,464.2[M+H] + .

[0946] Example 61: 1 H NMR (400 MHz; DMSO-d 6 )δ:9.76(br s,1H),8.86(br s,1H),8.24(brs,1H),8.19(d,1H),7.67(t,1H),5.68–5.58(m,1H),4.29–4.18(m,2H),2.62(s,3H).LCMS(Method 14):1.98min,464.2[M+H] + .

[0947] Example 62: 8-cyano-N-(5-cyano-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2- (Trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0948] Example 63: 8-cyano-N-(5-cyano-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2- (Trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0949]

[0950] To a stirred solution of intermediate 97 (0.11 g, 0.37 mmol) and 5-amino-2-(triazol-2-yl)pyridine-3-carbonitrile (0.10 g, 0.46 mmol, CAS 2097854-16-3) in DCM (1.7 mL) at 0°C was added triethylamine (0.19 mL, 1.37 mmol) and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (0.11 g, 0.38 mmol) in DCM (1.7 mL) was added and the mixture was stirred at room temperature for 1 h. The mixture was diluted with water and extracted with DCM. The combined organics were washed with water, brine and washed with anhydrous Na 2 SO 4 The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 0-100% ethyl acetate in petroleum ether) to give a racemic compound (48 mg). The product was purified by chiral preparative SFC (Chiralpak IJ, 30×250 mm×5 μm, flow rate: 100 g / min, 60% CO2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 62 (12 mg), Peak 2 provided Example 63 (15 mg).

[0951] Embodiment 62: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.19(br s,1H),8.95(br s,1H),8.82(brs,1H),8.57(d,1H),8.27(s,2H),5.63(br s,1H),4.35–4.30(m,1H),4.23(dd,1H),2.63(s,3H).LCMS(Method 14):1.63min,456.3[M+H] + .

[0952] Embodiment 63: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.16(br s,1H),8.90–8.87(m,2H),8.57(d,1H),8.29(s,2H),5.69–5.65(m,1H),4.33–4.21(m,2H),2.64(s,3H).LCMS(Method 14):1.63min,456.3[M+H] + .

[0953] Example 64: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-cyano-7-methyl 2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0954] Example 65: N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-cyano-7-methyl 2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0955]

[0956] To a stirred solution of intermediate 97 (0.15 g, 0.57 mmol) and 6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-amine (0.14 g, 0.63 mmol, CAS 1832582-59-8) in DCM (10 mL) at 0°C was added triethylamine (0.24 mL, 1.72 mmol) and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (0.17 g, 0.57 mmol) in DCM (3 mL) was added and the mixture was stirred at room temperature for 1 h. The mixture was diluted with water and extracted with DCM. The combined organics were washed with water, brine and washed with anhydrous Na 2 SO 4The mixture was dried, filtered and concentrated under reduced pressure. The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 0-50% ethyl acetate in petroleum ether) to give a racemic compound (90 mg). The mixture was purified by chiral preparative SFC (Chiralpak-IJ, 30×250 mm×5 μm, flow rate: 100 g / min, 80% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 64 (28 mg), Peak 2 provided Example 65 (28 mg).

[0957] Embodiment 64: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.23(br s,1H),8.93(br s,2H),8.58(d,1H),8.17(s,2H),5.66(br s,1H),4.38–4.20(m,2H),2.64(s,3H).LCMS(Method 14):1.83min,499.3[M+H] + .

[0958] Embodiment 65: 1 H NMR (400 MHz; DMSO-d 6 )δ:10.23(br s,1H),8.93(br s,2H),8.58(d,1H),8.17(s,2H),5.65(br s,1H),4.38–4.21(m,2H),2.64(s,3H).LCMS(Method 14):1.83min,499.3[M+H] + .

[0959] Example 66: 8-cyano-N-(6-(cyclopropyl(methyl)carbamoyl)-5-(difluoromethyl)pyridin-3-yl)- 7-Methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0960] Example 67: 8-cyano-N-(6-(cyclopropyl(methyl)carbamoyl)-5-(difluoromethyl)pyridin-3-yl)- 7-Methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide

[0961]

[0962] To a stirred solution of intermediate 97 (70 mg, 0.28 mmol) and intermediate 107 (70 mg, 0.29 mmol) in THF (5 mL) at 0°C was added DIPEA (0.12 mL, 0.70 mmol) and the mixture was stirred at 0°C for 5 min. A solution of triphosgene (69 mg, 0.23 mmol) in DCM (1 mL) was added and the mixture was stirred at 60°C for 1 h. The mixture was diluted with water and extracted with EtOAc. The combined organics were washed with water, brine and washed with anhydrous Na 2SO 4 The crude product was purified by flash column chromatography (silica gel, 230-400 mesh, eluted with 0-100% ethyl acetate in petroleum ether) to give a racemic compound (80 mg). The product was purified by chiral preparative SFC (Chiralpak-IK, 30×250 mm×5 μm, flow rate: 100 g / min, 75% CO 2 The racemic compound was purified by HPLC-MS / MS (HPLC-MS / MS): Peak 1 provided Example 66 (18 mg), Peak 2 provided Example 67 (20 mg).

[0963] Embodiment 66: 1 H NMR (400 MHz; DMSO-d 6 )δ:9.92(br s,1H),8.89(br s,1H),8.79(brs,1H),8.25(s,1H),7.11(t,1H),5.63(br s,1H),4.38–4.15(m,2H),3.01(s,3H),2.83(d,1H),2.62(s,3H),0.46–0.37(m,4H).LCMS(Method 14):1.73min,511.4[M+H] + .

[0964] Embodiment 67: 1 H NMR (400 MHz; DMSO-d 6 )δ:9.92(br s,1H),8.91(br s,1H),8.77(brs,1H),8.25(s,1H),7.10(t,1H),5.62(br s,1H),4.38–4.15(m,2H),3.01(s,3H),2.83(d,1H),2.62(s,3H),0.46–0.37(m,4H).LCMS(Method 14):1.73min,511.4[M+H] + .

[0965] Biological assays

[0966] MALT1 Protease Assay 1 (Assay 1)

[0967] In vitro MALT1 protease activity was assessed by measuring the cleavage of a fluorogenic tetrapeptide substrate.

[0968] A protein containing 6-His-hMALT-1 (residues 339-715) fused to ubiquitin via an 8×GGS linker (MALT1-GS-Ub) was expressed in E. coli according to standard protocols and purified using chitin resin to remove contaminants, followed by affinity purification and size exclusion chromatography.

[0969] Briefly, MALT1-GS-Ub (300-600 nM) was incubated with substrate (Ac-LVSR-AMC, 100 μM) in a reaction buffer containing 50 mM HEPES (pH 7.0), 25 mM KCl, 0.1% (v / v) CHAPS and 1 mM TCEP.

[0970] Test compounds dissolved in DMSO were dispensed into assay plates (384-well, black, light ProxiPlate). 7 μl of enzyme solution was added and incubated at room temperature for 30 min to allow compound binding. 2 μl of substrate solution was then added and fluorescence was read every 15 min using a suitable plate reader (excitation 360 nm, emission 460 nm). The final DMSO concentration was determined to be 1%. Linearity within 60 min was confirmed and the assay signal was calculated by subtracting the original count at 0 from the original count at 60 min. The % inhibition was calculated for each well, with 100% inhibition control without enzyme and 0% inhibition control without compound. IC was calculated using GraphPadPrism using a 4-parameter nonlinear regression curve fit. 50 value.

[0971] MALT1 Protease Assay 2 (Assay 2)

[0972] In vitro MALT1 protease activity was assessed by measuring the cleavage of a fluorogenic tetrapeptide substrate.

[0973] For a more sensitive assay, commercially available FL hMALT1 enzyme (Abcam, 1-10 nM) was incubated with substrate (Ac-LVSR-AMC, 100 μM) in a reaction buffer containing 50 mM HEPES (pH 7.0), 25 mM KCl, 0.1% (v / v) CHAPS, 1 mM TCEP, and 0.7 M sodium citrate.

[0974] Test compounds dissolved in DMSO were dispensed into assay plates (384-well, black, light ProxiPlate). 7 μl of enzyme solution was added and incubated at room temperature for 30 min to allow compound binding. 2 μl of substrate solution was then added and fluorescence was read every 15 min using a suitable plate reader (excitation 360 nm, emission 460 nm). The final DMSO concentration was determined to be 1%. Linearity within 60 min was confirmed and the assay signal was calculated by subtracting the original count at 0 from the original count at 60 min. The % inhibition was calculated for each well, with 100% inhibition control without enzyme and 0% inhibition control without compound. IC was calculated using GraphPadPrism using a 4-parameter nonlinear regression curve fit. 50 value.

[0975] Human IL-2 release phenotype assay (Assay 3)

[0976] The assay measures the inhibitory effect of MALT1 inhibitors on IL-2 release from stimulated Jurkat cells, a human immortalized T lymphocyte cell line. IL-2 production by Jurkat cells is regulated by the activation of NFκB signaling, which in turn is regulated by MALT1 protease activity.

[0977] Jurkat cells (clone E6-1, ATCC) were cultured in RPMI1640 supplemented with 10% (v / v) FBS and 1% (v / v) penicillin / streptomycin (100-fold liquid stock). Cells were seeded at 50,000 cells / well in 96-well white tissue culture treated plates (Perkin Elmer) and incubated at 37°C, 5% CO 2 Incubate overnight at 4 °C. Add the test compound diluted in DMSO in half logarithm to the cells and incubate for 30 min. The final DMSO concentration is 0.5%. The cells are then stimulated with 200 ng / mL PMA+300 ng / mL ionomycin and incubated for 48 h. The IL-2 present in the supernatant is then determined by ELISA according to the kit instructions (ELISAMAX Deluxe Set Human IL-2, BioLegend). For the 100% inhibition control, 30 μM of the commercially available MALT1 inhibitor MLT-748 is used, and for the 0% inhibition control, no compound is used, and the % inhibition of each well is calculated. IC is calculated using GraphPad Prism using 4-parameter nonlinear regression curve fitting. 50 value.

[0978] The results of testing the example compounds in one or more of the three in vitro assays described above are shown in Table 1.

[0979] Table 1: MALT1 assay data

[0980]

[0981]

[0982]

[0983] IL-2 release PK / PD model

[0984] Female C57BL / 6 mice of approximately 6 weeks of age were grouped according to body weight and orally administered with the compound at time T-1h in a vehicle containing 20% ​​HPBCD (w / v), 0.5% Tween 80 (v / v) and 10% (v / v) N,N-dimethylacetamide in saline at a volume of 10 mL / kg. One hour later, at T0, the mice were treated with an intravenous injection of anti-CD3 antibody (Ultra-LEAF TM , #100340Biolegend) was challenged with the antibody appropriately diluted in sterile PBS at a dose of 10 μg / mouse in a volume of 100 μL. 4 h after aCD3 challenge, mice were anesthetized and terminal blood samples were collected from the carotid artery. 20 μL of blood samples were transferred to EDTA tubes, then diluted 1:1 with water and frozen at -20°C until subsequent bioanalysis by LC-MS / MS. The remaining blood samples were allowed to clot for 30 min, serum was separated by centrifugation, quickly frozen and stored at -80°C until IL-2 analysis by ELISA (Mouse IL-2 DuoSet ELISA, R&D Systems). IL-2 concentrations in serum were calculated by interpolation from the standard curve. Statistical analysis (ordinary one-way ANOVA and Dunnett's multiple comparisons) was performed using GraphPad Prism.

Claims

1. A compound according to formula I or a pharmaceutically acceptable salt thereof: in: X 1 is N or CH; X 2 Yes O, NR 7 or CR 8 R 9 ; X 3 is N or CH; X 4 Is N or CR 10 ; The condition is X 3 and X 4 It can’t all be N; R 1 Selected from hydrogen, C 1-4 Alkyl, hydroxyl, C 1-4 Alkoxy, C 1-4 Haloalkyl, halogen, NR 11 R 12 , C 3-7 Cycloalkyl and OC 3-7 Cycloalkyl; R 2 Selected from hydrogen, C 1-4 Alkyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, halogen, cyano, NR 13 R 14 、C(O)OR 15 、C(O)NR 16 R 17 , OR 18 , 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl and phenyl, wherein the 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Substitution of alkyl, halogen and cyano groups; R 3 and R 4 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, hydroxyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, cyano, NR 19 R 20 , 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl, wherein the C 1-4 Alkyl, 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Alkyl, hydroxyl, C 1-4 Alkoxy, halogen and cyano substituents; or R 3 and R4 together with the carbon atom to which they are attached form an oxo group, a 4- to 7-membered heterocyclic ring, or a 3- to 6-membered cycloalkyl ring; R 5 Selected from hydrogen, C 1-4 Alkyl, C 1-4 Alkoxy and C 1-4 Haloalkyl; R 6 Selected from hydrogen, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, cyano and C 1-4 Haloalkyl; R 7 It is hydrogen, C 1-4 Alkyl, C 3-7 cycloalkyl, 5- or 6-membered heteroaryl or 4- to 7-membered heterocyclyl, wherein the C 1-4 Alkyl, C 3-7 Cycloalkyl, 5- or 6-membered heteroaryl and 4- to 7-membered heterocyclyl are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-4 Alkoxy, halogen and cyano substituents; or R 7 and R 3 Together with the atoms to which they are attached, they form a 5- or 6-membered heterocyclic ring, optionally substituted by one or more selected from C 1-4 Alkyl, C 1-4 Substitution of alkoxy, halogen and cyano substituents; R 8 and R 9 are independently selected from hydrogen, C 1-4 Alkyl, C 2-4 Alkenyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, hydroxyl, C 1-4 Alkoxy, C 1-4 Haloalkoxy, halogen, cyano, NR 21 R 22 , 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl, wherein the C 1-4 Alkyl, 4 to 7 membered heterocyclyl, 5 or 6 membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-4 Alkoxy, halogen and cyano substituents; or R 8 and R 9 Together with the carbon atoms to which they are attached, they form a 4- to 7-membered heterocyclic ring or a 3- to 6-membered cycloalkyl ring; R 10 Selected from C(O)NR 23 R 24 , C 1-4 Halogenated alkoxy, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 3-7 Cycloalkyl, 4- to 7-membered heterocyclyl, and 5- or 6-membered heteroaryl, wherein the C 3-7 Cycloalkyl, 4- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl are optionally substituted by one or more selected from C 1-4 Alkyl, C 1-3 Alkylene-R 25 , hydroxyl, NR 26 R 27 and halogen substituted substituents; R 11 and R 12 are independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl and C 1-4 haloalkyl; or R 11 and R 12 Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocyclic ring; R 13 and R 14 are independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl and C 1-4 haloalkyl; or R 13 and R 14 Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocyclic ring; R 15 Is H or C 1-4 alkyl; R 16 and R 17 are independently selected from hydrogen, C 1-4 Alkyl, C 3-7 Cycloalkyl and C 1-4 haloalkyl; or R 16 and R 17 Together with the nitrogen atom to which they are attached, they form a 4- to 7-membered heterocyclic ring; R 18 Selected from hydrogen, C 1-4 Alkyl, C 1-3 Alkylene-R 23 , C 1-4 Haloalkyl, C 3-7 Cycloalkyl, 4- to 7-membered heterocyclyl, and 5- or 6-membered heteroaryl; R 19 , R 20 , R 21 and R 22 Each independently selected from H and C 1-4 alkyl; R 23 and R 24 are independently selected from hydrogen, C 1-4 Alkyl and C 3-7 Cycloalkyl; R 25 Selected from OH, C 1-4 Alkoxy, C 3-7 Cycloalkyl, NR 28 R 29 、C(O)OR 30 and C(O)NR 31 R 32 ; R 26 , R 27 , R 28 , R 29 , R 30 , R 31 and R 32 Each independently selected from H and C 1-4 alkyl; n is 0, 1 or 2.

2. The compound according to claim 1, wherein X 1 It is N.

3. The compound according to claim 1 or 2, wherein X 2 Is O or NR 7 .

4. A compound according to any one of claims 1 to 3, wherein X 3 is N and X 4 Yes CR 10 .

5. A compound according to any one of claims 1 to 4, wherein R 1 Selected from: a. Hydrogen, C 1-4 Alkyl, hydroxyl, C 1-4 Alkoxy and NR 11 R 12 ; b. Hydrogen, C 1-4 Alkyl and NR 11 R 12 ; c. hydrogen, methyl and NH2; or d. Hydrogen and methyl.

6. A compound according to any one of claims 1 to 5, wherein R 2 Selected from: a. Hydrogen, C1-4 alkyl, C 3-7 Cycloalkyl, halogen, cyano, OR 18 , 5- or 6-membered heteroaryl and phenyl, wherein the 5- or 6-membered heteroaryl and phenyl are optionally substituted by one or more selected from C 1-4 Substitution of alkyl, halogen and cyano groups; b. Hydrogen, C 3-7 Cycloalkyl, halogen, cyano, OR 18 , 5- or 6-membered heteroaryl and phenyl; c. hydrogen, cyclopropyl, halogen, cyano, methoxy, 5-membered heteroaryl and phenyl; d. halogen, cyano, methoxy, 5-membered heteroaryl and phenyl; e. halogen and cyano; or f. Chlorine and bromine.

7. A compound according to any one of claims 1 to 6, wherein R 3 and R 4 Independently selected from: a. Hydrogen, C 1-4 Alkyl, C 2-4 Alkynyl, C 1-4 Haloalkyl, C 3-7 Cycloalkyl, hydroxyl, C 1-4 Alkoxy, halogen, cyano, 4- to 7-membered heterocyclyl, 5- or 6-membered heteroaryl, and phenyl; b. Hydrogen, C 1-4 Alkyl, C 2-4 Alkynyl, C 1-4 Alkyl halides and cyano groups; c. Hydrogen, C 1-4 Alkyl, ethynyl, trifluoromethyl and cyano; or d. Hydrogen, methyl, ethyl, propyl, isopropyl, trifluoromethyl and cyano.

8. A compound according to any one of claims 1 to 6, wherein R 3 and R 4 Together with the carbon atoms to which they are attached, they form a 5- to 6-membered heterocyclic ring or a 3- to 5-membered cycloalkyl ring.

9. A compound according to any one of claims 1 to 8, wherein R 5 is hydrogen or methyl; for example hydrogen.

10. A compound according to any one of claims 1 to 9, wherein R 6 Selected from halogen and C 1-4 Halogenated alkyl.

11. The compound according to claim 10, wherein R 6 It's chlorine.

12. A compound according to any one of claims 1 to 11, wherein R 7 Selected from: a. Hydrogen, C 1-4 Alkyl and 4 to 7 membered heterocyclic group; b. Hydrogen and C 1-4 Alkyl; or c. Hydrogen and methyl.

13. A compound according to any one of claims 1 to 11, wherein R 7 and R 3 Together with the atoms to which they are attached they form a 5- or 6-membered heterocyclic ring; for example a pyrrolidine ring or a piperidine ring.

14. A compound according to any one of claims 1 to 13, wherein R 8 and R 9 are independently selected from hydrogen and C 1-4 Alkyl groups; for example, hydrogen and methyl.

15. A compound according to any one of claims 1 to 13, wherein R 8 and R 9 It's all hydrogen.

16. A compound according to any one of claims 1 to 15, wherein R 10 Selected from C(O)NR 23 R 24 , C 1-4 haloalkoxy, 4 to 7 membered heterocyclyl and 5- or 6-membered heteroaryl, wherein the 4 to 7 membered heterocyclyl and 5- or 6-membered heteroaryl are optionally substituted by one or more selected from C 1-2 Alkyl, C 1-2 Alkylene-R 25 and halogen substituents.

17. A compound according to claim 16, wherein R 10 is a 5- or 6-membered heteroaryl group (such as triazolyl), optionally substituted by one or more selected from C 1-2 Alkyl and C 1-2 Alkylene-R 25 substituted by a substituent.

18. A compound according to any one of claims 1 to 17, wherein n is 0 or 1; for example 1.

19. The compound according to claim 1, wherein the compound is selected from one of the following compounds or a pharmaceutically acceptable salt thereof: 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,4-dihydroquinoline-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-bromo-3,4-dihydroquinoline-1(2H)-carboxamide; N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-methoxy-3,4-dihydroquinoline-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2-methyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2-cyano-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide; N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-cyano-3,4-dihydroquinoline-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(pyridin-3-yl)-3,4-dihydroquinoline-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(oxazol-2-yl)-3,4-dihydroquinoline-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(thiazol-2-yl)-3,4-dihydroquinoline-1(2H)-carboxamide; cis-N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-bromo-3,4-dimethyl-3,4-dihydroquinoline-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-phenyl-3,4-dihydroquinoline-1(2H)-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-5-(1,3,4-thiadiazol-2-yl)-3,4-dihydroquinoline-1(2H)-carboxamide; 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,3-dimethyl-3,4-dihydroquinoline-1(2H)-carboxamide; 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-4-methyl-3,4-dihydroquinoxaline-1(2H)-carboxamide; 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3,4-dihydro-1,7-naphthyridine-1(2H)-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-cyano-2-methyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethynyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-5-cyclopropyl-3,4-dihydro-1,7-naphthyridine-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-bromo-2,2-dimethyl-2,3-dihydro-4H-benzo[b][1,4]oxazine-4-carboxamide; N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyclopropyl-2,2-dimethyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; (S)-1-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-6a,7,8,9-tetrahydropyrido[3,4-e]pyrrolo[1,2-a]pyrazine-5(6H)-carboxamide; (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1,2-dimethyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide; 8'-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-4,5-dihydro-2H-spiro[furan-3,2'-pyrido[4,3-b][1,4]oxazine]-4'(3'H)-carboxamide; 1-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-6,6a,7,8,9,10-hexahydro-5H-bipyrido[1,2-a:3',4'-e]pyrazine-5-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-methyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-methyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1,2,2-trimethyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide; 8-Chloro-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,2-dimethyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-1-(tetrahydro-2H-pyran-4-yl)-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide; (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethyl-1-methyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide; (R)-8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-isopropyl-1-methyl-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide; 7-amino-8-bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)-2,3-dihydropyrido[3,4-b]pyrazine-4(1H)-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-ethyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-isopropyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-2-cyclopropyl-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyano-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-cyano-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-8-methoxy-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 5-Bromo-N-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-cyano-3,4-dihydro-1,7-naphthyridine-1(2H)-carboxamide; N-(6-(2H-1,2,3-triazol-2-yl)-5-(trifluoromethyl)pyridin-3-yl)-8-cyano-7-methyl-2-(trifluoromethyl)pyridin-3-yl)- 1,4-dihydro-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-Cyano-N-(5-cyano-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-cyano-N-(6-(cyclopropyl(methyl)carbamoyl)-5-(difluoromethyl)pyridin-3-yl)-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; 8-cyano-7-methyl-2-(trifluoromethyl)-N-(2-(trifluoromethyl)pyridin-4-yl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide; and N-(5-chloro-6-(difluoromethoxy)pyridin-3-yl)-8-cyano-7-methyl-2-(trifluoromethyl)-2,3-dihydro-4H-pyrido[4,3-b][1,4]oxazine-4-carboxamide.

20. A pharmaceutical composition comprising a compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

21. A compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 20 for use in therapy.

22. A compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 20 for use in treating a disease or condition mediated by MALT1.

23. A compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 20 for use in the treatment of non-Hodgkin's lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt's lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Macroglobulinemia, lymphoblastic T-cell leukemia, chronic myeloid leukemia (CML), hairy cell leukemia, acute lymphoblastic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal cancer / colon cancer, prostate cancer, including non-small cell lung cancer, gastric cancer, endometrial cancer, melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, Ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial carcinoma, vulvar cancer, esophageal cancer, salivary gland cancer, nasopharyngeal cancer, cheek cancer, oral cancer, GIST (gastrointestinal stromal tumor), Arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatitis, Crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allograft rejection, acute or chronic graft-versus-host disease, dermatitis including atopic dermatitis, dermatomyositis, psoriasis, Behcet's disease, uveitis, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Sjögren's syndrome, vesicular disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic disease, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, lung disease including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, berylliosis, or polymyositis.

24. A method of treating a disease or condition mediated by MALT1, the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 20.

25. A method for treating the following diseases: non-Hodgkin lymphoma (IN-IL), B-cell NHL, diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), follicular lymphoma (FL), mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin lymphoma, Burkitt lymphoma, multiple myeloma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Macroglobulinemia, lymphoblastic T-cell leukemia, chronic myeloid leukemia (CML), hairy cell leukemia, acute lymphoblastic T-cell leukemia, plasmacytoma, immunoblastic large cell leukemia, megakaryoblastic leukemia, acute megakaryocytic leukemia, promyelocytic leukemia, erythroleukemia, brain (glioma), glioblastoma, breast cancer, colorectal cancer / colon cancer, prostate cancer, including non-small cell lung cancer, gastric cancer, endometrial cancer, Melanoma, pancreatic cancer, liver cancer, kidney cancer, squamous cell carcinoma, ovarian cancer, sarcoma, osteosarcoma, thyroid cancer, bladder cancer, head and neck cancer, testicular cancer, Ewing's sarcoma, rhabdomyosarcoma, medulloblastoma, neuroblastoma, cervical cancer, kidney cancer, urothelial carcinoma, vulvar cancer, esophageal cancer, salivary gland cancer, nasopharyngeal cancer, cheek cancer, oral cancer, GIST (gastrointestinal stromal tumor), arthritis, inflammatory bowel disease, gastritis, ankylosing spondylitis, ulcerative colitis, pancreatitis, Crohn's disease, breast cancer Celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatic fever, gout, organ or transplant rejection, chronic allogeneic transplant rejection, acute or chronic graft-versus-host disease, dermatitis including atopic dermatitis, dermatomyositis, psoriasis, Behcet's disease, uveitis, myasthenia gravis, Graves' disease, Hashimoto's thyroiditis, Sjögren's syndrome, vesicular disease, antibody-mediated vasculitis syndrome, immune complex vasculitis, allergic diseases, asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, lung diseases including edema, embolism, fibrosis, sarcoidosis, hypertension and emphysema, silicosis, respiratory failure, acute respiratory distress syndrome, BENTA disease, berylliosis or polymyositis, the method comprising administering to a subject in need of the treatment a therapeutically effective amount of a compound according to any one of claims 1 to 19 or a pharmaceutically acceptable salt thereof or a pharmaceutical composition according to claim 20.

Citation Information

Patent Citations

  • CD86 variants with improved affinity for CTLA-4

    WO2014207063A1

  • Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors

    WO2015181747A1

  • Novel pyrazolo pyrimidine derivatives

    WO2017081641A1

  • Substituted thiazolo-pyridine compounds as malt1 inhibitors

    WO2018020474A1

  • Pyrazolopyrimidine as malt-1 inhibitors

    WO2018226150A1